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Abstract 
Hypohalous acids, including hypochlorous (HOCl), hypobromous (HOBr) and 
hypothiocyanous (HOSCN) acids, are produced by neutrophils, monocytes and some 
macrophages at sites of inflammation. These species are generated by a myeloperoxidase 
(MPO)-catalysed reaction of hydrogen peroxide (H2O2) with chloride (Cl
-
), bromide (Br
-
) 
or thiocyanate (SCN
-
) ions, respectively. Although these hypohalous acids are potent 
oxidants which effectively inactivate invading pathogens, they can also damage host 
tissue when produced in excess or at inappropriate times or locations. Although the 
involvement of MPO and HOCl in the inflammation-related diseases, such as cancer, 
neurodegenerative disorders and atherosclerosis, has been studied extensively, the role of 
HOSCN remains elusive. This thesis investigates the effects of this oxidant. 
 
Plasma levels of thiols, SCN
-
 and MPO were measured in plasma samples obtained from 
people who survived a first heart attack, and these parameters were correlated with 12-
year all cause mortality. Patients with elevated plasma SCN
-
 levels (up to 200 μM, 
typically smokers) exhibited increased plasma thiol oxidation when exposed to a 
simulated inflammatory episode (addition of MPO and H2O2). However, elevated plasma 
SCN
-
 in combination with low plasma MPO levels correlated with a significant increase 
in 12-year survival, when compared to patients with lower levels of both (89% vs. 70% 
survival, respectively). This suggests that increased levels of SCN
-
 might be of benefit 
under certain conditions. It has been proposed that increased plasma levels of SCN
-
 shift 
the balance in the oxidants produced by MPO towards HOSCN at the expense of more 
damaging HOCl, thereby providing some level of protection from irreversible, HOCl-
induced damage. 
 
In order to examine intracellular effects of HOSCN, J774A.1 murine macrophage-like 
cells were used as a model. HOSCN has been reported to specifically oxidise low pKa 
protein thiol and selenol groups. This has particularly important implications in cells due 
to an abundance of such low pKa residues at active sites of multiple intracellular 
enzymes. This thesis examined the effects of HOSCN (and compared them to HOCl) on 
x 
 
glutathione peroxidase (GPx), thioredoxin reductase (TrxR), peroxiredoxins (Prxs), and 
glutathione (GSH).  
 
It has been shown previously that the activity of seleno enzymes can be manipulated by 
selenium supplementation. In the present study J77A.1 cells were supplemented with 
either sodium selenite or seleno-L-methionine overnight and then treated with MPO-
derived oxidants. Both forms of selenium significantly increased the activity of the seleno 
enzymes TrxR and GPx. Whilst 200 μM HOSCN treatment significantly inhibited the 
activity of TrxR (~80% decrease in activity) irrespective of selenium supplementation, 
exposure of J774A.1 cells to HOCl resulted in the significant, dose-dependent decrease in 
GPx activity (75 – 85% loss). This decrease was significantly lower in selenium 
supplemented cells, suggesting the protection of GPx from HOCl-induced damage by 
selenium supplementation. 
 
The effects of hypohalous acids on intracellular GSH levels were assessed by HPLC 
method. HOSCN treatment of J774A.1 cells caused a statistically significant decrease in 
GSH levels and an increase in GSSG formation, which was significantly higher in seleno-
L-methionine supplemented cells compared to the control, non-supplemented cells. 
However, the level of GSSG formed could not account for all of GSH loss, suggesting the 
formation of other products, such as glutathione sulfonamide and mixed protein disulfides 
(S-glutathionylation). In contrast, HOCl did not cause any marked changes in the levels 
of GSH or GSSG.  
 
Differential susceptibility to HOSCN or HOCl was also observed between the three 
isoforms of Prxs examined in this study. The extent of Prx dimer formation (oxidation) in 
J774A.1 cells following selenium supplementation and oxidant treatment was assessed by 
Western blotting. As such, ~100% of cytosolic Prx1 was in the dimeric form upon 
exposure to 100 μM HOSCN, whereas Prx2 was oxidised to the same extent with 200 μM 
HOSCN. In contrast, HOCl (200 μM) caused almost complete oxidation of mitochondrial 
Prx3, whereas 200 μM HOSCN oxidised only ~50% of this Prx isoform. Furthermore, 
HOSCN treatment led to accumulation of hyperoxidised (Prx-SO2H/Prx-SO3H) isoforms 
of Prxs, which was modulated by selenium supplementation. 
xi 
 
Further studies were carried out to examine the importance of individual Prx isoforms in 
the defence against MPO-derived oxidants. This was achieved by reducing the expression 
of each Prx isoform by siRNA silencing, and measuring the change in total protein S-
glutathionylation and metabolic activity following oxidant treatment. Hypohalous acid 
treatment of J774A.1 cells caused a moderate increase in protein S-glutathionylation 
(assessed by immunoblotting with anti-GSH antibody) in both Prx silenced and control 
cells. Whilst the increase in protein S-glutathionylation induced by HOCl was 
significantly lower in Prx3 silenced cells compared to control cells, the silencing of other 
Prx isoforms (Prx1 and Prx2) did not seem to affect the extent of S-glutathionylation 
caused by HOCl or HOSCN. Moreover, Prx silencing did not affect mitochondrial 
metabolic activity, assessed by MTT assay following oxidant treatment, suggesting that 
cells can tolerate the decrease in activity of individual Prx isoforms provided that the 
other Prx isoforms are functional. 
 
Overall, the studies presented in this thesis provide new information about intracellular 
targets of HOSCN, the efficiency of intracellular defences against this oxidant as well as 
its potential involvement in the outcomes of inflammation-related diseases. 
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1.1 General overview 
Chronic inflammation has been linked to the pathogenesis of a number of human 
pathologies, including neurodegenerative diseases, cancer and atherosclerosis. Reactive 
oxygen and nitrogen species are produced in significant amounts during inflammation 
and, although effective in eliminating some of the inducers of inflammation such as 
microorganisms, these can also damage host tissue.  
 
Myeloperoxidase (MPO) is an enzyme secreted by activated immune cells during the 
inflammatory process, which produces powerful oxidants, such as hypochlorous (HOCl), 
hypobromous (HOBr) and hypothiocyanous (HOSCN) acids, to kill invading pathogens. 
Despite the positive aspects of this oxidant generation by MPO in the immune response, 
there is also compelling evidence that the generation of these oxidants at inappropriate 
concentrations, times or locations, can damage host tissue, and this has been associated 
with a large number of human diseases, including heart disease (atherosclerosis), asthma, 
rheumatoid arthritis, cystic fibrosis, kidney disease, some neurodegenerative conditions 
and cancers (1).  
 
In the light of the known role of MPO in inflammation and the need to understand its 
mechanisms of action further, this thesis examines the role of HOSCN, a relatively poorly 
studied MPO-derived oxidant, in cellular damage under inflammatory conditions. The 
intracellular targets of HOSCN and potential defence mechanisms against this oxidant 
have also been examined. Understanding the effects of HOSCN is particularly important 
for smokers, as they have elevated plasma levels of HOSCN precursor thiocyanate  
(SCN
-
), and increased risk of cardiovascular events.  
1.2 Atherosclerosis 
Atherosclerosis is the principal source of morbidity and mortality in most parts of the 
developed world (2). The development of atherosclerosis starts as an accumulation of 
cholesterol-laden macrophage cells (foam cells) in the intima of large- and medium-sized 
elastic and muscular arteries and progresses though a number of stages to the formation 
of atherosclerotic plaques. These may be susceptible to rupture through mechanical forces 
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of blood flow, leading to thrombosis and ultimately a stroke or a heart attack (a loss of 
brain or heart function, respectively, as a result of diminished oxygen supply) (reviewed 
in (3)). 
1.2.1 Development and progression 
One of the earliest events in the development of atherosclerosis (Figure 1.1) is the 
retention of lipoproteins in the subendothelial space which is followed by an 
inflammatory response ultimately manifesting in monocyte adhesion and transmigration 
through the endothelial layer and subsequent differentiation into macrophage and 
dendritic cells (reviewed in (4)). Low-density lipoproteins (LDL), which accumulate in 
the subepithelial space of the intima, are susceptible to oxidative modification by various 
reactive oxygen species (ROS) which are produced by cells in response to inflammatory 
mediators. The cellular sources of ROS in the vessel wall include resident macrophages, 
smooth muscle cells (SMC), dendritic cells, T-cells, neutrophils and other leukocytes. 
Oxidatively modified LDL (oxLDL) is taken up by these cells, which transforms them 
into the lipid-laden foam cells (Figure 1.1); these cells express a plethora of pro-
inflammatory mediators. Further progression of an atherosclerotic plaque is characterised 
by the recruitment of SMC from the media layer to the plaque area, under the influence of 
pro-inflammatory cytokines expressed by highly active foam cells. During this process a 
fibrous cap is also formed at the surface of the plaque. In addition, the plaque becomes 
more complex as activated SMC secrete extracellular matrix components such as 
collagen, fibronectin, elastin and laminin. Cell proliferation and an increase in 
extracellular matrix contribute to the plaque growth and a consequential narrowing of the 
blood vessel lumen. Eventually, calcified fibrous plaques can be formed, with a necrotic 
core consisting of cell debris and cholesterol crystals. At this stage the atherosclerotic 
plaque can be unstable and prone to rupture, leading to the formation of a thrombus 
which impedes blood flow resulting in a stroke or myocardial infarction. In addition, a 
thrombus can dislodge, become embolic and travel to a distant part of body through the 
vasculature, where it may occlude a narrowed artery (due to atherosclerosis), leading to 
tissue necrosis, the extent of which depends on the size of the artery. 
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Figure 1.1 Current model for atherosclerosis development 
 
1.2.2 Risk factors 
Major risk factors for atherosclerosis (also known as traditional risk factors) include 
arterial hypertension, smoking, obesity, sedentary lifestyle, elevated levels of LDL in the 
blood and elevated total cholesterol levels (5). These traditional risk factors have been 
successfully utilised as therapeutic targets, although their role as prognostic biomarkers of 
cardiovascular events remains limited (6). One example is the use of levels of blood LDL 
as a predictive biomarker for cardiovascular disease (CVD). The role of LDL in the 
initiation of atherosclerosis has been extensively studied in the past 50 years, and 
although lipid lowering therapies have helped to reduce cardiac events to some extent, a 
significant proportion of people suffering from coronary artery disease do not have 
markedly elevated levels of LDL. In contrast, people with coronary artery disease tend to 
have consistently increased markers of inflammation (e.g. C-reactive protein (CRP) and 
interleukin-6 (IL-6)) (7), which is an emerging risk factor. This has led to the exploration 
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of alternative strategies to prevent and combat atherosclerosis, including the use of anti-
inflammatory agents (8). 
 
Although the etiology and pathogenesis of atherosclerosis are very complex and by no 
means completely understood, it is now accepted that atherosclerosis is primarily a 
chronic inflammatory disease (9-12). To this end, there is plentiful evidence of the 
presence of systemic inflammation in all conditions which are considered as traditional 
risk factors for atherosclerosis, including hypertension (13), obesity (14), smoking (15) 
and physical inactivity (16, 17). Therefore, understanding the mechanisms of 
inflammation, and its function and consequences in the development of atherosclerosis, is 
of the utmost importance. This has been demonstrated in a significant number of recent 
studies, investigating various aspects of atherosclerosis-related inflammation (18-21).   
1.3 Inflammation 
Inflammation is a defence mechanism which enables the host organism to respond to 
injury (toxic, infectious, traumatic or autoimmune) (22). The inflammatory response is 
initiated by the release of numerous inflammatory mediators and chemoattractants, 
including cytokines, chemokines and eicosanoids, in the extracellular space. This is 
followed by the migration of polymorphonuclear (PMN) leukocytes through the blood 
vessels to the damaged area. The outcome or resolution of acute inflammation is 
characterised by the destruction of the pathogen by leukocytes, which phagocytose the 
invading pathogen, and subsequent repair of the damaged tissue. A failure in the 
resolution of inflammation results in chronic inflammation. The sources of inflammation 
can be both exogenous and endogenous, as detailed in Scheme 1.1. 
 
During inflammation caused by infectious agents, PMN leukocytes recruited to the 
damaged area become activated and secrete the content of their granules in an attempt to 
destroy the pathogen; these include various reactive oxygen and nitrogen species (ROS 
and RNS, respectively), elastase, cathepsin G and proteinase 3 (23). This also results in 
local tissue damage as the oxidants secreted from the storage granules do not discriminate 
between the pathogen and the surrounding healthy tissue (24). Normally, once 
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elimination of a pathogen has occurred, further PMN leukocyte recruitment is inhibited 
by lipoxins, followed by monocyte migration to the site of damage to initiate tissue repair 
(reviewed in (25)). 
 
Other types of inflammatory processes, not associated with infection, are not as well 
characterised and understood as infectious inflammation. The chronic inflammatory 
process is believed to be a response of the endothelium to atherosclerosis risk factors (26) 
(also described in Section 1.2.2). The involvement of inflammation in the pathogenesis of 
atherosclerosis is supported by the uptake of leukocyte oxidant-modified LDL, by 
macrophages in the vessel wall, with the subsequent formation of cholesterol-rich foam 
cells, a hallmark of atherosclerosis (27). 
  
 
Scheme 1.1 Classification of inflammatory sources 
PAMPs – pathogen-associated molecular pattern; ECM – extracellular matrix (taken from 
(25)) 
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1.3.1 Neutrophils and the “oxidative burst” 
Neutrophils are the primary effector cells of the immune defence response (28). 
Neutrophils rapidly respond to stimuli from the invading pathogens or other possible 
threats to the host organism (12). Upon activation, neutrophils ingest the pathogen, 
forming a phagosome (membrane-bound vacuole) where a chain of events termed ―the 
oxidative burst‖ takes place (Scheme 1.2). 
During the oxidative burst, the contents of the primary granules are either emptied 
intracellularly into the phagosome, or released extracellularly (e.g. into the blood or 
extracellular matrix) (29). This extracellular secretion has been linked to surrounding 
tissue damage (30). At the same time, activated membrane bound nicotinamide adenine 
dinucleotide phosphate (NADPH)-oxidase (NOX) uses NADPH, originating from the 
pentose phosphate pathway, to reduce O2 to superoxide (O2
•-
), which, in turn, can be 
converted spontaneously or catalytically (via superoxide dismutase (SOD)) to hydrogen 
peroxide (H2O2). Neutrophils, monocytes and some tissue macrophages release the heme 
enzyme MPO, which uses H2O2 as a cofactor for the formation of powerful bactericidal 
and bacteriostatic oxidants from halide and pseudohalide ions at physiological pH 
(reviewed in (1, 29)). These ions include chloride (Cl
-
), bromide (Br
-
) and thiocyanate 
(SCN
-
), which form HOCl, HOBr and HOSCN, respectively. MPO can also utilise iodide 
(I
-
) to produce hypoiodous acid and react with nitrite (NO2
-
) to generate NO2
•
 (reviewed 
in (31)). 
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Scheme 1.2 Schematic representation of MPO participation in the “oxidative burst” 
(adapted from (32)) 
1.3.2 Myeloperoxidase (MPO) 
Myeloperoxidase (MPO) is a heme enzyme contained in the primary granules of PMN 
leukocytes (neutrophils, monocytes and some tissue macrophages) (1). Activated MPO, 
secreted into phagosomes and/or released extracellularly, is a complex heme glycoprotein 
with molecular mass ~150 kDa. Biosynthesis of MPO begins during myelocyte 
differentiation in the bone marrow, and is completed by the time the mature granulocytes 
and monocytes are released into the blood (33, 34).  
 
Depending on the availability of substrates (including H2O2, O2
•-
, nitric oxide radical 
(NO
•
), halides, SCN
-
, tyrosine, urate, and ascorbate (35)), MPO is detected in various 
intermediate oxidation states, with ferric MPO (MPO Fe(III)) being the ground state of 
the enzyme. MPO Fe(III) (Figure 1.2) reacts readily with H2O2 (formed by the oxidative 
burst of the activated leukocytes as well as other processes) producing the highly reactive 
species, Compound I (MPO Fe(IV=O) with a porphyrin radical cation). Compound I can 
be converted back to the resting state by one of two processes (detailed in Figure 1.2). 
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The ―halogenation cycle‖ involves a single two-electron reduction reaction in the 
presence of physiological concentrations of halide and pseudohalide ions, to form 
(pseudo)hypohalous acids. Alternatively, the ―peroxidase cycle‖ involves the formation 
of a second intermediate (Compound II) by one-electron reduction. The Fe (III) ground 
state form is subsequently reached following a second one-electron reduction of the metal 
centre (36). 
 
MPO-derived oxidants (especially HOCl, HOBr and HOSCN) are highly reactive species 
that react rapidly with sulfur and nitrogen atoms which are abundant in proteins and on 
other targets such as DNA and phospholipid head groups. Such reactivity allows them to 
destroy invading pathogens quickly and effectively (32). 
 
 
                 
Figure 1.2 The catalytic cycle of MPO  
(adapted from (37)) 
 
Halogenation cycle
Peroxidase cycle
10 
 
1.3.3 The role of MPO in inflammation-mediated diseases 
Despite being an essential agent in the innate immune system, MPO has also been 
implicated in the pathogenesis of a number of inflammation-associated diseases such as 
cystic fibrosis, rheumatoid arthritis, kidney disease, atherosclerosis and CVD, asthma, 
neurodegenerative diseases and some cancers (reviewed in (1)). 
 
A number of studies suggest that MPO is able to penetrate the endothelial barrier through 
protein (including albumin)-mediated transcytosis. This process occurs via albumin-
binding proteins, located in the caveolae of endothelial cells (38). In the subendothelial 
space, MPO can cause oxidative modification of extracellular matrix proteins, 
proteoglycans and glycosaminoglycans, which results in tissue remodelling at sites of 
inflammation (39). 
 
During inflammation, the level of plasma MPO is increased (40-42). MPO, being a 
cationic protein, can bind to negatively charged extracellular material (particularly 
glycosaminoglycans) or cell membranes, and, if the right substrate is available, can cause 
oxidative damage to the tissue at the site of inflammation (39). 
1.3.3.1 MPO and atherosclerosis 
There is considerable evidence to support a major role for MPO in atherogenesis (34, 43-
46). Firstly, it has been shown by immunohistochemistry and by mass spectrometry that 
MPO and MPO-derived products, including chlorinated protein residues (e.g. 3-
chlorotyrosine (3-Cl-Tyr)), chlorinated DNA/RNA bases, and chlorinated lipids, are 
present in atherosclerotic plaques but not in the normal intima (47, 48). Furthermore, 
active MPO has been detected in shoulder regions of atherosclerotic plaques in human 
arteries, the place most susceptible to rupture (47). Analysis of apolipoprotein A-I (the 
main protein component of cardioprotective high-density lipoproteins (HDL)), extracted 
from atherosclerotic lesions or from plasma of patients suffering from CVD, has shown 
elevated levels of 3-Cl-Tyr when compared to healthy individuals (49). Such 
modifications may be important in the pathogenesis of CVD, since oxidatively-modified 
HDL has impaired ability with respect to cholesterol removal from lipid-laden 
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macrophages in the arterial wall (50, 51). Oxidatively-modified LDL, an established 
trigger of atherosclerosis development, has been shown to be produced upon reaction 
with species generated by MPO (52). Additionally, it has been shown that by consuming 
endogenous NO
•
 MPO might contribute to the development of endothelial dysfunction. 
As such, MPO has been reported to increase the catabolism of NO
•
 during myocardial 
ischemia and reperfusion (53). 
 
Increased levels of MPO have been reported to be a predictor of adverse outcomes in 
patients with acute coronary syndromes (43, 54), heart failure (55) and chest pain (45, 56) 
as well as an independent prognostic marker of long-term post-myocardial infarction 
mortality (57). 
 
Conversely, there is evidence for protective function of MPO in atherosclerosis in MPO-
deficient mice (58). Brennan et al showed that MPO-deficient mice, when fed a high-fat 
diet, exhibit >50% increase in lesion formation compared to wild type mice. The authors 
conclude that MPO-deficient animals might be a powerful model for studying the effects 
of MPO in various inflammation-mediated pathologies. 
1.4 Hypohalous acids and their reactions with biological targets  
Various inflammatory processes, including atherosclerosis, involve the formation of the 
MPO-derived hypohalous acids, HOCl and HOBr as well as the pseudohypohalous acid, 
HOSCN. Their origin and role in human physiological and pathological processes is 
discussed in the following sections. 
1.4.1 Hypochlorous acid 
Hypochlorous acid (HOCl, the active component of household bleach) is a strong oxidant 
produced by the catalytic oxidation of Cl
-
 by H2O2 and MPO (Reaction 1.1). MPO is the 
only enzyme with a high enough redox potential to oxidise Cl
-
 under physiological 
conditions (59, 60). Physiological concentrations of Cl
-
 ions (100 – 140 mM in plasma) 
are considerably higher than other halides (Br
-
, I
-
) and pseudohalides (SCN
-
) (20 – 100 
µM) (61), which are present at micromolar levels. There is substantial evidence that 
12 
 
HOCl is one of the major products used by cells to kill invading pathogens (bacteria, 
viruses, parasites) inside phagosomes (reviewed in (62), see also section 1.3).  
 
H2O2 + Cl
-
 + H
+    
           HOCl + H2O                                                            (Reaction 1.1)  
 
Due to the highly oxidising nature of HOCl, it is not only bactericidal, but may also be 
cytotoxic to the neutrophils that release MPO due to increased apoptosis following 
activation of these cells. The primary targets of HOCl-induced oxidation in vivo are likely 
to be proteins due to their high abundance; recent studies suggest that the reactivity of 
HOCl is greatest with Met and Cys residues (3.8 x 10
7
 M
-1
s
-1
) followed by cystine, His, 
Trp, Lys, Tyr, Arg, backbone amide, Gln and Asn (Figure 1.3) (1). 3-Cl-Tyr, a product of 
the reaction of HOCl with the aromatic side-chain of Tyr, is widely used as a specific 
marker of HOCl mediated damage to proteins (63). Cys (and to a lesser extent Met) 
residues are often present at the active sites of various enzymes and also are important, in 
the formation of intracellular disulfide bonds (64, 65). Oxidative damage through the 
action of HOCl may therefore be detrimental to enzyme activity and protein folding (66). 
 
HOCl-modified LDL particles have been detected in human atherosclerotic lesions along 
with active MPO (47, 67, 68). The protein component of LDL (apolipoprotein B-100), 
rather than phospholipids, cholesterol esters and triglycerides, has been shown to be a 
major kinetic target for HOCl (69).  
 
Other biological targets of HOCl include the double bonds in cholesterol and unsaturated 
fatty acids, with these resulting in the formation of chlorohydrins (RCH=CHR´ + HOCl 
 RCHCl—CHOHR´) that can be potentially damaging to the lipid bilayer of cell 
membranes; these reactions are however slower than with most protein side chains (69). 
1.4.1.1 Chloramines 
HOCl reacts rapidly with nitrogen-containing functional groups, such as amines, resulting 
in the formation of highly reactive chloramines and dichloramines (RNHCl and RNCl2, 
respectively) (70-72). Chloramines are formed on α-amino groups of free amino acids, 
MPO 
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the amine groups on the side-chains of Lys, His and Arg side-chains; DNA, RNA and 
free nucleotides, and on glycosaminoglycans and proteoglycans. 
 
Chloramines retain the oxidising capacity of HOCl and therefore can mediate significant 
damage to cells and tissues (73). Indeed, chloramines are regarded as more detrimental to 
cells than HOCl, due to their ability to penetrate cell membranes and the selectivity of 
their reactions with low pKa thiols (32, 74). It has been shown that chloramines in small 
molecules and proteins react readily with SCN
-
 to produce hypothiocyanate (
-
OSCN) and 
a parent amine; 
-
OSCN then can also react with chloramines (75). Therefore, the damage 
caused by chloramines to proteins can be repaired to some extent by physiological levels 
of SCN
-
 and HOSCN; however, HOSCN can also be potentially harmful to proteins (75); 
these possibilities are discussed further below. 
 
                         
Figure 1.3 Rate constants for the reaction of HOCl and HOBr with protein 
components. 
α-NH2 – alpha amino; Arg – arginine; Asn – asparagine; BB – backbone amide; Cys – 
cysteine; Gln – glutamine; His – histidine; Lys – lysine; Met – methionine; -S-S- – 
cystine; Trp – tryptophan, Tyr - tyrosine (adapted from (1)). 
HOCl HOBr
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1.4.2 Hypobromous acid 
Hypobromous acid (HOBr) is the major product of the reaction of eosinophil peroxidase 
(EPO), the oxidoreductase present in eosinophils. EPO mediates extracellular elimination 
of large invading pathogens such as helminthic parasites (76) (Reaction 1.2). It has been 
shown that there is a correlation between asthma severity and blood levels of EPO (77); 
however, the increased levels of HOBr do not appear to correlate significantly with lung 
function in asthmatic patients (78). HOBr is also formed by MPO to a limited extent  
(5 - 15%, (79)). 
 
H2O2 + Br
-
 + H
+
                    HOBr + H2O     (Reaction 1.2) 
 
HOBr is almost as powerful an oxidant as HOCl, and as such is also capable of killing 
parasites and bacteria effectively (80). However, as with HOCl, HOBr is not specific and 
does not discriminate between the invader and host tissue, and therefore can be damaging 
when misplaced or excessive production occurs (81). 
 
HOBr, similarly to HOCl, preferentially reacts with proteins, however, the reaction rates 
with various components of proteins are different from HOCl (Figure 1.3).  
1.4.3 Thiocyanate and hypothiocyanous acid 
The pseudohalide anion SCN
-
, originates from cyanide or cyanogenic compounds in food 
stuffs including broccoli, cauliflower and cabbage as well as other sources (see below). It 
is normally present in human physiological fluids such as tears, saliva and milk in 
millimolar concentrations, and in plasma at micromolar levels (10 – 100 μM) (82). The 
reason why SCN
-
 is called a ‗pseudohalide‘ is because although not a halide, SCN- reacts 
in a similar manner to halides in a number of peroxidase-catalysed reactions (83). 
 
Studies have shown that SCN
-
 is a preferred substrate of MPO, as the specificity 
constants for Cl
-
, Br
-
 and SCN
-
 are 1:60:730, respectively (84). As such it has been 
reported that as much as 50% of the H2O2 consumed by MPO under physiological 
EPO/MPO 
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conditions is used to oxidise SCN
-
, with the rest of the H2O2 oxidising primarily Cl
-
 
(~45% of H2O2) and, to a lesser extent, Br
-
 (~5% of H2O2 consumed) (84). 
 
SCN
-
 levels in biological fluids vary markedly, with this influenced by smoking, diet and 
drugs (37). It is well established that smoking independently increases the risk of certain 
cancers, CVD and stroke, amongst other adverse events (85, 86). Tobacco combustion 
releases hydrogen cyanide (HCN) and increases blood cyanide (CN
-
) concentrations (87); 
subsequent detoxification by the enzyme rhodanese generates SCN
- 
(87, 88). SCN
-
 levels 
in children not exposed to cigarette smoke are ~20 M (89), with ~40  24 M detected 
in adult non-smokers, and ~130  31 M in heavy smokers (90). SCN- levels can also be 
elevated by consumption of plant-derived cyanogenic alkaloids and glycosides (91), drug 
exposure (e.g. sodium nitroprusside) (92), and metabolism of organic compounds and 
solvents (e.g. acetonitrile) (93). 
 
Hypothiocyanous acid (HOSCN) and its conjugate anion hypothiocyanite (
-
OSCN), the 
major products of SCN
-
 oxidation by the MPO/H2O2 system, are mild oxidants with 
bacteriostatic properties (81). At neutral pH 
-
OSCN is the major form of this oxidant  
(pKa = 5.3) (31). HOSCN is also a major product of other peroxidases, including EPO, 
lactoperoxidase (LPO), gastric peroxidase (GPO) and salivary peroxidase (SPO) 
(reviewed in (94)).  
 
HOSCN is also generated under physiological conditions by the fast non-enzymatic 
reaction of HOCl and HOBr with SCN
-
 (Reaction 1.3); thus, it has been proposed that 
SCN
-
 could be a major scavenger of these more potent products of MPO/H2O2 (95), 
excessive production of which could be detrimental to host tissues. To this end, 
potentially protective effects of SCN
-
 have been demonstrated against H2O2 induced 
apoptosis in HL-60 human leukemia cells, where the addition of SCN
-
 resulted in the 
inhibition of apoptosis (96). A recent study has also shown that human lung epithelial 
cells (Calu-3), mouse neuroblastoma cells (Neuro2a), mouse pancreatic β cells, and 
human aortic endothelial cells were protected from MPO-associated damage by           
100 – 400 µM SCN- (97). 
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HOX + SCN
-
            X
-
 + OSCN
-
 + H
+ 
    ( X = Cl
-
 or Br
-
)                              (Reaction 1.3) 
  
Although HOSCN is a less powerful and less reactive oxidant than HOCl or HOBr, it is 
considerably more specific, oxidising primarily sulfhydryl groups on proteins and low-
molecular mass thiols (rate constants range 10
4
 - 10
6
 M
-1
s
-1
) (35, 98, 99). The decreased 
reactivity of HOSCN allows it to pass through mammalian cell membranes and cause 
oxidative modifications to important intracellular targets, such as protein thiol groups and 
glutathione (GSH) (100) (Reaction 1.4). Indeed, it has been shown that HOSCN can 
induce apoptosis and necrosis in murine macrophage-like cells (J774A.1) and human 
coronary artery endothelial cells (HCAEC) at lower concentrations than HOCl and HOBr 
(101). HOSCN and other SCN
-
-derived oxidants may, therefore, influence the activity of 
a number of thiol dependent enzymes with catalytic Cys residues; examples include 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), glutathione-S-transferase (GST), 
protein tyrosine phosphatises (PTP), membrane adenosine-5'-triphosphatases (ATPases), 
and creatine kinases (CK) (102-104).  
 
HOSCN + RSH           RS-SCN + H2O                                                        (Reaction 1.4) 
 
HOSCN rapidly decomposes at physiological pH, forming various species including 
cyanate (
-
OCN) - an anion believed to be, at least partially, responsible for the protein 
carbamylation detected in CVD (15) (Reaction 1.5). Cyanate is also a minor product of 
the MPO-catalysed oxidation of SCN
-
 (Reaction 1.6) (15). 
 
RNH2 + H
+
 + 
-
OCN         RNHC(=O)NH2                                                    (Reaction 1.5) 
SCN
-
 + H2O2          HOSCN + 
-
OCN
 
                                                               (Reaction 1.6) 
  
Carbamylation of Lys by 
-
OCN results in the formation of homocitrulline (Scheme 1.3) 
which serves as a non-specific biomarker of SCN
-
-derived oxidation in vivo; however, its 
formation can also occur via alternative pathways which do not include 
-
OCN formed by 
MPO catalysed reactions, such as urea decomposition (reviewed in (94)). 
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Smoking is a major risk factor for atherosclerosis (105), and elevated levels of SCN
-
 
found in smokers may contribute to oxidative modification of LDL, rendering it 
atherogenic (106, 107). In contrast to HOCl, a study (108) has shown that MPO-derived 
HOSCN may preferentially oxidise lipid moieties of LDL but not the apoB-100 protein. 
Moreover, it has been shown that in the presence of Cl
-
, MPO preferentially uses SCN
-
 as 
a substrate, since increasing concentrations of Cl
-
 failed to suppress SCN
-
-induced lipid 
oxidation (108). However, it is possible that any HOCl generated by MPO in these 
experiments, reacted rapidly with SCN
-
 to give HOSCN thereby explaining the lack of 
effect of Cl
-
 (as per Reaction 1.3).  
                     
Scheme 1.3 Schematic illustration of protein carbamylation by cyanate 
 (adapted from (15)) 
 
1.5 Antioxidants and antioxidant systems 
Antioxidants are substances that protect cells against oxidative damage. There is no 
universal classification of antioxidants; the system most commonly used is based on the 
molecular mass of an antioxidant species (3). The first group in this classification 
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includes low-molecular mass antioxidants: some amino acids, polyamines, urea, uric acid, 
GSH, bilirubin, ascorbate, α-tocopherol and β-carotene. These can be further divided into 
subclasses, e.g. hydrophilic and lipophilic (Figure 1.4). The second group includes high-
molecular mass species such as enzymes (SOD, catalase, glutathione peroxidase (GPx), 
glutathione reductase (GR), thioredoxin reductase (TrxR), peroxiredoxins (Prxs), etc.) 
and metal binding proteins (albumins, transferrin, ferritin, lactoferrin) (Figure 1.4). The 
following sections discuss these antioxidant systems further. 
 
 
Figure 1.4 Simplified classification of intracellular antioxidants.  
Abbreviations: +e
-
 – electron transfer; GPx – glutathione peroxidase; GR – glutathione 
reductase; Prx – peroxiredoxins; SOD – superoxide dismutase; MM – molecular mass 
1.5.1 Low-molecular mass antioxidants 
1.5.1.1 Glutathione 
The most abundant low-molecular mass antioxidant in cells is glutathione (L-γ-glutamyl-
L-cysteinyl-glycine, GSH), a tripeptide with molecular mass of 307 Da (Figure 1.5 A). 
GSH synthesis from its parent amino acids glutamine, Cys and Gly is catalysed by γ-
glutamyl-cysteine synthase and glutathione synthase through the formation of the unique 
peptidic γ-bond which is resistant to degradation by aminopeptidases (109). 
+e-
Lipophilic:
ubiquinone, tocopherol, vitamin A, 
carotenoidsLow MM
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High MM
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Figure 1.5 Structure of (A) reduced (GSH) and (B) oxidised (GSSG) glutathione. 
 
GSH is synthesised in the liver and then transported to various organs and tissues where it 
reduces protein disulfide bonds, α-tocopherol and dehydroascorbic acid, and is 
consequently converted to its oxidised form, GSSG (Figure 1.5 B). In the liver, GST 
carries out the conjugation of GSH (S-glutathionylation) with various electrophilic 
compounds which are then excreted in urine (110). Post-translational modification of 
proteins by S-glutathionylation plays an important role in controlling the activity and 
transcription of a number of enzymes and extracellular proteins. Glutathionylation of Cys 
residues of proteins (especially active site Cys) is believed to protect them from further 
oxidation (hyperoxidation) by numerous oxidants, particularly thiol-specific oxidants 
such as HOSCN. The extent of S-glutathionylation is therefore often increased under 
conditions of oxidative stress (111). Subsequent de-glutathionylation can be catalysed by 
glutaredoxins (Grx) (discussed in Section 1.5.2.7), abundant low-molecular mass 
enzymes that are uniquely suited for the reduction of S-glutathionylated proteins (112). In 
addition, GSH can also participate in the removal of H2O2 and other organic peroxides 
with the formation of GSSG via the reactions catalysed by GPx (113, 114), some Prxs 
(115, 116) and GST (117). 
  
GSH is present intracellularly at 5 - 10 mM (118), and often provides the first line of 
defence against oxidative damage. Decreased levels of GSH in tissues have been detected 
SH
20 
 
in a number of chronic degenerative diseases including Alzheimer‘s and Parkinson‘s 
diseases (109), and CVD (atherosclerosis) (119, 120). Conversely, increased levels of 
GSH can promote survival of cancerous cells and impart resistance to chemotherapeutic 
drugs (reviewed in (121)). 
 
GSH is present mainly in the reduced state in cells, with the GSH:GSSG ratio reported to 
be up to 300:1 under physiological conditions (122). The GSH:GSSG ratio is an indicator 
of cell redox state, and an important determinant of redox potential which correlates with 
a biological status of a cell. Redox potentials can reach -240 mV during cell proliferation, 
-200 mV at differentiation and -170 mV during apoptosis (123). 
 
The GSH redox status is defined as the fraction GSH/[GSH+GSSG] and can decrease 
significantly under conditions of oxidative stress, through the oxidation of GSH by 
reactive oxygen species, including MPO-derived HOCl (124-126). GSH:GSSG is often 
referred to as the main redox buffer of the cell due to high abundance of GSH 
intracellularly (122).  
1.5.1.1.1 Other low pKa SH-compounds 
Apart from GSH, there are other important low-molecular mass thiols with antioxidant 
properties, including Cys, cystine (oxidised Cys) and lipoic acid (127). Thiol containing 
compounds have been proposed to play a leading role in protecting cells from hydroxyl 
radicals (OH
•
). Because of its short half life and small diffusion radius in biological 
systems, OH
•
 is not inactivated by antioxidant enzymes and is therefore able to exert 
cytotoxic and mutagenic effects on cells (128). 
 
Thiol-containing species, including Cys, GSH, Met, human serum albumin and SCN
-
 (35) 
are also powerful scavengers of HOCl. 
1.5.1.2 Ascorbate 
The replenishment of ascorbate through the reduction of dehydroascorbic acid plays an 
important role in antioxidant defence systems because ascorbic acid is one of the major 
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water-soluble low-molecular mass antioxidants (Figure 1.6). Unlike the majority of 
animals, humans and other primates cannot synthesise ascorbate, but have to obtain it 
from dietary sources. 
 
                          
Figure 1.6 Structure of (A) ascorbic and (B) dehydroascorbic acids. 
 
The antioxidant mechanism of ascorbate involves the donation of one electron and/or 
proton from ascorbate to an oxidant (mainly 1e
-
 oxidants) with the formation of 
(mono)ascorbyl free radical (AFR) and reduced oxidant (Reaction 1.7) (reviewed in (3).  
 
RO
•
 + Asc
-
            ROH + Asc
•-
                                                                   (Reaction 1.7) 
AFR readily dismutates to ascorbate and dehydroascorbic acid (DHA). The recycling of 
ascorbate occurs through the reduction of AFR by TrxR and DHA reduction by GSH, and 
GSH- and NADPH-dependent enzymes following DHA uptake into cells via glucose 
transporters (129), (130). In the case of a significant decrease of intracellular GSH levels, 
the TrxR1-dependent system becomes an alternative mechanism of DHA reduction; 
however, not all cell types utilise this mechanism (131). 
 
Ascorbate effectively reduces the α-tocopheroxyl radical, peroxides and the O2
•-
 (132). In 
addition, it has been shown that ascorbate diminishes HOCl-induced oxidation of LDL 
and plasma proteins (reviewed in (3)), and decreases the risk of atherosclerotic plaque 
development by preventing the formation of lipid hydroperoxides (133). 
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1.5.1.3 Urate, bilirubin, α-tocopherol and β-carotene  
Other low-molecular mass oxidants have been shown to play important roles in 
antioxidant defence. Urate, a major product (at neutral pH) of purine metabolism, can be 
present at high concentrations in the blood (but not intracellularly) of humans due to the 
absence of the urate metabolising enzyme, urate oxygenase (134). Urate has been shown 
to neutralise peroxynitrite (ONOO
-
), ozone, and scavenge OH
•
 and peroxyl radicals 
directly (135), but does not react particularly rapidly with HOCl. 
 
Bilirubin is an end-product of heme catabolism in mammals; as such, it is produced in 
significant amounts (reviewed in (3)). Although bilirubin by itself is a lipophilic 
compound, its predominant form is albumin bound and therefore primarily water-soluble. 
Its antioxidant properties include the inhibition of LDL and plasma lipid peroxidation, 
and α-tocopheroxyl radical reduction (136). 
 
Alpha-tocopherol is an important lipophilic antioxidant located primarily in cell 
membranes and lipoproteins. It has been shown that α-tocopherol effectively scavenges 
lipid peroxyl radicals. The resulting α-tocopheroxyl radical can be reduced back to the 
active form by ascorbate and bilirubin, suggesting interplay between water- and lipid-
soluble antioxidants (137). 
 
Although β-carotene (vitamin A) is a potent scavenger of singlet oxygen and has been 
shown to reduce the risk of CVD and cancer, several studies have shown no, or a 
deleterious effect of β-carotene supplementation on CVD prevention and lung cancer 
incidents in smokers (reviewed in (138, 139)). 
1.5.1.4 Selenium 
Selenium is an essential trace element in human nutrition that can be incorporated from 
the diet into proteins as selenomethionine and selenocysteine (140-142). The 
incorporation of selenomethionine is random and non-specific, and occurs only at high 
levels of selenium or selenomethionine intake. On the other hand, incorporation as 
selenocysteine (Sec, the 21
st
 coded amino acid) is highly specific and requires a unique 
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Sec tRNA (143). Selenium is also found in vivo in a range of other low-molecular mass 
compounds, including selenite, methylselenol or selenomethylcysteine (142). The most 
biologically important form of selenium is Sec which is found in the active sites of a 
number of enzymes (144). Examples of such enzymes include GPx and TrxR, which are 
discussed in Sections 1.5.2.8 and 1.5.2.6. 
 
Selenium is related to sulfur, being in the same group in the periodic table, but selenium 
is a much better nucleophile; the selenium-containing analogues of thiols, selenols (Se-H, 
e.g. Sec), are more acidic (pKa = 5.3) and therefore more reducing than thiols (145). This 
property is employed by GPx to quickly reduce H2O2, at the expense of GSH, before it 
can react with other cellular targets; by this process signal transduction and damage 
caused by H2O2 is controlled (146). Thioredoxins (Trxs), which are important enzymes 
regulating functions including transcription, protein folding and degradation, DNA 
synthesis and repair, and cell-cell communication, are maintained in the reduced form by 
the seleno enzyme TrxR (147).  
 
Apart from GPx and TrxR, a large number of other seleno proteins exist. Examples 
include thyroid hormone deiodinases, methionine sulfoxide reductase B1, and 
selenoprotein P (140). A number of cell and animal studies have shown that under the 
conditions of dietary selenium deprivation, TrxR (142, 148, 149) and GPx (149) activities 
decrease, whereas supplementation of selenium causes an increase in the activities of 
these enzymes. These studies show the importance of selenium in human metabolism. 
 
In contrast to the beneficial effects of selenium, there is a large body of data related to 
selenium cytotoxicity (reviewed in (150)). Excessive production of certain products of 
selenium metabolism, such as hydrogen selenide, selenotrisulfide and methylselenol, can 
lead to various adverse outcomes, including the induction of apoptosis, cell cycle arrest 
and DNA damage (151). These properties of selenium have been studied in the field of 
cancer research in order to develop effective selenium containing chemotherapeutics 
(152). 
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1.5.2 High-molecular mass antioxidants 
1.5.2.1 Superoxide dismutase 
A key enzyme of the cellular antioxidant defence system is superoxide dismutase (SOD), 
which catalyses the dismutation of O2
•-
 to H2O2 and O2 (Reaction 1.8). 
 
O2
•-
 + O2
•-
 + 2H
+ 
         H2O2 + O2   
 
                                                            (Reaction 1.8) 
 
There are several isoforms of SOD which are grouped according to the metal ions present 
in the protein: Cu/Zn-SOD (intracellular SOD1 and extracellular SOD3), Mn-SOD 
(SOD2, mitochondrial), Fe-SOD (found in bacteria and plants) and Ni-SOD 
(prokaryotic). Cu/Zn-SOD consists of two identical subunits of 16.3 kDa each and is 
present in all eukaryotic cells (153). In most mammalian cells it is mainly found in the 
cytosol, though it is also found in the mitochondrial intermembrane space, in the nucleus 
of neurons and also in small amounts in lysosomes and peroxisomes (154). Mn-SOD is 
present in liver and mitochondria in the vicinity of anion channels; however its synthesis 
also occurs in the cytosol. Mn-SOD consists of four 20-kDa subunits with a Mn in the 
active centre of each subunit (155). 
 
The SOD isoforms described above are all intracellular enzymes that are quickly 
degraded in extracellular fluids (blood plasma, lymph, synovial fluid). However, an 
extracellular form of SOD (SOD3) exists: this 120-kDa Cu/Zn enzyme binds to heparan 
sulfate of the endothelial glycocalyx, locally protecting it from free radical damage. SOD 
significantly increases the rate of O2
•-
 dismutation; however, despite the high specificity 
of the enzyme, under certain conditions Cu/Zn-SOD can react with H2O2 and thus act as a 
pro-oxidant (110).  
 
Hydrogen peroxide, which is formed as a result of disproportionation of O2
•-
, is removed 
by other antioxidant enzymes, including catalase, Prxs and GPx. 
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1.5.2.2 Catalase 
Catalase is a ~240 kDa chromoprotein, comprising four 60 kDa subunits with one heme 
group each. Catalase is localised mostly in peroxisomes and to the lesser extent in 
microsomes, as well as in very limited amounts in the cytosol. It has been reported that 
catalase does not have a high affinity for H2O2 and cannot effectively decompose this 
compound at the low concentrations that are found in the cytosol. However, in 
peroxisomes, where H2O2 levels are high, catalase actively reduces H2O2 to water and 
molecular oxygen in a two-step reaction (156) (Reactions 1.9a and 1.9b). 
 
Fe(III)-Cat + H2O2       O=Fe(IV)-Cat + H2O         (Reaction 1.9a) 
O=Fe(IV)-Cat + H2O2      Fe(III)-Cat + H2O (Reaction 1.9b) 
          
In its oxidised form catalase functions as a peroxidase with ethanol, methanol, formate, 
formaldehyde and other donors of hydrogen as potential substrates (157).  
 
The activities of catalase and SOD may be coordinated with each other, possibly through 
the switching of the direction of electron current from one transport chain to the other. 
Under such conditions, SOD and catalase may act as a part of a unified system that 
utilises oxygen in different cell compartments (158). 
1.5.2.3 Thioredoxin- and glutathione-dependent enzyme systems 
Redox-dependent processes play a central role in the functional activity of many proteins 
and participate in the regulation of cell proliferation, differentiation and apoptosis. Redox 
proteins, the activity of which results from the redox-active amino acids, such as Cys or 
Sec residues, play a key role in thiol-disulfide regulation. Examples of such proteins are 
Trx and Grx. These multifunctional enzymes play an important role in the maintenance of 
intracellular redox homeostasis (Figure 1.7). Both systems protect cells against the 
destructive actions of oxidative stress such as intra- and intermolecular disulfide bond 
formation in proteins, oxidation of SH-groups to sulfonic acids and proteosomal 
degradation of proteins (159, 160). 
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Figure 1.7 Glutathione- and thioredoxin-dependent antioxidant systems. 
GPx – glutathione peroxidase; GR – glutathione reductase; Grx(SH)2/Grx-S2 – 
reduced/oxidised glutaredoxin; GSH – reduced glutathione; GSSG – oxidised glutathione, 
NADPH/NADP
+
 - reduced/oxidised nicotinamide adenine dinucleotide phosphate; 
Prx(SH)2/Prx-S2 – reduced/oxidised peroxiredoxins; Trx(SH)2/Trx-S2 – reduced/oxidised 
thioredoxin; TrxR – thioredoxin reductase; R - protein 
1.5.2.4 Peroxiredoxins (Prx) 
Peroxiredoxins (Prxs), which reduce H2O2, organic hydroperoxides and ONOO
-
, are a 
key part of cellular antioxidant defences (161). Prxs are members of a superfamily of 
seleno-independent peroxidases. Unlike Trxs (discussed below), most Prxs do not have 
an active di-Cys site that forms an intramolecular disulfide bond upon oxidation; 
however, they contain an easily oxidised Cys residue that can form intermolecular 
disulfide bonds. Depending on the number and origin of active Cys residues, the Prx 
family is commonly divided into three groups: typical 2-Cys (Prx1-Prx4), atypical 2-Cys 
(Prx5) and 1-Cys (Prx6) (162). All of them contain an active site Cys residue in the N-
terminal region; the Prx1-Prx4 isoforms have an additional conserved Cys at the C-
terminal region which is essential for catalytic function. Prx1-Prx5 use Trx as an electron 
donor whereas Prx6 uses GSH.  
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Reduction of H2O2 by all Prxs occurs through the formation of a sulfenic acid (Cys-SOH) 
from the active site Cys SH-group (163). The Prx1-Prx4-derived sulfenic acid then reacts 
further to form intermolecular disulfide bonds which are reducible by Trx (164) (Figure 
1.8). A similar mechanism occurs with Prx5; however the resulting disulfide bond is 
intramolecular, between Cys47 and Cys151 (165). In contrast, Prx6 uses low-molecular 
mass thiols, including GSH, as electron donors (166). In addition, Prx6 is able to reduce 
phospholipid hydroperoxides, as well as exhibiting phospholipase A2 activity (166).  
 
A number of human diseases associated with oxidative stress are accompanied by an 
elevated level of Prx expression. Such pathologies include neurodegenerative diseases 
(Alzheimer‘s and Parkinson‘s), atherosclerosis, various cancers and radiation-induced 
tissue damage (167-170). It has been proposed that cells induce the expression of Prxs in 
order to neutralise the increased levels of ROS generated under conditions of oxidative 
stress. As such, Prx1-knockout (KO) mice showed signs of premature aging in the form 
of hemolytic anemia and multiple tumors (fibrosarcoma, osteosarcoma, hepatocellular 
carcinoma, B- and T-lymphomas) (171). Prx6-KO mice, although they show normal 
development, are very sensitive to oxidative stress (172), whereas mice overexpressing 
Prx6 are resistant to oxidative stress damage under hyperoxic conditions (173). 
 
Apart from cellular protection from oxidative stress, Prxs have been shown to regulate 
H2O2-dependent redox-signalling processes. The basis for this Prx function lies in the 
peculiarity of the Prx catalytic cycle (Figure 1.8). Prx active site Cys residues are prone to 
hyperoxidation (i.e. the formation of sulfinic and sulfonic acid derivatives) upon 
treatment with higher than stoichiometric concentrations of H2O2 (174). Such sensitivity 
to its own substrate might seem limiting to the function of Prxs, however it appears to 
allow for a temporary local increase in H2O2 levels and associated signal transduction 
(175). Indeed, it has been shown that Prxs can regulate H2O2-induced oxidation and 
activation of stress-inducible mitogen-activated protein kinase (MAPK) (176). In 
addition, Prxs have been reported to regulate the activation of nuclear factor kappa-light-
chain-enhancer of activated B cells (NF-κB) (165, 177). Overexpression of Prx1 and Prx2 
has also been shown to cause a decrease in intracellular H2O2 generated in response to 
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tumour necrosis factor α (TNFα) (165), p53, epidermal growth factor (178) and 
thyrotropin (179).  
 
 
Figure 1.8 Catalytic cycle of typical 2-Cys peroxiredoxins (Prx1 – Prx4) 
Sp – peroxidatic Cys; Sr – resolving Cys; SpOH – sulfenic acid intermediate; SpO2H – 
sulfinic acid intermediate; SpO3H – sulfonic acid intermediate; TrxR – thioredoxin 
reductase; Trx – thioredoxin; NADPH - nicotinamide adenine dinucleotide phosphate. 
Adapted from (180). 
 
 
Prx1 is the most abundantly expressed of all Prxs; it is present in almost every tissue 
(normal tissue and malignant tumors) and several cellular compartments, including the 
cytosol, peroxisomes and nucleus (181). To this end, Prx5 is similar to Prx1 as it is also 
found in various organelles (cytosol, peroxisomes, mitochondria and to a lesser extent, in 
the nucleus), however, its tissue distribution is more limited (kidney transitional 
epithelium and alveolar epithelium) (182, 183). In contrast, other isoforms of Prxs are 
more restricted in their intracellular distribution; Prx2 is located in the cytosol and 
nucleus (163), Prx4 is present in lysosomes and cytoplasm (184), Prx3 is exclusively 
mitochondrial (163), whilst Prx6 has been only found in the cytosol (172). This wide 
distribution of Prxs suggests they play an important role in antioxidant defence at 
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strategic intracellular sites of ROS production (mitochondria, peroxisomes, lysosomes 
and cytosol). Although the reactions and efficiency of Prxs against peroxides have been 
studied extensively, an understanding of their reactivity with other ROS, including MPO-
derived oxidants, is currently lacking. 
1.5.2.5 Thioredoxins (Trx) 
Thioredoxin (Trx) is a multifunctional low-molecular mass protein containing an active 
thiol/disulfide region that plays a key role in the NADPH/TrxR/Trx/Prx system. To date, 
the only known isoforms of mammalian Trxs are cytosolic Trx1 and mitochondrial Trx2 
(185, 186). 
 
Human cytosolic Trx1 is a 12 kDa protein consisting of 105 amino acids that is found 
mostly in the cytoplasm, but is also present in the nucleus and plasma. The highly 
conserved active site sequence (Trp-Cys-Gly-Pro-Cys-Lys) of Trxs contains 2 active Cys 
residues (Cys32 and Cys35 in Trx1, Cys90 and Cys93 in Trx2), which are oxidised to 
intramolecular disulfides as a result of the transfer of two reducing equivalents to a 
substrate (187). Subsequently, the active site disulfide is reduced by NADPH-dependent 
TrxR. Unlike mitochondrial Trx2, cytosolic Trx1 contains 3 additional Cys residues, 2 of 
which (Cys63 and Cys69) form another thiol/disulfide pair (188). These additional Cys 
residues, especially Cys72, located near the active site, can be oxidised with the 
formation of disulfide-linked Trx dimers and loss of catalytic activity (189). The higher 
resistance to oxidation of Trx2 can be explained by the absence of the additional Cys 
residues, as well as by a greater abundance of Trx2 in metabolically active cells (190). 
 
Trxs participate in a number of important physiological functions, including growth 
promotion, mitogenic activity, prevention of apoptosis, regulation of the activity of a 
number of transcriptional factors and protein folding (reviewed in (191)). In addition, 
Trx1 serves as an electron donor to a number of enzymes, including Prxs, ribonucleotide 
reductase and Msr (Figure 1.9). Various types of cells, including tumour cells, secrete 
Trx1, which is presumed to be an oxidised form of Trx (192). It is still unclear whether 
the secreted Trx1 can provide protection for cells against xenobiotics and oxidative stress; 
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however, it has been shown to play an important role in the inflammatory response (64). 
To this end, elevated levels of Trx1 have been reported in plasma of patients suffering 
from chronic inflammatory disorders such as rheumatoid arthritis, asthma, hepatitis C and 
AIDS (193). 
 
 
Figure 1.9 Summary of the main functions of thioredoxins 
(data taken from (194)) 
 
Furthermore, studies have shown that Trxs participate in the development of cancer cell 
resistance to chemotherapeutics and afford protection against oxidative stress (195-199). 
Apart from the ability of Trxs to reduce Prxs and GPxs, thereby maintaining their 
catalytic activities, they can also directly reduce H2O2, GSSG and other disulfides (200). 
Additionally, both isoforms of Trx have been shown to quench hydroxyl radicals and 
singlet oxygen (201). 
1.5.2.6 Thioredoxin reductases (TrxR) 
The thioredoxin reductase (TrxR) enzymes are a family of NADPH-dependant 
homodimers of an oxidoreductase (with one flavin adenine dinucleotide (FAD) per 
subunit), which by reducing the active centre disulfide of oxidised Trx serve to facilitate 
the reduction of a wide variety of other oxidised substrates (Figure 1.10) (194, 202).  
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Figure 1.10 Reactions catalysed by thioredoxin-dependent system. 
Electrons are transferred from NADPH to thioredoxin reductase (TrxR) and then to the 
thioredoxins (Trx) which reduce disulfides in the target substrates, including 
peroxiredoxins (Prx). 
 
 
There are three known isoforms of mammalian TrxR: cytoplasmic (TrxR1), 
mitochondrial (TrxR2), and a testis-specific TrxR3 (203, 204). TrxR3 is also known as 
thioredoxin glutathione reductase (TGR) due to its ability to catalyse the reduction of 
both Trx and GSSG (205). The existence of TGR illustrates the functional overlap 
between the Trx- and GSH-systems. As an example, Drosophila melanogaster does not 
have GR so the reduction of GSSG is accomplished exclusively by a Trx-dependent 
system (206). 
 
All three isoforms have the same domain structure which is characterised by the presence 
of Sec at the C-terminal active site (Gly-Cys-Sec-Gly-COOH) (207). The presence of 
selenium is crucial for enzyme activity (208-210). Previous studies have shown decreased 
TrxR activity under low selenium conditions, whereas selenium supplementation 
markedly increased its activity (142, 148, 211). 
 
Similarly to GR and lipoamide dehydrogenase, the mechanism of TrxR catalysis in 
mammals includes the process of TrxR reduction at the expense of NADPH. Electron 
transfer initially proceeds from NADPH through FAD to the disulfide in the active centre, 
which consists of two Cys residues in positions 59 and 64 at the N-terminal domain, and 
is analogous to the domain in GR. The electrons are subsequently transferred from the 
dithiol of one dimer subunit to the selenylsulfide at the C-terminus of the other dimer 
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subunit. The reduced C-terminus Sec participates in the reduction of numerous TrxR1 
substrates in mammals (210). 
 
The substrates for TrxR1 include protein disulfides and numerous low-molecular mass 
disulfides, as well as species that are not disulfides (e.g. H2O2, lipoic acid, selenite and 
ebselen). A large number of disulfides are also reduced by TrxR-reduced Trx. For 
example, GSSG and insulin are not substrates for TrxR but can be effectively reduced by 
Trx1 (212). 
 
Peroxides, including lipid hydroperoxides and H2O2, can be reduced directly by TrxR1 
(118). By means of this mechanism, TrxR1 functions as an alternative pathway for the 
enzymatic detoxification of lipid hydroperoxides. However, the high Km value (~2.5 mM) 
of TrxR1 for H2O2 makes the role of this enzyme significant only at elevated levels of 
H2O2 (210). TrxR1 also reduces various low-molecular mass compounds such as 
antibacterial polypeptides (213), cystine, alloxan (214) and vitamin K (215). 
 
TrxR1 is known to reduce a number of seleno compounds, including (inorganic) selenite 
(SeO3
2-
), and the active site of GPx in plasma. In order to be actively incorporated into 
seleno proteins, inorganic selenium in the form of selenite has to be converted to selenide 
(HSe
-
). This reduction can be catalysed by TrxR1 with or without assistance of Trx1 
(216) and can include the formation of selenoglutathione (GS-Se-SG) as an intermediate. 
The formation of GS-Se-SG occurs in the presence of GSH, the level of which is 
maintained by GR that is also capable of reducing GS-Se-SG directly (217). Overall, 
TrxR plays an essential role in the metabolism of seleno compounds (218) and is an 
important link between selenium metabolism and cellular antioxidant defences. 
1.5.2.7 Glutaredoxins (Grx) 
Glutaredoxins (Grx) are GSH-dependent oxidoreductases that structurally belong to the 
thioredoxin superfamily and play a significant role in redox-dependent cellular processes. 
There are currently three known mammalian Grxs: one cytosolic (Grx1) and two 
mitochondrial (Grx2 and Grx5) (160, 219). These enzymes participate in the regulation of 
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a wide range of biological processes including cell differentiation, transcription, apoptosis 
and iron homeostasis.  
 
In the Grx-dependent system, the transfer of electrons occurs from NADPH-dependent 
GR to GSSG; the GSH formed, in turn, reduces oxidised Grx (Figure 1.11). The 
substrates for Grx are disulfides and mixed disulfides. 
 
                   
Figure 1.11 Simplified mechanism of the Grx-dependent system. 
Electrons are transferred from NADPH to glutathione reductase (GR), glutathione (GSH) 
and then to the Grxs which in turn reduce disulfides in the target substrates. 
 
 
Reduction of protein disulfides by Grx can be achieved by two mechanisms – dithiol and 
monothiol (Figure 1.12). The result of dithiol reduction is the formation of a reduced 
protein target (protein-(SH)2) and oxidised Grx (Grx-S2), whilst the monothiol 
mechanism forms a glutathionylated Grx (Grx-S-SG) intermediate which is reduced back 
to Grx by GSH (160).  
 
Mixed protein and GSH disulfide formation (S-glutathionylation) is believed to be a very 
important signalling process in the regulation of cell responses to oxidative stress.          
S-glutathionylation protects proteins from irreversible oxidation of SH-groups (220). A 
number of species result from SH-group oxidation, including sulfenic acids (Cys-SOH), 
sulfinic acids (Cys-SO2H) and sulfonic acids (Cys-SO3H). Sulfonic acids are not 
reducible and their generation leads to proteasomal degradation of a protein. In contrast, 
sulfenic acids can be reduced by Grx and Trx, whereas sulfinic acids, such as those 
present in Prxs, can be reduced by Srx (159). Grx is an enzyme which is able to catalyse 
both the formation and reduction of mixed disulfides. Normally the reduction of mixed 
disulfides is the preferred reaction, however in some cases, when the level of GSH is low 
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and GSSG concentration is increased, the formation of mixed disulfides is favoured over 
the reduction (160).  
 
Figure 1.12 Dithiol (A) and monothiol (B) glutaredoxin oxidoreductase mechanisms  
(adapted from (160)) 
 
1.5.2.8 Glutathione peroxidase (GPx) 
Glutathione peroxidase (GPx) is a seleno-dependant enzyme consisting of four identical 
subunits, each containing one selenium atom. Currently, there are seven GPxs known to 
be present in mammals, which differ by their locations and substrate specificities. The 
first identified and most studied intracellular GPx is GPx1, which catalyses the reduction 
of H2O2 at the expense of GSH (221). GPx1 is found mostly in the cytoplasm, but can 
also be located in mitochondria (222, 223). A number of studies have shown that GPx1-
KO mice do not produce any pathological phenotype in regards to development or 
fertility; however, GPx1 deficient mice were susceptible to the development of diseases 
caused by normally avirulent strains of viruses (e.g. coxsackievirus B3) (224). These 
finding are of particular importance to the studies of Keshan disease caused by selenium 
deficiency which can, in turn, result in GPx1 deficiency and therefore, predispose the 
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sufferers of this disease to develop cardiomyopathy associated with coxsackievirus 
infection (224, 225). 
 
The involvement of GPx1 in atherogenesis has been studied in several animal models, 
including GPx1
-/-
 (226) and GPx1
-/-
/ApoE
-/-
 mice (227). Depending on the model, GPx1 
deficiency has been reported either to enhance the atherosclerotic lesion formation 
(GPx1
-/-
/ApoE
-/-
 model) or have no effect on the progression of atherosclerosis (GPx1
-/-
 
model). Such inconsistency has been attributed to very discrete lesion formation in   
GPx1
-/-
 model, confined to the aortic root, whereas lesion development in GPx1
-/-
/ApoE
-/-
 
model is more widespread (227). 
 
In contrast to other GPxs, mammalian GPx4-deficient mice have been shown to die at an 
early stage of development, making GPx4 the only GSH-dependent peroxidase that is 
essential for survival (228). Along with H2O2, GPx4 (also known as phospholipid 
hydroperoxide glutathione peroxidase; PHGPx), uses phospholipid hydroperoxides as 
substrates in cell membranes and GSH, 2-mercaptoethanol and L-Cys as electron donors 
(221, 229). GPx4 has been proposed to function as a redox sensor in cells, preventing a 
unique caspase-independent proapoptotic signalling cascade caused by oxidative stress 
(228).   
1.5.2.9 Glutathione reductase (GR) 
The main function of the flavoenzyme GR is to maintain intracellular GSH in the reduced 
state (161). This is achieved by the transfer of electrons from NADPH, produced by the 
pentose phosphate pathway, through the FAD subunit of GR to oxidised GSSG. High 
intracellular GSH:GSSG ratios, even in pathological conditions (i.e. oxidative stress), 
reflect an exceptional efficiency of the enzyme. While several studies have shown that 
inhibition of GR leads to an increase in intracellular thiol oxidative stress (230), studies 
with GR-deficient mice showed that these mice, despite being clearly deficient in 
erythrocyte GR activity, did not have hemolytic anemia (231). In addition, several studies 
have shown the importance of GR in the oxidative burst (232) and host defence against 
bacterial challenge (233).  
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1.5.2.10 NADPH/NADP+ system 
Both the GSH/GPx/Grx and Trx/TrxR systems (Figure 1.7) use NADPH as a source of 
reducing equivalents. NADPH is produced via the pentose phosphate pathway, and apart 
from producing the reducing power for various cellular processes it is also used in fatty 
acid and cholesterol synthesis (234). The production of NADPH is regulated by the 
NADPH/NADP
+
 ratio, which in turn can be affected by a number of factors including 
intracellular redox state and glucose-6-phosphate dehydrogenase deficiency (235). 
Studies have shown that a genetically determined deficiency in glucose-6-phosphate 
dehydrogenase, the only enzyme capable of regenerating NADPH in red blood cells 
(RBC), correlates with an increased sensitivity of erythrocytes to hemolysis caused by 
xenobiotics, bacterial and viral infections, and stress (236).  
1.6 Oxidative damage repair 
Defence against oxidative damage also includes repair mechanisms. There are known 
repair systems for Cys and Met, which are highly susceptible to oxidation (237-239). The 
Cys repair systems were discussed in the Section 1.4; this Section describes some 
mechanisms involved in Met repair. 
 
Modification of Met residues by various reactive oxidant species, including ONOO
-
, 
some chloramines and HOCl (240), results in the formation of methionine sulfoxide and 
often subsequent loss of protein function or enzymatic activity. Methionine sulfoxide can 
be reduced back to methionine by multiple methionine sulfoxide reductases (MsrA and 
MsrB isoforms) in the presence of Trx (Figure 1.13). 
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Figure 1.13 Mechanism of methionine sulfoxide reduction by methionine sulfoxide 
reductases  
(taken from (241)) 
 
In addition to being a protein repair mechanism, this reduction has been shown to be an 
important regulatory pathway for many biological processes, including aging and 
neurodegenerative disease development (241). One of the MsrB isoforms, MsrB1, is a 
seleno protein with a Sec residue replacing one of the Cys in the active site. It has been 
shown that the catalytic activity of mammalian MsrB1 is 100 times higher than its Cys-
containing mutant; activities of MsrB3 and MsrB2 (Cys-containing) were also lower, but 
to a lesser degree. Based on these results, it has been suggested that the overall role of 
methionine sulfoxide reduction can be regulated by dietary intake of selenium (241). 
1.7 Hypohalous acids and antioxidants 
Among hypohalous acids, HOCl reactions with high- and low-molecular mass 
antioxidants have been studied the most extensively due to its high abundance and greater 
reactivity compared to HOSCN (35). It has been shown that in RBC GSH is rapidly 
oxidised by HOCl, with only small percentage of the oxidised GSH being present as 
GSSG (242). Other cell types showed stoichiometric conversion of GSH to GSSG upon 
treatment with HOCl (125). Decreased levels of GSH increase cellular susceptibility to 
oxidative stress and subsequent damage to intracellular targets (243, 244).  
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A number of studies have investigated Prx involvement in the detoxification of HOCl and 
chloramines in various cell types, including RBC (242) and HUVEC (245). Exposure of 
RBC or HUVEC to HOCl resulted in the formation of reversibly oxidised Prx1, Prx2 or 
Prx3 dimers without any measurable hyperoxidation. To this end, purified human Prx2 
has been shown to react rapidly with HOCl, however the oxidation of Prx2 Cys residues 
was not selective to the active site Cys (246). Despite the fact that HOSCN reacts 
preferentially with low pKa thiols (98), which are present at the active site of all 2-Cys 
Prxs (reviewed in (164)), no studies to date have examined the effects of HOSCN on the 
redox state of Prxs.  
1.8 Hypothesis and aims of this thesis 
As discussed in the previous Sections, (pseudo)hypohalous acids have been shown to 
rapidly react with protein thiol groups, with HOSN being the most specific for low pKa 
thiols. A number of thiol-containing enzymes, involved in antioxidant defence systems, 
including GR, Grx, Prx and Trx, have catalytic low pKa Cys residues at their active sites 
and, therefore, are hypothesised to be preferred targets for MPO-derived oxidants. 
Moreover, it has been recently shown that HOSCN also reacts very rapidly (in vitro) with 
seleno groups which are present at the active sites of seleno enzymes, including TrxR and 
GPx. GSH has a reasonably high pKa (~8) and, therefore, does not always protect 
enzymes from damage, despite being present at much higher concentration (5 - 10 mM). 
HOCl, HOBr and HOSCN may therefore affect the antioxidant defence systems in 
several ways. The first is by modulating the activity of enzymes through direct reactions 
with their SeH and SH-groups. Inhibition of activities of crucial seleno- and thiol-
dependent antioxidant enzymes can result in increased oxidative stress, apoptosis and cell 
death (125, 247). The second is by oxidation of protein thiols, with subsequent repair by 
GSH/GR/NADPH or Trx/TrxR/NADPH systems. Finally, the (pseudo)hypohalous acids 
can affect the antioxidant defence system by being potential substrates for thiol- and 
seleno enzymes themselves. A number of studies have been performed to elucidate the 
effects of HOCl on these processes, including studies on HOCl reactivity with Prxs (248), 
GPx (249) and protein thiols (245). Hypothiocyanous acid, however, has only become a 
subject of interest relatively recently, when it was shown that this relatively mild oxidant 
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can actually be quite damaging to cells due to its high specificity for SH-groups (101), 
though these data have been disputed (250, 251). 
 
In light of these data, the hypothesis for this thesis is that the major MPO-derived 
oxidants HOSCN and HOCl inhibit multiple thiol- and seleno-dependent cellular 
antioxidant enzymes, thus perturbing the redox balance in cells and plasma, inducing 
cellular dysfunction, and potentially enhancing atherosclerosis.  
 
This hypothesis was examined by investigating the following specific aims: 
 
1. To investigate whether elevated levels of MPO substrate SCN- in plasma correlate 
with changes in redox balance under inflammatory conditions and if so, does this 
play a role in survival in people who have suffered a myocardial infarction? 
 
2. To establish whether HOSCN and HOCl specifically target GSH/GPx/Grx and 
TrxR/Trx/Prx systems and to elucidate the role of individual components of these 
enzyme systems in the defence against these MPO-derived oxidants.  
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CHAPTER 2. Materials and Methods 
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2.1 General information 
This Chapter provides information about the general Material and Methods used in this 
Thesis. Any modifications made to the general methods are specified in Figure legends 
and text of the relevant Chapters. 
 
Water used in all experiments was filtered through a four-stage Milli-Q system. 
 
Unless stated otherwise, all concentrations of solutions are final. 
2.2 Materials 
Chemicals and assay kits used in the experiments are listed in the Table 2.1 
 
Table 2.1. Suppliers of reagents 
Reagent Supplier 
Acetonitrile HPLC Grade Merck (Whitehouse Station, NJ, USA) 
Acetic acid AR (glacial) Merck (Whitehouse Station, NJ, USA) 
Acrylamide/bis-acrylamide (37.5:1) 
solution 
Bio-Rad (Hercules, CA, USA) 
Albumin, Bovine Serum (Fraction V) 
(BSA) 
Sigma-Aldrich (St. Louis, MO, USA) 
Ammonium persulfate (APS), ACS grade Astral Scientific (Caringbah, NSW, 
Australia) 
Annexin V-FITC Apoptosis Detection Kit BD Biosciences (San Diego, CA, 
USA) 
Bicinchoninic acid (BCA) reagent Pierce (Rockford, IL, USA) 
Boric acid Sigma-Aldrich (St. Louis, MO, USA) 
Bromophenol blue Sigma-Aldrich (St. Louis, MO, USA) 
Catalase Sigma-Aldrich (St. Louis, MO, USA) 
Chelex 100 resin, analytical grade Bio-Rad (Hercules, CA, USA) 
Chloroform BDH (Poole, Dorset, UK) 
CellLytic M Cell Lysis reagent Sigma-Aldrich (St. Louis, MO, USA) 
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CellTiter 96 Non-radioactive cell 
proliferation assay 
Promega (Alexandria, NSW, Australia) 
Coomassie blue G-250 Dye  Sigma-Aldrich (St. Louis, MO, USA) 
Dansyl chloride Sigma-Aldrich (St. Louis, MO, USA) 
Diethylenetriaminepentaacetic acid  Sigma-Aldrich (St. Louis, MO, USA) 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich (St. Louis, MO, USA) 
5,5’-dithiobis(2-nitrobenzoic acid) (DTNB) Sigma-Aldrich (St. Louis, MO, USA) 
Dulbecco’s modified Eagles medium  JRH Biosciences (Lenexa, KS, USA) 
ECL Plus chemiluminescence reagents GE Healthcare 
Ethylenediaminetetraacetic acid (EDTA) Sigma-Aldrich (St. Louis, MO, USA) 
L-Glutamine Sigma-Aldrich (St. Louis, MO, USA) 
Glutathione reductase (GR), baker’s yeast Sigma-Aldrich (St. Louis, MO, USA) 
Glutathione, reduced (GSH) Sigma-Aldrich (St. Louis, MO, USA) 
Glutathione, oxidised (GSSG) Sigma-Aldrich (St. Louis, MO, USA) 
Glycerol, biotechnology grade Amresco (Solon, OH, USA) 
Glycine Amresco (Solon, OH, USA) 
H-Glu(Glu-OH)-OH Bachem (Torrance, CA, USA) 
Hydrogen peroxide (H2O2) Merck (Whitehouse Station, NJ, USA) 
Iodoacetic acid (IAA) Sigma-Aldrich (St. Louis, MO, USA) 
Kaleidoscope Prestained Standards Bio-Rad (Hercules, CA, USA) 
Lactoperoxidase (LPO) Calbiochem (Kilsyth, VIC, Australia) 
Lipofectamine 2000 Transfection Reagent Invitrogen (VIC, Australia) 
Lipofectamine RNAiMAX Transfection 
Reagent 
Invitrogen (VIC, Australia) 
ß –Mercaptoethanol Sigma-Aldrich (St. Louis, MO, USA) 
Methanol  Merck (Whitehouse Station, NJ, USA) 
Methionine Sigma-Aldrich (St. Louis, MO, USA) 
Mini Protean Precast TGX gradient Gels Bio-Rad (Hercules, CA, USA) 
Myeloperoxidase (MPO) Planta Natural Products (Vienna, 
Austria)  
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MPO ELISA kit Immundiagnostik AG (Bensheim, 
Germany) 
N-ethylmaleimide (NEM) Sigma Chemical Co. (St. Louis, MO, 
USA) 
Nitrate/nitrite quantification kit Cayman Chemicals (Ann Arbor, MI, 
USA) 
Opti-MEM Reduced Serum Medium Invitrogen (VIC, Australia) 
Perchloric acid (PCA) Ajax (NSW, Australia) 
Phosphate buffered saline (PBS) Amresco (Solon, OH, USA) 
Ponceau S Bio-Rad (Hercules, CA, USA) 
Protease inhibitor cocktail Sigma-Aldrich (St. Louis, MO, USA) 
Seleno-L-methionine Sigma-Aldrich (St. Louis, MO, USA) 
siRNAs (Prx1, Prx2, Prx3 and SCR) Ambion Inc. (Austin, TX, USA) 
Skim milk powder Bonlac Foods Ltd (Melbourne, 
Australia) 
Sodium acetate trihydrate Sigma-Aldrich (St. Louis, MO, USA) 
Sodium bromide Sigma-Aldrich (St. Louis, MO, USA) 
Sodium carbonate Amresco (Solon, OH, USA) 
Sodium bicarbonate Amresco (Solon, OH, USA) 
Sodium chloride Astral Scientific (Caringbah, NSW, 
Australia) 
Sodium diphosphate Sigma-Aldrich (St. Louis, MO, USA) 
Sodium dodecyl sulfate (for 
electrophoresis, approx 99%) (SDS) 
Sigma-Aldrich (St. Louis, MO, USA) 
Sodium hydroxide solution Sigma-Aldrich (St. Louis, MO, USA) 
Sodium hypochlorite BDH (Poole, Dorset, UK) 
Sodium monophosphate Sigma-Aldrich (St. Louis, MO, USA) 
Sodium selenite Sigma-Aldrich (St. Louis, MO, USA) 
Sodium thiocyanate Sigma-Aldrich (St. Louis, MO, USA) 
Tetramethylethylenediamine (TEMED) Sigma-Aldrich (St. Louis, MO, USA) 
Tris  Amresco (Solon, OH, USA)  
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Trypan blue Sigma-Aldrich (St. Louis, MO, USA) 
Tween-20 detergent solution Sigma-Aldrich (St. Louis, MO, USA) 
Western lightning chemiluminescence 
reagent 
Perkin Elmer (Waltham, MA, USA) 
 
2.3 Methods 
2.3.1 Human studies 
Human plasma samples used in this study were generously donated by collaborators from 
University of Otago, Christchurch, New Zealand (Prof. C. Winterbourn, Prof. A. M. 
Richards and Tessa Mocatta). These samples were originally obtained from patients 
participating in the large prospective study, Christchurch Cardioendocrine Post 
Myocardial Infarction Study, New Zealand, between 1994 and 2001. The study was 
approved by the Canterbury Ethics Committee (study reference: CTY/94/08/783) and 
conformed to the principles outlined in the Declaration of Helsinki. All participants gave 
written informed consent. Blood samples were taken 24 - 96 hr after admission to 
hospital; the majority of patients received heparin treatment within few hours of 
admission. 2.5% of patients received statin treatment at the time of admission. Plasma 
samples were prepared from venous blood using EDTA tubes (Becton Dickinson 
Vacutainer) and stored at -80 
o
C, and subsequently assayed.  
 
A subgroup of 176 acute myocardial infarction survivors was randomly selected from this 
larger cohort and used in the current study. These were grouped according to their 
smoking status at the time of hospital admission: non-smokers represented 42% (n = 74), 
current smokers 26% (n = 46) and past smokers 32% (n = 56).  
2.3.2 Myeloperoxidase-induced thiol oxidation in plasma 
In order to simulate inflammatory conditions in plasma, a previously described method 
was used (252) involving dilution of the plasma 5-fold with sodium phosphate buffer 
(100 mM, pH 7.4) prior to addition of four aliquots of H2O2 at 0, 5, 10 and 15 min to a 
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final concentration of 200 µM. Myeloperoxidase (MPO, 100 nM) was either added or not 
to the reaction mixture. Samples were incubated for a total of 30 min at 22 ºC after the 
first addition of H2O2, with the reaction subsequently stopped by the addition of catalase 
(100 µg/mL) and methionine (10 mM). Plasma thiols were quantified immediately 
following this reaction as detailed below (Section 2.3.3)  
2.3.3 Quantification of plasma thiols 
Thiols were quantified spectrophotometrically using 5,5‘-dithionitrobenzoic acid (DTNB) 
as previously described (253). GSH (0 - 0.5 mM), prepared in npH2O was used as a 
standard. DTNB (0.5 mM) was prepared in Chelex-treated sodium phosphate buffer, pH 
7.4. Plasma samples (diluted 6.25 fold) and standards were pipetted into 96-well plates in 
duplicate with a final volume of 20 µL per well. A second set of the same dilutions of 
plasma was aliquoted into the same plate to be used for blanks. DTNB solution (200 μL 
of 0.5 mM) was added to all standards and one set of plasma samples. To the rest of wells 
containing plasma, 200 µL of sodium phosphate buffer was added. Following mixing, the 
plate was incubated for 30 min in the dark at room temperature. The absorbance was 
measured at 412 nm using Benchmark Plus plate reader (Bio-Rad). Final concentration 
was adjusted by subtracting the absorbance measured in the blanks from the absorbance 
of samples with added DTNB. 
2.3.4 Quantification of plasma MPO 
MPO protein levels were measured by commercial ELISA kit according to 
manufacturer‘s instructions. Samples, standards and controls were analysed in duplicate. 
Data from different plates were standardised by running 2 (quality control) plasma 
samples on all plates. 
2.3.5 Quantification of plasma bromide and thiocyanate concentrations 
Determination of plasma SCN
-
 and Br
-
 was performed as previously described (90). 
Plasma proteins in the samples were removed by precipitation with acetonitrile (1:1 ratio) 
and centrifugation (7 min, 5 000 x g, 4 ºC). The supernatant was subsequently filtered 
through 0.2 µM centrifuge filters (Pall Life Sciences (Ann Arbor, MI, USA), 500 µL 
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capacity, 3 min, 9 300 x g, 4 
o
C). Plasma anions were then separated using a Dionex 
chromatographic system (AS3500 autosampler, GP40 gradient pump, ASRS 300 anion 
suppressor and an ED40 electrochemical detector). For Br
-
 detection an IonPac AS12A 
analytical column and AG12A guard were used, with 1 mM sodium carbonate/1.5 mM 
sodium bicarbonate in water as eluent, and a 28 min run time. The flow rate was 1.5 
mL/min, and suppressor current 100 mA. To quantify SCN
-
, anions were separated using 
an IonPac AS16 analytical column and AG16 guard column (15 min run time) using 50 
mM sodium hydroxide in water. The eluent flow rate was 1.5 mL/min, with suppressor 
current of 300 mA. Standard curves for SCN
-
 and Br
-
 quantification were prepared using 
NaSCN and NaBr standards (10 - 200 µM). Peak areas of standards and samples were 
determined by PeakNet Chromatography Workstation software (Release 4.30). 
2.3.6 Determination of plasma nitrite concentration 
Plasma nitrite (NO2
-
) was quantified by fluorescence using a commercial nitrate/nitrite 
(NO3
-
/ NO2
-
) quantification kit. In this assay, total NO2
-
 resulting from (NO3
-
 + NO2
-
) is 
assayed, by reduction of NO3
-
 to NO2
-
 with the enzyme nitrate reductase. Sample 
preparation included filtering the plasma through 10 kDa molecular mass cut-off filters 
(Pall Life Sciences), to remove hemoglobin (5 min, 10 000 x g, 4 ºC). Data from different 
plates were standardised by running 2 plasma samples on all plates. 
2.3.7 General tissue culture conditions 
The J774A.1 murine macrophage-like cells were obtained from American Type Culture 
Collection (ATCC, Manassas, VA, USA; catalogue number TIB-67). Cell were 
maintained in T175 tissue culture flasks in Dulbecco‘s modified Eagle‘s medium 
(DMEM), supplemented with 10% fetal bovine serum (FBS) and 2 mM L-glutamine at 37 
ºC, in humidified 5% CO2 atmosphere. Cells were split twice a week at a 1:10 ratio by 
mechanical detachment with a cell scraper. Cells were discarded after 20 passages.  
2.3.8 Cell culture conditions for selenium supplementation experiments 
Selenium supplementation has been previously reported to increase the activity of seleno-
dependent enzymes TrxR and GPx both in animal and cell-based models (141, 149, 254). 
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The effects of selenium supplementation on J774A.1 cells were examined in the current 
study. 
 
J774A.1 cells were seeded at 5 x 10
5
 cell/mL in 6-well culture plates and incubated for 
approximately 17 hours in media containing DMEM, 10% FBS, 2 mM L-glutamine and 
equal volumes of either 500 nM sodium selenite (inorganic seleno compound), 5 µM 
seleno-L-methionine (organic form of selenium) or the vehicle npH2O (control 
conditions). During the incubation period cells were maintained at 37 °C in a humidified 
atmosphere containing 5% CO2. Following overnight incubation, the media was removed 
and cells were washed twice with either warm (37 ºC) phosphate buffered saline (PBS) 
(for Western blotting analysis, some HPLC, enzyme activity and metabolic activity 
experiments) or Hank‘s buffered salt solution (HBSS) (HPLC, siRNA and viability 
experiments). 
2.3.9 Oxidant preparation 
2.3.9.1 HOCl preparation 
The concentration of 
-
OCl ions in the NaOCl stock solution was determined by diluting 
the stock with 0.1 M NaOH and measuring the absorbance at pH 11 and a wavelength of 
292 nm. A molar absorption coefficient (ε) of 350 M-1cm-1 was used to calculate the 
concentration. The stock NaOCl was then diluted in npH2O to a final concentration of   
20 mM, followed by the dilution to the desired concentration into PBS or HBSS 
immediately before the addition to cells. 
2.3.9.2 HOSCN preparation 
HOSCN was prepared enzymatically by the reaction of SCN
-
 ions with H2O2 in the 
presence of LPO (83). Specifically, a reaction mixture containing 2 μM LPO and 7.5 mM 
NaSCN in 10 mM potassium phosphate buffer (pH 6.6) was incubated with 3.75 mM 
H2O2 (added as five 10 μL aliquots 1 min apart) for 15 min, followed by quenching the 
reaction with 1 mg/mL catalase (5 min incubation). In order to remove LPO and catalase, 
the reaction mixture was filtered through 10 kDa cut-off filtering devices (Pall Life 
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Sciences) at 10 000 x g, 4 °C for 5 min. The concentration of the resulting HOSCN was 
measured by TNB assay as detailed below (Section 2.3.10). Following quantification, 
HOSCN stock was diluted to the working concentration with PBS or HBSS and used 
immediately. 
2.3.10 TNB assay 
HOSCN and HOCl react with yellow 5-thio-2-nitrobenzoic acid (TNB) to produce the 
colourless product 5,5-dithio-bis(2-nitrobenzoic acid) (DTNB). TNB reagent was 
prepared freshly every day by alkaline hydrolysis as previously described (253). Briefly, 
1 mM DTNB was dissolved in 50 mM NaOH and vortexed until the solution turned a 
dark yellow/orange colour. This stock solution was further diluted (50-fold) into PBS and 
the absorbance of the working solution was measured at 412 nm. Depending on the extent 
of hydrolysis, the typical absorbance was 0.45 – 0.6. HOSCN (50 μL) was added to 1 mL 
of TNB working solution and incubated for 15 min in the dark at 22 °C prior to reading 
the absorbance at 412 nm. A blank sample containing PBS (50 μL) was used to allow for 
the possible decomposition of TNB reagent. 
2.3.10.1 Oxidant treatment of J774A.1 cells 
Unless stated otherwise, J774A.1 cells were treated with 0, 100 and 200 μM HOSCN or 
HOCl for 1 hr at 22 °C. The equal volumes of hypohalous acids were added to PBS or 
HBSS to obtain the required concentrations followed by addition to cells. The final 
volumes of the reaction mixtures were 2 mL, 1 mL and 0.5 mL per well when carried out 
in 6-, 12- or 24-well tissue culture plates, respectively. Cells were exposed to oxidants for 
1 hr at room temperature on an orbital mixer. Prior to, and following oxidant treatment 
cells were washed twice with warm buffer (37 ºC, PBS or HBSS), unless stated othrwise. 
2.3.11 GSH/GSSG quantification  
In order to measure the levels of both reduced (GSH) and oxidised (GSSG) forms of 
glutathione, a HPLC separation method was used. J774A.1 cells (5 x 10
5
 cells/mL, 6-well 
plates, unless stated otherwise) were treated with oxidants as previously described in 
Section 2.3.10.1. Prior to HPLC analysis, cells were lysed in 500 µL of npH2O followed 
49 
 
by derivatisation with dansyl chloride, as previously described (255). Briefly, 200 µL of 
derivatisation buffer (5% v/v perchloric acid (PCA), 2 mM diethylenetriaminepentaacetic 
acid (DETAPAC) and 0.2 mM boric acid) was added to 200 µL of cell lysates. Before 
adjusting the pH of the samples to 8.0 - 8.5 with 2 mM NaOH, the mixture was alkylated 
with 1 µM iodoacetic acid (IAA) with the addition of the internal standard (4 nM H-
Glu(Glu-OH)-OH). Samples were then incubated for 30 min at 22 °C. Following 
incubation, 1 mg/mL dansyl chloride in acetonitrile was added to each sample in a 1:1 
ratio, then mixed and incubated for 1 hr at 22 ºC in the dark. In order to remove excess 
dansyl chloride and concentrate derivatised samples, an equal volume of chloroform was 
added to each tube. The upper phase of the chloroform/sample mixture (200 µL), 
containing GSH/GSSG was used for HPLC separation.  
 
Separation and quantification of GSH and GSSG was carried out by HPLC, using a 
Shimadzu (Shimadzu, Rydalmere, NSW, Australia) HPLC system with Supelco 
LiChrospher Amino column with Pelliguard LC-NH2 guard column at 30 °C with         
1.3 mL/min flow rate. Buffer A was 80 % methanol (MeOH), buffer B contained 0.4 M 
sodium acetate, 72% MeOH (v/v) and 7.6% (v/v) glacial acetic acid. A linear gradient of 
buffer B from was maintained for 20 min, followed by 10 min of 100% buffer B and 10 
min re-equilibration to 0% buffer B. Dansyl chloride-derivatised GSH/GSSG and internal 
standard peaks were detected with Shimadzu RF-20A XS fluorescence detector at λex 328 
nm and λem 541 nm and quantified using GSH/GSSG standard curves. GSH and GSSG 
standards (0 – 100 µM GSH and 0 – 20 µM GSSG) were prepared in PCA-DETAPAC-
boric acid buffer and derivatised in the same manner as the cell lysates. 
2.3.12 Western blot analysis 
Following oxidant treatment (2.3.10.1), cells were lysed in CelLytic M Cell Lysis 
Reagent containing 1% Protease Inhibitor Cocktail and 100 mM N-ethylmaleimide 
(NEM). After 15 min incubation with lysis buffer, cell debris was pelleted down by 
centrifugation at 16 000 x g for 5 min, 4 ºC. Supernatants (20 µg) were added to a loading 
buffer (62.5 mM Tris (pH 6.8), 2% (w/v) SDS, 10% (v/v) glycerol and 0.01% (w/v) 
bromophenol blue) and resolved on 15% SDS-PAGE with 4% acrylamide stacking gels 
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(Table 2.2) or 4 - 15% Mini Protean Precast TGX gradient Gels. When reducing 
conditions were required, samples were incubated in the presence of 5% (v/v)                 
β-mercaptoethanol in the loading buffer for 5 min at 95 ºC prior to separation on SDS-
PAGE. Kaleidoscope Prestained Standards were used for the molecular mass markers. 
 
Table 2.2. Composition of 15% running gel and 4% stacking gel for SDS-PAGE 
Reagent 15 % running gel 4% stacking gel 
npH2O 8.2 mL 8.5 mL 
2 M Tris pH 8.8 4 mL - 
0.5 M Tris pH 6.8 - 650 μL 
40% Acrylamide/bis  7.5 mL 1 mL 
10% SDS 200 μL 100 μL 
10% Ammonium persulfate (APS) 66.6 μL 100 μL 
Tetramethylethylenediamine 
(TEMED) 
13.4 μL 
2.5 μL 
 
 
Following electrophoresis, proteins were transferred from the gel to a nitrocellulose 
membrane by use of an iBlot apparatus (Invitrogen, 7 min) and then blocked for 1 hr with 
blocking buffer, containing 5% (w/v) skim milk, Tris-buffered saline (TBS) and                
0.01% (v/v) Tween20. Membranes were probed with the experiment-appropriate primary 
antibody (Table 2.3) overnight at 4 °C followed by 1 hr incubation with secondary 
antibody at 22 °C. Proteins were visualised by capturing the chemiluminescence 
produced by the horseradish peroxidase immunoglobulin G (HRP-IgG) secondary 
antibody bound to the primary antibody upon addition of the ECL Western Lightning 
Chemiluminescence Reagent. The images were taken after the initial exposure of 60 sec 
every 30 sec for 10 min using a Chemi-Doc XRS imager (Bio-Rad) or every 10 sec for     
5 min using a LAS-4000 machine (GE Heathcare). Densitometry analysis was performed 
by ImageJ (1.46r / Java 1.6.0_20 (64-bit)), free software downloaded from National 
Institute of Health (NIH, USA, http://rsbweb.nih.gov/ij/). 
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2.3.13 Protein staining of membranes 
In order to ensure equal protein loading on the nitrocellulose membranes, they were 
stained after chemiluminescence analysis with 0.05% (w/v) Coomassie R-250 in 
isopropanol/acetic acid/water (50:20:30) for 5 min. Following staining, membranes were 
destained using a solution containing isopropanol/acetic acid/H2O (12.5:10:77.5) for       
24 hr. Following this, the membranes were washed with water and allowed to air dry 
before scanning and densitometry analysis by ImageJ software. 
 
Table 2.3 List of primary and secondary antibodies used. 
Antibody Supplier Dilution 
Primary 
Rabbit anti-mouse Anti-Prx1 polyclonal Abcam (Cambridge, MA, USA) 1:2000 
Rabbit anti-mouse Anti-Prx2 polyclonal AbFrontier ( Korea) 1:2000 
Rabbit anti-mouse Anti-Prx3 polyclonal AbFrontier ( Korea) 1:2500 
Rabbit anti-mouse Anti-PrxSO2/3 
polyclonal 
AbFrontier ( Korea) 1:2500 
Mouse monoclonal anti-GSH IgG ViroGen Corporation 
(Watertown, MA, USA) 
1:2000 
Rabbit anti-mouse anti-GPx1 polyclonal Abcam (Cambridge, MA, USA) 1:2000 
Rabbit anti-mouse anti-TrxR1 polyclonal Abcam (Cambridge, MA, USA) 1:2000 
Rabbit anti-mouse anti-GAPDH 
polyclonal 
Santa Cruz Biotechnology 
(Santa Cruz, CA, USA) 
1:2000 
Secondary 
Goat anti-rabbit IgG (H+L), HRP-
conjugated 
Calbiochem, Merck 
(Whitehouse Station, NJ, USA) 
1:2000 
Goat anti-mouse, HRP-conjugated 
Santa Cruz Biotechnology 
(Santa Cruz, CA, USA) 
1:4000 
 
2.3.14 Thioredoxin reductase (TrxR) activity assay 
TrxR activity was quantified by measuring the rate of TNB formation in the presence of 
NADPH (Reaction 2.1), as previously described (247). 
 
DTNB + NADPH + H
+
                 2TNB + NADP
+
 Reaction 2.1 
 
TrxR 
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Briefly, the activity of TrxR is calculated as the difference between the rate of TNB 
formation in the presence and absence of the specific TrxR inhibitor auranofin (256). 
J774A.1 cells (1 x 10
6
 cells/well) were treated with oxidants (Section 2.3.10.1) for 1 hr, 
and subsequently lysed in npH2O on ice for 15 min. Cells were then collected in an 
eppendorf tube and centrifugated for 10 min at 10 000 x g, 4 ºC in order to remove cell 
debris. Supernatants (100 µL) were transferred to 96-well plate, containing 100 µL of 
TrxR reaction buffer (5 mM EDTA, 0.24 mM NADPH, 0.2 mg/mL BSA, 10 mM DTNB 
in 50 mM phosphate buffer, pH 7.4). Treatment wells had 500 nM auranofin dissolved in 
DMSO, whereas control wells (no TrxR inhibitor) contained 11.1% (v/v) vehicle DMSO. 
The rate of TNB formation was measured (412 nm, 22 °C) using a 96-well plate reader at 
1 min intervals for 5 min. 
2.3.15 Glutathione peroxidase (GPx) activity assay 
GPxs comprises a family of seleno-dependent enzymes that reduce H2O2 (and in the case 
of GPx4 organic hydroperoxides) using GSH as a reducing co-factor at the expense of 
NADPH (141).         
GPx activity was quantified indirectly by measuring NADPH consumption in the 
presence of GR and GSH during the reduction of t-butyl hydroperoxide (t-Bu-OOH), 
Reaction 2.2 and 2.3 (257, 258). 
 
t-Bu-OOH + 2GSH                   t-Bu-OH + GSSG + H2O Reaction 2.2 
GSSG + NADPH + H
+
                  2GSH + NADP
+
 Reaction 2.3 
 
Following oxidant treatment J774A.1 cells (1 x 10
6
 cells/well) were washed twice with 
PBS and then lysed in npH2O for 15 min on ice (500 µL of npH2O per well in 6-well 
plate) prior to scraping with a syringe plunger. GPx reaction buffer was prepared using   
50 mM sodium phosphate buffer, pH 7.4, 5 mM EDTA, 8.8 mM GSH, 0.5 units of 
baker‘s yeast GR, and 0.5 mM NADPH. 
 
GPx 
GR 
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Following lysis, 50 μL aliquots of lysate were transferred to 96-well plate wells and 
incubated with 130 µL of GPx reaction buffer for 1 min followed by the addition of       
20 µL of 1 mM t-Bu-OOH. Three wells were left cell-free (only GPx reaction buffer and 
t-Bu-OOH added) to serve as a blank. NADPH consumption was monitored 
spectrophotometrically at 340 nm for 15 min at 1 min intervals at 37 °C. The rate of 
NADPH oxidation in blank wells was subtracted from control wells to correct for non-
specific absorbance by the reaction buffer. 
2.3.16 Total protein quantification  
The amount of protein in cell lysates was determined by the bicinchoninic acid (BCA) 
assay according to the manufacturer‘s instructions. Samples (20 µL) were transferred to 
triplicate wells of a 96-well tissue culture plate. BSA standards (0 – 1 mg/mL) were also 
prepared in triplicate. BCA reagent A was combined 50:1 with reagent B and 200 µL of 
the mixture was added to each well containing samples or standards. After mixing the 
samples briefly on a plate shaker, the plate was incubated for 30 min at 60 °C. The 
absorbance was measured at 562 nm and the sample protein concentrations determined 
from the BSA standards, to which a second order polynomial curve was fitted. 
2.3.17 Metabolic activity: MTT assay 
Metabolic activity following oxidant treatment was measured by MTT assay that 
measures the reduction of the yellow tetrazolium salt 3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide (MTT) to its purple formazan product by mitochondrial 
succinate dehydrogenase in metabolically active cells. 
 
J774A.1 cell were seeded at 1 x 10
5
 cells/mL in 24-well plates and supplemented with 
selenium as previously described (Section 2.3.8), for 17 hr, followed by oxidant treatment 
(0 – 200 µM HOSCN or HOCl for 1 hr). Following oxidant removal, cells were washed 
twice with PBS or HBSS and 425 µL of media was returned to each well. MTT reagent 
(75 µL) was added to all wells and cells were incubated for 4 hr at 37 °C, 5% CO2. Any 
formazan crystals which formed during incubation were solubilised by the addition of 
500 µL of solubilisation solution for 1 hr. The contents of each well were then transferred 
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to 96-well plates in triplicate and absorbance was read at 570 nm and 655 nm. The 
corrected absorbance was calculated by subtracting absorbances read at 655 nm from 570 
nm. Cellular mitochondrial function was calculated as percentage by comparing to 
control (non oxidant-treated) cells which were defined as 100% functional. 
2.3.18 Cell viability: flow cytometric analysis 
J774A.1 cells were plated at 0.5 x 10
6
 cells/mL in 6-well tissue culture plates and 
supplemented with selenium overnight (or left untreated) followed by the treatment with 
oxidants as described in Section 2.3.10.1. Following the removal of the oxidants, cells 
were washed twice with cold PBS and resuspended in 1 mL of Annexin V Binding Buffer 
(10 mM HEPES/NaOH pH 7.4, 140 mM NaCl and 2.5 mM CaCl2) by gently pipetting the 
buffer up and down. This technique avoids excessive mechanical damage to cells caused 
by a cell scraper. The cell suspension (100 µL, ~1 x 10
5
 cells) was subsequently 
transferred to 5 mL polystyrene culture tubes, followed by the addition of 5 µL of 
Annexin V- fluorescein isothiocyanate (FITC) and 5 µL of propidium iodide (PI) to each 
tube. Tubes were incubated for 15 min in the dark followed by the addition of 400 µL of 
binding buffer to each tube. Samples were then analysed by flow cytometry (FACSVerse, 
BD) within 1 hr. Cells negative for both Annexin V and PI were considered to be viable, 
cells positive for Annexin V only were designated as early apoptotic, whilst cells positive 
for both Annexin V and PI were assigned as late apoptotic/necrotic. 
2.3.19 siRNA inhibition of Prxs 
J774A.1 cells (6.5 x 10
4
 cells/mL) were plated in 12-well tissue culture plates and left to 
adhere overnight at 37 °C in 5% CO2 in normal DMEM supplemented with 10% FBS and 
L-glutamine. Prior to addition to the cells, for each well 1 μL of Lipofectamine 
RNAiMAX transfection reagent was incubated with 75 μL Opti-Mem reduced serum 
medium for 5 min. Stock annealed double-strand siRNA was added to a separate Opti-
Mem aliquot (75 μL) to a final concentration of 35 nM. Transfection reagent and siRNA 
aliquots were gently mixed and incubated for 20 min at 22 °C to allow complex 
formation. Following incubation, the siRNA-transfection reagent complexes were added 
drop-wise into tissue culture wells containing cells and normal media (150 μL/well). 
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Transfection conditions were maintained for 48 hr (siPrx2) or 72 hr (siPrx1 and siPrx3) 
prior to the oxidant treatment as described in section 2.3.10.1. Scrambled siRNA (SCR 
siRNA) was used as a negative control in all experiments. Transfection efficiency was 
confirmed by Western blotting as described in Section 2.3.12.  
2.4 Statistical analysis 
Statistical analysis throughout this thesis was performed using GraphPad Prism v. 5 or v. 
6 for Windows (GraphPad Software, San Diego, USA). Statistical tests include: 1- and 2-
way analysis of variance (ANOVA) with Tukey‘s or Bonferroni‘s post-test (with 3 
comparisons per family); Pearson (r
2
) and Spearman (r) correlations, Kaplan-Meyer 
survival analysis. Significance was assumed when P < 0.05. Data are mean ± SEM from 
at least 3 independent experiments unless stated otherwise. Details of the statistical tests 
used in particular analyses are given in the text and appropriate figure legends. 
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CHAPTER 3. Effects of thiocyanate on plasma thiols and correlation 
with post-myocardial infarction mortality in non-smokers, smokers 
and past smokers 
 
  
57 
 
3.1 Introduction 
As discussed in Chapter 1, the heme enzyme MPO is released by activated leukocytes 
during inflammation. Strong experimental and epidemiological evidence links elevated 
MPO levels with damage at sites of inflammation, and adverse health outcomes (1, 34, 
259); smoking exacerbates these effects (reviewed in (260)). MPO catalyses the reaction 
of H2O2 with Cl
-
, Br
-
 and SCN
-
 ions yielding the oxidants HOCl, HOBr and HOSCN 
respectively (1, 259). Although Cl
-
 is the most abundant plasma substrate (> 100 mM; cf. 
Br
-
 20 – 100 M; SCN- 20 – 250 M (84, 90)), MPO has a much higher specificity 
constant for SCN
-
 resulting in ~45% of the H2O2 consumed being converted to HOSCN 
in heavy smokers (84, 90).  
 
Elevated SCN
- 
levels can modulate both the concentration and nature of the oxidants 
generated by MPO, and hence the pattern of biological damage (90, 261). Kinetic 
modelling studies predict that > 90% of the H2O2 consumed by MPO is converted to 
HOCl with a plasma SCN
-
 concentration of 10 M, whereas at 250 M SCN- this changes 
to ~45 % HOCl and ~45% HOSCN ((90), Pattison et al. (unpublished data)). Unlike 
HOCl and HOBr, which react with multiple targets (32, 37), HOSCN is selective for thiol 
(RSH, Cys) and selenium (e.g. Sec) species (98, 262, 263). This selectivity increases thiol 
and selenol oxidation, and decreases damage to other targets (261). Perturbation of the 
reduced:oxidised thiol ratio is a powerful indicator of oxidative stress, and an 
independent predictor of early atherosclerosis (119, 120, 264). Exposure of human 
plasma from smokers and non-smokers to identical oxidative insults, results in greater 
thiol depletion in the smokers, and a strong correlation between thiol depletion and SCN
-
 
levels (90). Furthermore, plasma SCN
-
 levels correlate in a negative manner with the 
HOCl-biomarker 3-Cl-Tyr (261), suggesting that less HOCl is produced by MPO in the 
presence of elevated SCN
- 
levels. 
  
Whilst the role of HOCl is relatively well defined, less information is available for 
HOSCN (37, 94), although data have been presented for SCN
-
-derived damage in animal 
models of atherosclerosis, and in humans with CVD (15, 107, 265, 266). In contrast, 
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other studies have proposed that elevated SCN
-
 levels are protective ((97, 250, 267), 
reviewed in (37)). 
3.2 Aims 
The above data indicate that SCN
-
 levels modulate damage induced by MPO, and that 
elevated MPO is associated with adverse cardiovascular outcomes. Therefore, the aim of 
this Chapter was to examine whether elevated plasma levels of MPO substrate SCN
-
 
correlate with adverse changes in redox balance, such as oxidation of plasma thiols, under 
inflammatory conditions, and if so, whether this plays a role in the adverse outcomes in 
subjects who survived a first myocardial infarction. 
3.3 Study design 
3.3.1 Background to current study 
The cohort contributing cases to the current study was drawn from the prospectively 
designed Christchurch Cardioendocrine Post Myocardial Infarction study. This study was 
comprised of patients admitted to Christchurch Hospital (New Zealand) between 1994 
and 2001. Entry criteria included onset of myocardial infarction symptoms within 24 
hours prior to hospital admission and survival for at least 24 hours after admission. 
Occurrence of a myocardial infarction was confirmed by a plasma CK activity > 400 
U/mL and subsequent troponin assay. Over 80% of the recruited cohort had ST elevation 
myocardial infarction, with the remainder having unstable angina, indicative of 
unequivocal acute myocardial infarction. The subjects underwent both cardiac ultrasound 
examination and radionuclide scanning for left ventricular function during the index 
admission and again 4 months later. Blood samples were taken 24 to 96 hours after 
admission to hospital; the majority of patients received heparin treatment within few 
hours of admission. Plasma samples were prepared from venous blood using EDTA tubes 
(Becton Dickinson Vacutainer) and stored at -80
 o
C. Patient outcomes were 
systematically followed and documented for up to 12 years.  
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There are a number of published articles resulting from the Christchurch Cardioendocrine 
Post Myocardial Infarction study, which examined various biochemical parameters of 
plasma samples, and cardiac function, and examined the patients short- and long-term 
survival. Thus, two of these studies demonstrated the utility of plasma brain natriuretic 
peptide (BNP) and N-terminal pro-brain natriuretic peptide (N-BNP), as novel 
biomarkers of cardiac function, as they were found to be independently predictive of left 
ventricular function and prognostic of 2-year survival post myocardial infarction (268), or 
12 months all-cause mortality and/or hospital admission with heart failure in patients with 
stable ischemic heart disease (269). Another study showed that high plasma MPO levels 
were a risk factor and independent prognostic marker of long-term mortality following 
myocardial infarction (57). In addition, this study demonstrated that myocardial infarction 
patients had significantly elevated levels of plasma carbonyls, which is indicative of the 
presence of oxidative stress. This increase, however, was not associated with any 
measurable change in 3-Cl-Tyr, a specific biomarker of HOCl formation, even in samples 
with the highest level of MPO. The authors concluded that MPO activity was an unlikely 
source of protein carbonyls in myocardial infarction patients, and low levels of 3-Cl-Tyr 
might be associated with a low chlorinating ability of circulating MPO. In the current 
study, further insights into the role of MPO and MPO-derived oxidants in the changes in 
plasma redox state and patient survival post myocardial infarction were obtained. 
3.3.2 Current study 
For the current study, a randomly selected sample of 176 patients was grouped according 
to their smoking status at the time of hospital admission: non-smokers represented 42% 
(n = 74), current smokers 26% (n = 46) and past smokers 32% (n = 56). Clinical and 
other data for these subjects are given in Table 3.1. All characteristics were not 
significantly different between smoking groups with the exception of age: on average, 
smokers were 10 years younger than both non-smokers and past smokers. 
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Table 3.1 Demographics of the myocardial infarction patients in the current study 
Characteristic Non-smokers Smokers Past smokers 
Number (M/F) 74 (56/18) 46 (37/9) 56 (45/11) 
Age (y) 63.7 ± 10.8 58.4 ± 10.8 
a,b
 64.8 ± 10.1 
Age range (y) 38 - 80 36 - 78 37 - 78 
Mortality over 12 years of follow-up 25 (34%) 12 (27%) 15 (27%) 
Total cholesterol (mmol/L) 5.8 ± 1.2 6.2 ± 1.1 5.7 ± 1.2 
LDL cholesterol (mmol/L) 3.8 ± 1.0 4.1 ± 1.0 3.8 ± 1.0 
 
Data are presented as mean ± SD. Only statistically significant differences are noted: 
a 
significantly different vs. non-smokers (P < 0.05), 
b 
significantly different vs. past-
smokers (P < 0.05). These demographic data were kindly provided by Tessa Mocatta. 
 
3.4 Results 
3.4.1 Quantification of plasma MPO  
Plasma MPO levels have been previously reported to be elevated in the total cohort 
compared to non-myocardial infarction controls (57); however this study was interested 
in levels in the different groups (smokers, past smokers and non-smokers) who had 
suffered a myocardial infarction, rather than in comparison to healthy controls. MPO 
levels were known for the majority of the samples; MPO levels for the remainder of the 
samples were measured using an MPO ELISA kit according to the manufacturer‘s 
instructions as detailed in Section 2.3.4. A number of samples with previously measured 
MPO levels (57) were run on the same ELISA plate in order to determine whether the 
results of the two different methods were comparable. There was no significant difference 
between the two measurements; therefore the MPO levels determined both previously 
and using the commercial ELISA kit were used for further analyses.  
 
Analysis of plasma MPO levels in the entire cohort showed that there were no significant 
differences in MPO concentrations between the 3 groups (Figure 3.1, mean MPO level: 
non-smokers, 69 ± 42 ng/mL; smokers, 60 ± 43 ng/mL; past smokers, 76 ± 55 ng/mL). 
Heparin is known to mobilise MPO from endothelium into the blood and thus plasma 
MPO concentrations might be overestimated (270).The issue of heparin treatment on 
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admission to the hospital as a potential confounder in MPO measurements (270, 271) has 
been examined previously in the original cohort (57). It was found that the time between 
heparin treatment and blood sampling was sufficient that any heparin-derived elevations 
in MPO levels had normalised by the time of blood sampling; this is in line with the 
known short half-life of heparins in vivo (272). 
                 
Figure 3.1 Plasma MPO concentration in non-smokers, smokers and past smokers 
Most plasma MPO levels were previously determined by ELISA (57); any missing values 
were determined in the current study also by ELISA. There was no significant difference 
between groups as assessed by a Kruskal-Wallis test (using a Gaussian approximation as 
the data were not normally distributed) with Dunn‘s multiple comparison test. Mean 
levels are shown by ―+‖, whilst boxes represent medians (lines) and interquartile ranges, 
and whiskers represent the 5th and 95th percentiles. 
3.4.2 Quantification of MPO substrates in plasma 
The lack of any significant differences in MPO levels between the patient groups was 
beneficial in the present study, as it established a plasma MPO baseline. Accordingly, any 
differences in oxidants produced and MPO-dependent oxidation in the groups were 
expected to be due to the differences in plasma MPO substrate concentrations, rather than 
differences in MPO levels. 
 
Prior to measuring thiol levels and thiol oxidation in the plasma samples, it was 
imperative to quantify plasma concentrations of MPO substrates and determine whether 
the smoking status influences their levels. Ion-exchange chromatography (Dionex) was 
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employed to quantify plasma SCN
-
 (Figure 3.2 A) and Br
- 
(Figure 3.2 B) levels as 
described in Chapter 2, Section 2.3.5. As NO2
-
 determination by ion-exchange 
chromatography was not possible due to difficulties in integration of the NO2
-
 peak owing 
to its small size and close proximity to other components of the plasma, NO2
-
concentrations were determined by fluorescence using a commercial detection kit. 
 
 
Figure 3.2  Representative Dionex HPLC chromatogram of SCN
-
 and Br
-
 from 
plasma samples 
A) SCN
-
 trace, B) Br
-
 trace; red traces represent plasma samples obtained from smokers, 
black traces – non-smokers. Unlabeled peaks are unknown eluting species.  
 
Plasma SCN
-
 concentrations were determined to be significantly elevated in current 
smokers (mean SCN
-
: 106 ± 24 µM), compared to both non-smokers (mean SCN
-
:          
47 ± 26 µM, P < 0.0001) and past smokers (mean SCN
-
: 55 ± 24 µM, P < 0.0001;    
Figure 3.3 A). In contrast, neither plasma Br
-
 concentrations (mean Br
-
 : non-smokers    
97 ± 60 µM; smokers 80 ± 54 µM; past smokers 91 ± 59 µM; Figure 3.3 B), nor NO2
-
 
concentrations (mean NO2
-
: non-smokers, 4.2 ± 2.3 µM, smokers, 3.6 ± 2.4 µM;          
past smokers, 4.7 ± 2.5 µM; Figure 3.3 C) were significantly different between the 
groups. Plasma levels of Cl
-
 were not measured as this anion is present in plasma at 
significantly higher concentration than other MPO substrates (mM vs. µM) and small 
changes in its levels would not be expected to affect its availability for MPO. 
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Figure 3.3 Plasma concentrations of SCN
-
, Br
-
, and NO2
-
 in non-smokers, smokers, 
and past-smokers. 
Plasma levels of (A) SCN
-
, (B) Br
-
, and (C) NO2
-
. Mean levels are shown by ―+‖, whilst 
boxes represent medians (lines) and interquartile ranges, and whiskers represent the 5th 
and 95th percentiles. Statistical analysis was by 1-way ANOVA with Tukey‘s post-hoc 
test; ***P < 0.001 vs. both other conditions. There were no significant differences in 
panels B and C (P > 0.05). 
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3.4.3 Plasma thiol oxidation status 
The elevated SCN
-
 concentrations observed in the smokers might be expected to result in 
increased production of HOSCN by MPO. As HOSCN is predominantly a thiol-specific 
oxidant (98), it has been hypothesised that the elevated SCN
-
 levels might result in 
increased plasma thiol oxidation. This has previously been observed in a smaller study 
(90). To examine this phenomenon in the current study, experiments were conducted 
under simulated inflammatory conditions, whereby plasma (diluted 5-fold) was treated 
with MPO (100 nM) and H2O2 (200 µM); these levels are of a similar magnitude to those 
reported at sites of inflammation (63, 273). The method used in the current study 
measures the total plasma thiol concentration, including free low-molecular-mass thiols 
(very low levels present in plasma) and protein-bound thiols (predominantly human 
serum albumin, which contains a single Cys34 residue) (274). In contrast to the previous 
study, the extent of thiol loss in the presence of MPO plus H2O2 was not significantly 
higher in the smoking group than in the two non-smoking groups (Figure 3.4). 
3.4.4 Correlation studies 
The lack of a significant increase in MPO/H2O2-dependent thiol loss in the smoking 
group was surprising, since their elevated SCN
-
 levels might have been expected to result 
in increased HOSCN formation. This has been seen previously in smokers vs. non-
smokers (90). Therefore, in order to examine this phenomenon further, studies were 
carried out to determine whether MPO/H2O2-derived thiol loss correlated with the other 
parameters measured that are relevant to MPO function. 
 
The initial analysis examined possible correlations in the entire cohort. When 
MPO/H2O2-stimulated thiol losses for the whole cohort were plotted against their plasma 
SCN
-
 concentration, a significant positive correlation was observed whereby the patients 
with higher SCN
-
 concentrations exhibited increased MPO-induced thiol loss (r = 0.1894, 
P = 0.0099; Figure 3.5 A). In contrast, neither Br
-
 (Figure 3.5 B; r = 0.0493) nor NO2
-
 
(Figure 3.5 C; r = -0.0209) concentrations correlated significantly with MPO-induced 
thiol loss (P = 0.2830 and P = 0.4189, respectively).  
 
65 
 
Further correlation analysis was carried out, whereby patients were categorised according 
to their smoking status. This showed a strong, statistically significant, correlation between 
MPO-derived thiol loss and plasma SCN
-
 concentrations in the smokers (r
2
 = 0.3335,      
P < 0.0001; Figure 3.6 A), but not in the non-smokers (r
2
 = 0.0003, P = 0.4439; Figure 
3.6 B) or past smokers (r
2
 = 0.0089, P = 0.2654; Figure 3.6 C). Taken together, these 
results confirm that elevated SCN
-
, but not other MPO substrates, is associated with 
increased thiol loss under conditions mimicking those at inflammatory sites. 
 
                           
Figure 3.4 Loss of protein thiols in plasma samples of non-smokers, smokers and 
past smokers subjected to oxidative stress.  
Plasma samples from non-smokers, smokers, and past-smokers, were diluted five-fold, 
and incubated for 30 min at 21
o
C with added MPO (100 nM) and H2O2 (200 μM), before 
quantification of residual thiols by DTNB assay. Mean levels are shown by ―+‖, whilst 
boxes represent medians (lines) and interquartile ranges, and whiskers represent the 5th 
and 95th percentiles. Statistical analysis was by 1-way ANOVA with Tukey‘s post-hoc 
test; there were no significant differences between groups. 
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Figure 3.5 Correlation between MPO/H2O2-induced thiol loss and plasma SCN
-
, Br
-
 
and NO2
-
 concentrations  
Thiol loss was calculated as the difference between initial untreated plasma thiols, and 
those following incubation with MPO (100 nM) + H2O2 (200 μM) in plasma diluted       
5-fold and correlated with plasma concentrations of (A) SCN
-
 (r = 0.1894, P = 0.0099), 
(B) Br
-
 (r = 0.0493, P = 0.2830) and (C) NO2
- 
(r = -0.0209, P = 0.4189) in the entire 
cohort of post myocardial infarction patients. Correlation analysis was by one-tailed 
Spearman correlation. 
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Figure 3.6 Correlation plots comparing MPO/H2O2-induced thiol loss, and plasma 
SCN
- 
concentrations at the time of hospital admission 
MPO-dependent thiol oxidation in (A) smokers (r
2
 = 0.3335, P < 0.0001),                     
(B) non-smokers (r
2
 = 0.0003, P = 0.4439), and (C) past smokers (r
2
 = 0.0089,                 
P = 0.2654). Correlation analysis was by one-tailed Pearson correlation. 
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3.4.5 Survival analysis 
In the light of the correlation data, possible associations between SCN
-
 levels, MPO and 
long-term patient survival were investigated. 
 
Of the 176 patients, 51 (29%) died during the 12-year follow-up period. In order to 
examine any association between MPO and SCN
- 
concentrations and patient survival, 
Kaplan-Meier survival analyses were performed. When patients were classified according 
to their plasma MPO concentrations, those with above-median plasma MPO levels 
exhibited significantly decreased survival compared to those with below-median plasma 
MPO levels (62% vs. 80%, respectively; P = 0.0068; Figure 3.7 A). These results are 
consistent with the 5-year data reported previously (57) for the larger cohort of              
512 patients from which the current subjects were randomly selected. When the patients 
were classified according to their plasma SCN
-
 concentrations, those with above-median 
SCN
-
 exhibited significantly higher survival than those with below-median                
SCN
- 
(77% vs. 64%, respectively, P = 0.0478; Figure 3.7 B).  
 
The effects of elevated SCN
-
 on MPO-mediated damage were examined by stratifying the 
patients on the basis of their plasma MPO and SCN
-
 levels (above- and below-median 
MPO, above- and below-median SCN
-
). Those with below-median MPO and above-
median SCN
-
 had the highest survival after 12 years (89%). Furthermore, their survival 
was significantly higher when compared to subjects who had below-median MPO and 
below-median SCN
-
 (70% survival; P = 0.0285), as well as the groups with above-
median MPO, and either above-median SCN
-
 (64% survival; P = 0.0074) or              
below-median SCN
-
 (59% survival, P = 0.0009). There were no significant differences in 
survival between the other three groups (Figure 3.7 C). 
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Figure 3.7 Kaplan-Meier survival curves in post-myocardial infarction survivors 
over a 12-year follow-up period. 
Patients were classified according to above- and below-median levels of (A) plasma MPO 
(black: MPO < med, red: MPO > med), (B) plasma SCN
-
 (blue: SCN
-
 > med, green: SCN
-
 
< med), and (C) both MPO and SCN
-
 (purple: MPO < med / SCN
- 
> med; aqua: MPO < 
med / SCN
-
 < med; grey: MPO > med / SCN
-
 > med; orange: MPO > med / SCN
-
 < med). 
The median MPO level was 56.5 ng/mL, and the SCN
-
 median was 47.9 μM. Statistical 
comparison of survival curves was by log-rank test (Mantel-Cox). 
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3.4.5.1 Effect of age on survival 
The effect of age at admission on these results was examined in light of data indicating 
that people who smoke are significantly younger at the time of their first infarction 
compared to non-smokers (57, 275). Consistent with these data, those who smoked at the 
time of admission were significantly younger than both the non-smokers and past 
smokers (Table 3.1, P < 0.05, 1-way ANOVA with Tukey‘s post-hoc test). The patients 
who died during the 12-year follow-up were, as expected, also significantly older than 
those who survived (68.9 ± 9.0 vs. 58.9 ± 10.2 years, respectively; P < 0.0001, unpaired 
one-tailed t-test). However, when patients were stratified according to above- and below-
median MPO and SCN
-
 concentrations (Figure 3.8 A), there were no significant 
differences between the age at admission of the 4 groups. Thus initial age does not appear 
to confound the association between MPO and SCN
-
 levels and survival rates. Correlation 
analysis was also carried out to determine whether age had significant effects on plasma 
SCN
-
 or MPO concentrations. A significant negative correlation was detected between 
SCN
- 
concentrations and age at admission (r = -0.2561, P = 0.0019; Figure 3.8 B); 
however plasma MPO levels did not correlate significantly with age (r = 0.1464, P = 
0.0768; Figure 3.8 C). 
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Figure 3.8 Effects of age on survival in the post-myocardial infarction survivors 
Subjects were categorised according to (A) above- and below-median MPO and SCN
- 
concentrations, mean levels are shown by ―+‖, whilst boxes represent medians (lines) and 
interquartile ranges, and whiskers represent the 5th and 95th percentiles, (B) plasma SCN
-
 
concentrations and age at admission (r = -0.2561, P = 0.0019), and (C) plasma MPO 
concentrations and age at admission (r = 0.1464, P = 0.0768). Statistical analysis in (A) 
was by 1-way ANOVA with Tukey‘s post-hoc test, and in (B, C) by two-tailed Spearman 
correlation. 
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3.5 Discussion 
The data presented in this Chapter demonstrate that exposure of human plasma to a 
simulated inflammatory insult (added MPO and H2O2, as might occur at sites of 
inflammation) results in a positive correlation between the extent of oxidation-induced 
thiol loss and plasma SCN
-
 concentrations. This correlation is particularly powerful for 
smokers, when considered as a separate group. No correlation was seen with non-smokers 
when considered as a separate group, possibly as a result of the lower range of SCN
-
 
values detected in this group. These results are consistent with a previous small study of 
healthy subjects (90). Serum SCN
-
 levels have been reported to correlate with the extent 
of LDL deposition and fatty streak formation in the aortae of young people (265). 
Similarly, smokers with high SCN
-
 levels have greater macrophage foam cell populations 
compared to non-smokers (107). However, smoking per se has been shown to increase 
the levels of circulating leukocytes and H2O2 production which may account for some of 
this correlation (276, 277). These observations are supported by studies showing that 
SCN
-
 increases the extent of MPO-induced damage to plasma lipids and LDL (108, 278).  
 
The 12-year survival data reported in the present study are in agreement with numerous 
previous reports of an association between increased MPO levels and adverse 
cardiovascular outcomes (45, 54, 55, 57, 260, 279-281). Whilst these data strongly 
support a role for MPO and HOCl in damage in the inflamed arterial wall, the role of 
HOSCN, which appears to be generated by MPO in high yields under some 
circumstances (particularly in smokers), is less well established, though some indirect 
evidence supports a role for this oxidant in tissue damage at sites of inflammation. Thus 
elevated levels of carbamylated Lys residues (homocitrulline) have been detected on 
proteins from human atherosclerotic lesions, with this modified amino acid potentially 
arising from the reactions of 
-
OCN derived from HOSCN decomposition (15, 266). 
Carbamylation of HDL-associated proteins, and particularly apolipoprotein A-I, has been 
shown to render HDL dysfunctional in vitro, and markedly elevated levels of 
carbamylated HDL have been shown to be present in human atherosclerotic lesions (266, 
282). However, the mechanisms by which 
-
OCN induces this protein modification (from 
urea, HOSCN decay or other reactions) remain to be established (15, 282).  
73 
 
In the light of these data, and studies showing that the thiol redox state of plasma is 
associated with increased disease and is an independent predictor of early atherosclerosis 
(119, 120, 264), it was hypothesised that high plasma MPO and SCN
- 
levels would result 
in decreased long-term survival. Unexpectedly, this hypothesis was not supported by the 
current study, with the survival analysis results showing that above-median levels of 
SCN
-
 were associated with a decreased rate of mortality over the 12-year follow-up 
period. This effect was most marked in the patients with below-median MPO 
concentrations. This is consistent with reports that high SCN
- 
levels are protective in 
other situations ((97, 250), reviewed in (37, 251)). 
 
The enhanced thiol loss induced by adding MPO/H2O2 to plasma from subjects with high 
SCN
- 
levels is postulated to arise from increased HOSCN formation instead of HOCl. 
This switch from HOCl to HOSCN generation is consistent with previous data (90, 261) 
and may rationalise the absence of any correlation between MPO and plasma protein      
3-Cl-Tyr levels (mentioned in Section 3.3.1) in the larger cohort previously studied, of 
which the subjects in the current study are a subset (57). A recent study has reported that 
SCN
-
 levels correlate inversely (in both smokers and non-smokers) with plasma protein 
3-Cl-Tyr levels, thereby potentially confounding measurement of this biomarker (261). 
 
HOCl is the major oxidant formed by MPO when Cl
-
 is abundant and SCN
-
 
concentrations are low (84, 90). This oxidant reacts with multiple biological targets 
(reviewed in (32, 37)), and proteins in particular due to their abundance (283). Damage 
occurs at multiple protein residues with high HOCl concentrations, resulting in 
irreversible (non-repairable) oxidation (Scheme 3.1) and modulation of metabolic 
activity. In contrast, HOSCN reacts primarily with thiols (98, 101, 263) and seleno 
species (e.g. Sec) (262). Under conditions where high levels of HOSCN are formed (e.g. 
in smokers), thiol oxidation is therefore likely to be a major process in cells, given their 
high GSH and protein thiol levels (~1 – 10 mM and ~60 – 90 mM respectively (284)). 
This oxidation is likely to be repairable at low oxidant levels due to the plethora of 
cellular oxidised thiol repair systems (109, 160, 194, 285-287). In contrast, extracellular 
fluids have low free thiol levels (< 10 M low-molecular mass, and 600 – 700 M on 
proteins; primarily serum albumin Cys34 (61)), and there is limited repair capacity. Thus 
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with low oxidant fluxes, HOSCN generation may be protective as the extent of 
irreversible damage induced by this oxidant is likely to be low compared to HOCl. This 
may rationalise the protective effects of high SCN
-
 detected in people with cystic fibrosis 
(97), and the decreased mortality of people with high SCN
-
 levels observed here (cf. 
Scheme 3.1). These findings are in contrast to a large previous study that reported an 
increase in 15-year all-cause mortality in patients with elevated levels of serum SCN
- 
(288). The apparent discrepancy might be explained by the fact that SCN
-
 levels were 
measured using a colourimetric method which was not specific to SCN
-
, unlike the 
chromatographic method used in the current study. Additionally, patients in the current 
study were myocardial infarction survivors, with an age range 36 – 80 years at the time of 
infarction, whereas subjects the study by Heliovaara et al. were initially healthy 
volunteers aged between 40 and 59.  
 
The data reported in this Chapter may help rationalise the previously reported ―smoker‘s 
paradox‖ where smokers have a lower mortality rate following an acute myocardial 
infarction (289), with this potentially arising from enhanced formation of repairable (via 
HOSCN) compared to irrepairable damage (from HOCl). However, whilst low levels of 
HOSCN give rise to readily repaired Cys-derived oxidation products (e.g. RS-SCN 
adducts, sulfenic acids and disulfides, which can be repaired by GSH and enzymatic 
systems including Grxs and Trxs (285, 290, 291)), high oxidant fluxes or chronic 
exposure can result in over-oxidation of thiols with formation of irreversible products 
(e.g. cysteic acid) (103) and enhanced cellular dysfunction, apoptosis and necrosis (101). 
There may therefore be a limited window in which high levels of SCN
-
 are protective 
(Scheme 3.1). 
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Scheme 3.1 Proposed mechanism for the effect of plasma SCN
-
 levels on the nature, 
extent and consequences of biological damage induced by MPO-derived oxidants.  
In the top half of the scheme (non-smokers) stimulation of leukocytes results in the 
release of MPO and generation of H2O2 by NADPH oxidases. MPO uses the H2O2 to 
generate HOCl and HOSCN with the former predominating, due to the typically low 
plasma levels of SCN
-
 in these subjects. The generation of significant concentrations of 
these oxidants results in both reversible and irreversible damage at sites of inflammation. 
That generated by the low levels of HOSCN is believed to be predominantly reversible, 
whereas that arising from HOCl also encompasses significant levels of irreversible 
damage. In smokers (lower half of figure), there is enhanced oxidation formation, due to 
higher levels of superoxide (O2
•-
) generation, and the higher plasma levels of SCN
-
 results 
in increased formation of HOSCN over HOCl. The higher levels of HOSCN result in 
increased thiol oxidation, due to the specificity of this oxidant for such targets, and both 
reversible and irreversible damage. The latter arises from over-oxidation of thiols to oxy-
acids (e.g. cysteic acid) when oxidant fluxes are high.  
 
 
The current study has several limitations. The first of these is the relatively small sample 
size, though these patients have been studied over a relatively long time span that has 
resulted in a significant number of deaths. A second limitation is that the mortality data 
are for all causes, rather than CVD alone. However it is likely, given that the subjects all 
had well-established CVD, that a significant proportion of the deaths arose from this 
condition. The conclusions would be stronger if the study was extended to a larger cohort 
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with all the necessary data to conduct sophisticated studies of associations with well-
defined cardiovascular events including recurrent myocardial infarction, heart failure 
episodes, arrhythmic episodes, and cerebrovascular and peripheral vascular events; the 
current study can do no more than offer essentially univariate association data. Proven 
and putative independent predictors of outcome after acute myocardial infarction, that 
could be considered include infarct size, indices of left ventricular structure and function, 
plasma indices of neurohormonal activation, renal function, background hypertension, 
diabetes, surgical or percutaneous coronary interventions, the prescription (or not) of 
relevant drugs and continuation or resumption (or not) of smoking over the follow-up 
interval.  
 
The observation that subjects with low MPO and high SCN
-
 had the lowest rates of all-
cause mortality (and probably cardiovascular deaths) would be worth examination in a 
prospective study, as the current data are limited by the examination of patients who 
survived a first myocardial infarction. Thus the data and associations reported here may 
be skewed by the absence of data from those that did not survive, and the potential for 
younger smokers to be more likely to survive an initial event. The apparent protective 
effects of high SCN
-
 levels may also reflect other lifestyle effects, as SCN
- 
levels are 
elevated by particular foods (e.g. certain beans, fruits and vegetables). Elimination of this 
variable is not possible with the current data. Future studies should therefore measure 
plasma cotinine levels, as soon as practicable following admission, as this nicotine 
metabolite correlates positively with SCN
-
 concentrations (261, 292), and may clarify the 
contribution of smoking-derived SCN
-
. A final caveat arises from the observed inverse 
correlation between plasma SCN
-
 levels and patient age, which may confound some 
analyses. It is not clear whether this reflects diet (see above), or a decreased efficacy of 
cyanide detoxification to SCN
-
 by the mitochondrial enzyme rhodanese with uses 
thiosulphate as a co-factor (87, 88); quantification of this enzyme activity may help to 
address this question. 
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3.6 Conclusions 
Overall, this study indicates that elevated plasma MPO levels are associated with 
increased all-cause mortality over a 12-year period in patients who survived a first 
myocardial infarction. Patients with high plasma SCN
-
 levels had better survival than 
those with low levels; those who also had low levels of MPO had the highest survival 
rates. High plasma SCN
-
 levels were, however, associated with enhanced levels of 
MPO/H2O2-dependent thiol oxidation, with this ascribed to preferential formation of the 
highly selective oxidant HOSCN over the highly-damaging alternative oxidant HOCl. It 
is therefore proposed that elevated levels of plasma SCN
-
 may afford protection when the 
overall extent of oxidative insult is low; in contrast, extensive formation of HOSCN may 
result in selective damage to critical tissue targets, irreversible thiol oxidation and adverse 
outcomes.  
 
These studies on the mechanism of damage caused by MPO-derived oxidants are 
extended in the following Chapter to investigate the role of intracellular antioxidant 
systems of murine macrophage-like cells J774A.1 in providing possible protection 
against damage. A number of intracellular antioxidant enzymes involved in thiol repair, 
such as TrxR, GPx, Trxs, Grxs and Prxs, contain highly reactive low pKa Cys or Sec 
residues at their active sites and are therefore predicted to be targets for HOSCN. By 
modulating the levels of these enzymes in J774A.1 cells, it was hoped that further 
insights into their protective role against MPO-derived oxidants and the adequacy of this 
protection would be obtained.   
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CHAPTER 4. Effects of HOSCN and HOCl on seleno-dependent 
enzymes, glutathione and metabolic activity of J774A.1 murine 
macrophage-like cells 
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4.1 Introduction 
It is well documented that proteins are the main targets of (pseudo)hypohalous acids 
(HOCl, HOBr and HOSCN) (32). HOSCN is a less powerful and less reactive oxidant 
than HOCl and HOBr, but it is much more specific, oxidising primarily sulfhydryl groups 
on proteins and low-molecular mass thiols (rate constants range 10
4
 – 106 M-1s-1 (98)). It 
has been shown that protein thiol reactivity with HOSCN partially depends on the thiol 
pKa value; ionised (RS
-
, low pKa) thiols are stronger nucleophiles than neutral thiols 
(RSH, high pKa) and therefore react more rapidly (35, 98). A number of thiol-containing 
enzymes involved in antioxidant defence systems, including GR (217), Grxs (160), Prxs 
(293) and Trxs (194), have catalytic low pKa Cys residues at their active sites and, 
therefore, are likely to be preferred targets for MPO-derived oxidants (98). Moreover, it 
has been recently shown that HOSCN also reacts very rapidly (in vitro) with the selenium 
present in Sec located at the active sites of seleno enzymes, including TrxR (185) and 
GPx (221, 262). The GSH thiol has a relatively high pKa of ~8 (109) and, therefore, does 
not always protect lower pKa thiols from damage, despite being present at much higher 
concentrations (1 - 10 mM (284)).   
 
It has been shown that the recruitment of circulating monocytes into the inflamed arterial 
wall is an early event in the development and progression of atherosclerosis (10). 
Following recruitment, monocytes differentiate into macrophages under the influence of 
macrophage colony-stimulating factor (M-CSF), as well as other differentiation factors 
(reviewed in (9)) and these macrophages subsequently accumulate lipid from 
apolipoprotein B-containing lipoproteins (LDL) resulting in foam cell formation. As 
discussed in Chapter 3, MPO and MPO-derived oxidants have been implicated in the 
development of atherosclerosis and associated conditions. Therefore, it was of interest to 
investigate the effects of MPO-derived oxidants on macrophages given the importance of 
these cells in atherogenesis. J774A.1 murine monocyte-derived macrophage-like cells 
were chosen, as this is an established cell line used for inflammation and immune studies 
(101, 258, 294, 295).  
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It has been shown previously that J774A.1 cells consume HOSCN (101, 103), with 
subsequent perturbation of various cell functions, including the induction of apoptotic 
pathways (101), alteration of MAPK signalling, inhibition of protein tyrosine phosphatase 
(PTP) activity (104) and inactivation of GAPDH and CK (103). The effects of HOSCN 
on cellular seleno enzymes, however, have not been studied extensively though limited 
work has been carried out on isolated proteins (262).  
 
Previous studies have shown that the level and activity of GPx and TrxR in various cell 
types and animal models can be manipulated by selenium supplementation or deficiency 
(141, 148, 149, 216, 254, 296-298) due to the presence of a Sec residue at the catalytic 
sites of these enzymes. In the experiments presented in this Chapter, a similar approach 
has been employed to study the effects of HOSCN and HOCl on GPx and TrxR of 
J774A.1 macrophages. Two forms of selenium were chosen for supplementation: the 
inorganic salt, sodium selenite, and the organic, naturally occurring amino acid seleno-L-
methionine.  
4.2  Aims 
The aim of this Chapter was to investigate and compare the effects of HOSCN and HOCl 
on the J774A.1 macrophage seleno enzymes TrxR and GPx, and the low-molecular mass 
thiol GSH. The activities of these enzymes were manipulated by selenium 
supplementation, and the potential benefits of this supplementation on cell viability and 
function were examined. The effects of HOCl were studied in parallel with HOSCN, as 
much more is known about the reactions of HOCl with proteins and thiols. Thus it would 
be valuable to directly compare the reactivities of these two MPO-generated oxidants, in 
order to better understand the role of HOSCN on cells, particularly with respect to protein 
oxidation. 
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4.3 Results 
4.3.1 Glutathione peroxidase (GPx) activity  
In order to modulate the activity of GPx, J774A.1 cells were supplemented with           
500 nM sodium selenite or 5 µM seleno-L-methionine (diluted in the normal cell medium, 
containing DMEM, 10% FBS and L-glutamine) overnight. These concentrations of seleno 
compounds were previously determined to be sub-lytic for J774A.1 cells and therefore 
safe to use in the short-term supplementation experiments (299). Control samples did not 
contain any added seleno compounds in the medium. HOSCN and HOCl (0, 100 or     
200 μM) were prepared immediately before use (as described in Section 2.3.9) and 
incubated with cells for 1 hr at 22 °C. The incubation was followed by washing the cells 
with PBS, lysing them in water on ice, and measuring GPx activity by monitoring the 
change in NADPH consumption (340 nm, 15 min at 1 min intervals, 37 °C) in the 
presence of added GSH, GR and t-Bu-OOH. GPx activity was determined as a change in 
absorbance at 340 nm over time and expressed as the percentage of non-supplemented, 
untreated control cells (expressed as 100%).  
 
GPx activity significantly increased in cells that were not exposed to oxidants with both 
sodium selenite (Figure 4.1 A, black bar) and seleno-L-methionine (Figure 4.1 A, grey 
bar) supplementation. HOSCN treatment did not cause any measurable loss in GPx 
activity, regardless of selenium supplementation (Figure 4.1 B), whereas HOCl caused a 
significant concentration-dependent decrease in both non-supplemented and selenium-
supplemented cells (Figure 4.1 C). GPx activity loss was significantly greater in non-
supplemented compared to sodium selenite supplemented cells following exposure to  
100 µM HOCl (Figure 4.1 C, white vs. black bars), and significantly higher relative to 
both sodium selenite and seleno-L-methionine supplemented samples after treatment with 
200 µM HOCl (Figure 4.1 C, white vs. black and grey bars).  
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Figure 4.1 The effects of selenium supplementation and hypohalous acid treatment 
on GPx activity.  
J774A.1 cells (5 x 10
5
 cells/mL) were incubated overnight without selenium 
supplementation (white bars) or in the presence of either sodium selenite (black bars) or 
seleno-L-methionine (grey bars) followed by the exposure to 0 – 200 µM (B) HOSCN or 
(C) HOCl for 1 hr. Residual GPx activity was estimated from the rate of NADPH 
consumption in the presence of excess GSH, GR and t-Bu-OOH reduction, with this 
quantified by continuous measurement of light absorbance at 340 nm. Data represent 
mean ± SEM (n = 3) and results are expressed as a percentage of (A) non-supplemented, 
untreated control or (B and C) untreated control. *** indicates significant decrease in GPx 
activity compared to (A) non-supplemented, untreated cells or (B and C) untreated 
control cells (P < 0.001, 1-way ANOVA with Tukey‘s post-hoc tests), #/##/### denote 
significant difference (P < 0.05/0.01/ 0.001, respectively) compared to sodium selenite or 
seleno-L-methionine supplemented cells according to 2-way ANOVA with Bonferroni‘s 
post-hoc test.  
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4.3.2 Thioredoxin reductase (TrxR) activity 
Prior to the measurement of TrxR activity, cells were supplemented with selenium 
compounds in the same manner as described for GPx activity quantification. Following 
the incubation of J774A.1 cells with 0 – 200 µM HOSCN or HOCl for 1 hr at 22 ºC 
(detailed in Section 2.3.14.), TrxR activity was measured by monitoring the NADPH-
dependent reduction of DTNB in the absence or presence of the TrxR inhibitor auranofin. 
The inclusion of auranofin in the reaction was necessary for the correction of DTNB 
reduction by mechanisms other than TrxR mediated reactions, such as with GSH or other 
reductases. TrxR activity was calculated as the change in absorbance at 412 nm over 
time. Prior to calculating TrxR activity in samples, the background activity (0.092 ± 
0.005 μmol/min/mL) and background activity with added auranofin (0.042 ± 0.021 
μmol/min/mL) were determined. When corrected for non-TrxR-specific absorbance, the 
TrxR activity in non-supplemented, untreated cells was 1.76 ± 0.020 μmol/min/mL. The 
activity of the rest of the samples was expressed as a percentage of non-supplemented, 
untreated control cells (assigned as 100% TrxR activity) 
 
Sodium selenite supplementation significantly increased TrxR activity in non-oxidant 
treated cells (Figure 4.2 A, black bar); TrxR activity in seleno-L-methionine 
supplemented cells also increased compared to non-supplemented cells, however to a 
lesser degree (Figure 4.2 A, grey bar). J774A.1 exposure to 200 µM (but not 100 µM) 
HOSCN resulted in the statistically significant reduction in TrxR activity (~80% 
decrease) irrespective of selenium supplementation (Figure 4.2 B), whilst 100 µM HOCl 
caused a statistically significant (~28%) reduction of TrxR activity in non-supplemented 
cells compared to 0 µM oxidant (Figure 4.2 C white bars). Treatment of J774A.1 cells 
with 200 µM HOCl led to a significant, ~25% reduction of TrxR activity in sodium 
selenite supplemented cells (Figure 4.2 C, black bars) and did not result in further loss of 
TrxR activity in non-supplemented cells (~28% loss) (Figure 4.2 C, white bars). Seleno-
L-methionine supplementation appeared to prevent TrxR activity loss upon HOCl 
treatment, as no significant reduction of TrxR activity was observed in                    
seleno-L-methionine supplemented samples over the concentration range examined 
(Figure 4.2 C, grey bars). 
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Figure 4.2 The effect of selenium supplementation and hypohalous acid treatment 
on thioredoxin reductase activity. 
 J774A.1 cells (5 x 10
5 
cells/mL) were supplemented with seleno compounds and treated 
with oxidants as per Figure 4.1. White bars represent non-supplemented cells, black bars 
– sodium selenite supplemented cells and grey bars – seleno-L-methionine supplemented 
cells. TrxR activity was estimated from the rate of TNB formation from added DTNB, 
measured continuously at 412 nm. Data represent means ± SEM (n = 3) results are 
expressed as a percentage of (A) non-supplemented, untreated control or (B, C) untreated 
control. */**/*** indicate significant decrease in TrxR activity compared to (A) non-
supplemented, untreated cells or (B and C) untreated control cells (P < 0.05/0.01/0.001, 
respectively, as assessed by 1-way ANOVA with Tukey‘s post-hoc test). No significant 
difference was observed between non-supplemented cells and those supplemented with 
the seleno compounds as determined by 2-way ANOVA with Bonferroni‘s post-hoc tests 
at each oxidant concentration. 
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4.3.3 GPx and TrxR protein levels 
In order to confirm that the loss in GPx and TrxR activities was not due to the oxidant-
induced changes in protein expression levels of these enzymes, Western blot experiments 
were performed as detailed in Section 2.3.12. The effects of selenium supplementation on 
the levels of protein expression of these enzymes were also assessed. 
 
Treatment of J774A.1 cells with HOSCN or HOCl did not significantly change the levels 
of TrxR or GPx protein expression (Figure 4.3). This suggests that the observed changes 
in TrxR and GPx activities are not associated with impaired protein expression.  
 
Supplementation with either 500 nM sodium selenite (Figure 4.3 B (b)) or 5 μM     
seleno-L-methionine (Figure 4.3 B (c)) markedly increased the expression of TrxR and 
GPx proteins, which is consistent with previous studies (Rahmanto et al., unpublished 
data).        
 
4.3.4 Effects of selenium supplementation and oxidant treatment on levels of 
intracellular glutathione (GSH) in J774A.1 cells 
Previous studies have shown that GSH in various cell types is susceptible to oxidation by 
HOCl. Exposure of neutrophils (124), human umbilical vein endothelial cells (HUVEC) 
(125) or human RBC (242) to HOCl resulted in the concentration-dependent loss of GSH 
without any marked increase in GSSG levels. The effects of HOSCN, however, have not 
been studied as extensively. In order to determine the extent and possible fate of GSH 
upon HOSCN and HOCl treatment of J774A.1 cells following selenium supplementation, 
HPLC analysis was carried out as detailed in Section 2.3.11. Supplementation of J774A.1 
cells with selenium was performed as described in Section 2.3.8. 
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Figure 4.3 The effects of oxidant treatment and selenium supplementation on 
protein levels of TrxR1 and GPx1 in J774A.1 cells 
J774A.1 cells (5 x 10
5 
cells/mL) were supplemented with seleno compounds and treated 
with oxidants as per Figure 4.1. Protein expression levels of TrxR and GPx were 
examined by Western blotting of protein lysates separated by 15% SDS-PAGE under 
reducing conditions as described in Section 2.3.12. Representative blots of (A) non-
supplemented J774A.1 cells treated with 0 – 200 μM HOSCN or HOCl, (B) and (C) 
J774A.1 cells (a) non-supplemented or supplemented with (b) sodium selenite or (c)                     
seleno-L-methionine. The blots are representative images from 3 individual experiments. 
Densitometry (ImageJ) of 3 independent Western blots.  
 
 
Initial levels of GSH in J774A.1 cells were determined to be ~40 µM in the non-oxidant 
treated cells at the end of the incubation period (Figure 4.4) which is lower than the 
previously reported level of ~75 µM (101, 299). This might be due to the fact that 
previously J774A.1 cells were exposed to the oxidants for only 15 min (101) as opposed 
to 1 hr in the current study, or because the cells were incubated in glucose containing 
HBSS in one of the previous studies (299). Longer incubation times and the absence of 
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glucose might result in a stress on the cells, resulting in diminished antioxidant capacity 
manifesting itself in lower GSH levels. 
 
Nevertheless, the baseline levels (i.e. no oxidant treatment) of GSH in non-supplemented 
cells, and sodium selenite and seleno-L-methionine supplemented cells were not 
significantly different (Figure 4.4 A and C, 0 μM oxidant). HOSCN treatment caused a 
significant concentration-dependent decrease in GSH levels (Figure 4.4 A) with a 
corresponding increase in GSSG formation (Figure 4.4 B). As the stoichiometry of GSH 
oxidation to GSSG is normally 2:1, the observed loss in GSH did not exactly match the 
increase in GSSG levels. For every 10 µM decrease in GSH only 1 – 2.5 µM GSSG was 
formed, suggesting that other reactions, such as mixed disulfide formation, might be 
taking place. These possible alternative products of GSH oxidation were not investigated 
further in the current study. 
 
Interestingly, exposure of J77A.1 cells to HOCl did not result in any measurable loss of 
GSH or increase in GSSG levels (Figure 4.4 C; GSSG was not detected). 
 
Selenium supplementation did not make any significant difference to GSH levels after 
treatment of cells with HOSCN or HOCl (Figure 4.4 A and C). However,                 
seleno-L-methionine supplementation resulted in a significant increase in GSSG 
formation in J774A.1 cells treated with 200 µM HOSCN, in comparison to                 
non-supplemented cells (Figure 4.4 B, grey vs. white bars). 
88 
 
 
Figure 4.4 Intracellular GSH/GSSG levels in J774A.1 cells following selenium 
supplementation and oxidant treatment 
J774A.1 cells (5 x 10
5
 cells/mL) were non-supplemented (white bars) or supplemented 
with seleno compounds (black bars – sodium selenite, grey bars – seleno-L-methionine) 
and treated with (A and B) HOSCN or (C) HOCl as per Figure 4.1 caption and Sections 
2.3.8 and 2.3.10.1. GSH and GSSG levels were quantified by HPLC with fluorescence 
detection after derivatisation with dansyl chloride as outlined in Section 2.3.11. Values 
are mean (n = 3) ± SEM, *** indicates significant difference (P < 0.001) compared to the 
0 µM oxidant treatment; # denotes a significant difference (P < 0.05) between non-
supplemented and seleno-L-methionine supplemented cells, as assessed by 2-way 
ANOVA with Bonferroni‘s post-hoc test.  
4.3.5 Cellular function following oxidant treatment 
In order to investigate whether selenium supplementation has any beneficial effects on 
cellular mitochondrial function following oxidant treatment, an MTT assay was 
performed as described in Section 2.3.17. Metabolically active cells reduce the water-
soluble tetrazolium salt by mitochondrial dehydrogenase enzymes to form water-
insoluble purple formazan crystals; these are subsequently dissolved using a 
solubilisation agent and the absorbance of the resulting solution is directly proportional 
0 100 200
0
20
40
60
*** *** ***
* ** **
HOSCN (M)
G
S
H
 (

M
)
0 100 200
0
2
4
6
8
10
***
***
***
#
HOSCN (M)
G
S
S
G
 (

M
)
0 100 200
0
20
40
60
HOCl (M)
G
S
H
 (

M
)
A) B)
C)
89 
 
the cell number. The MTT assay is often referred to as a ―viability assay‖, however the 
activity of mitochondrial dehydrogenase enzymes does not necessarily reflect cell 
viability. For instance, RBC do not contain mitochondria and therefore do not have 
means to metabolise tetrazolium salt; however, this does not result in a loss of viability 
(300). Accordingly, in this thesis the MTT assay is used to assess cellular metabolic 
activity rather than cell viability. Metabolic activity was assessed as the percentage of 
control cells (treated with 0 µM oxidant) which were defined as 100% functional. 
Selenium supplementation conditions were as described in Sections 2.3.8 and 4.3.1. 
 
Initially, 100 µM and 200 µM concentrations of the oxidants were used. This resulted in a 
sharp drop in metabolic activity after 100 µM HOCl treatment (~75% decrease) and a 
moderate decrease upon exposure to 200 µM HOSCN (~20% decrease, Figure 4.5 A). In 
order to examine whether the decrease in metabolic activity with HOCl treatment was 
more gradual than with HOSCN, additional concentrations of the oxidants were used (25 
µM and 50 µM). Similarly, an additional higher concentration of HOSCN (400 µM) was 
used in an attempt to establish the level of this oxidant which is detrimental to metabolic 
activity.  
 
As expected, J774A.1 exposure to HOCl caused a concentration-dependent decrease in 
metabolic activity (Figure 4.5 B); this decrease was significantly higher than with 
HOSCN-treated cells (Figure 4.5 A). The decrease in metabolic activity became 
significant at 50 µM HOCl treatment (~50% reduction), with up to 90% loss observed 
with 200 µM HOCl (Figure 4.5 B). Conversely, 400 µM HOSCN was required to induce 
a ~50% loss in metabolic activity (Figure 4.5 A). Neither sodium selenite, nor                     
seleno-L-methionine supplementation had any beneficial effect on cell mitochondrial 
function over the range of oxidant concentrations examined (Figure 4.5, black and grey 
bars vs. white bars). 
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Figure 4.5 J774A.1 metabolic activity following selenium supplementation and 
oxidant treatment (MTT assay) 
J774A.1 cells were not supplemented (white bars) or supplemented with either sodium 
selenite (500 nM, black bars) or seleno-L-methionine (5 μM, grey bars) and plated 
overnight in a 24-well tissue culture plate (1 x 10
5
 cell/mL). Metabolic activity was 
determined following incubation with 0 – 400 μM HOSCN (A) or 0 – 200 μM HOCl (B) 
for 1 hr at 22 °C by MTT assay. Results are expressed as the percentage of MTT 
reduction to formazan compared to cells treated with PBS (denoted as 100% MTT 
reduction).    */**/*** represents statistically significant differences (P < 0.05/0.01/0.001, 
respectively) compared to the respective PBS-treated controls (2-way ANOVA with 
Bonferroni‘s post-hoc tests). No significant difference was observed between non-
supplemented cells and cells supplemented with seleno compounds. Values are means 
with ± SEM (n = 4). 
 
 
4.3.6 Effects of selenium supplementation and oxidant treatment on J774A.1 
apoptosis and necrosis 
In the light of the observed biochemical changes (TrxR activity loss, GSH depletion) and 
the absence of a significant loss in metabolic activity (as assessed by MTT reduction) 
following J774A.1 exposure to HOSCN, further experiments were conducted in order to 
examine potential differences in the mechanism of cell death (apoptosis vs. necrosis) 
induced by HOSCN and HOCl. Apoptotic cells exhibit a change in membrane 
morphology, characterised by the translocation of phosphatidylserine (PS) from the inner 
leaflet of the plasma membrane to the outside. Annexin V has a high affinity for PS, and 
when conjugated with a fluorescent tag such as FITC, can be used for the detection of 
apoptotic cells. One way of detecting Annexin V-FITC tagged cells is by flow cytometry, 
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where cells positive and negative for Annexin V-FITC can be separated in two distinct 
populations. Inclusion of the dye propidium iodide (PI) in the cell suspension allows the 
identification of dead or highly damaged cells with impaired membrane integrity, as PI is 
excluded by viable cells with intact membranes. J774A.1 cells were supplemented with 
selenium, and treated with oxidants as previously described (Sections 2.3.8 and 2.3.10.1) 
prior to flow cytometric analysis (described in Section 2.3.18).  
4.3.6.1 Annexin V-FITC method optimisation 
Initial flow cytometry experiments were unsuccessful due to considerable difficulties in 
sample preparation, which resulted in high levels of cell death in control cells. J774A.1 
cells are an adherent cell type, resistant to trypsin digestion, and therefore require 
mechanical detachment from tissue culture plates with a cell scraper. Unfortunately, this 
mode of detachment caused significant cell death (only ~50% of control, untreated cells 
remained viable), as evident from Figure 4.6 A, making it difficult to compare oxidant-
treated to untreated, control cells. 
 
In order to minimise cell damage during sample preparation, a number of optimisation 
steps were examined. Instead of scraping, cells incubated in Annexin V-FITC binding 
buffer were gently detached by pipetting the buffer up and down the well 2 - 3 times with 
a 1 mL pipette tip, until the well was clear of cells. Subsequently, 100 µL of cell 
suspension was prepared for the flow cytometric separation in the same manner as 
described in Section 2.3.18. Cell viability was significantly improved with this method 
(~82% viable cells, Figure 4.6 B) and was deemed suitable for use in further experiments. 
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Figure 4.6 Representative scatter plot of flow cytometric analysis  
The data are representative plots of untreated J774A.1 cell populations collected by (A) 
mechanical scraping and (B) pipetting up and down. Cell populations (represented as a % 
of total cells population) in the bottom left corner represent viable cells, the bottom right 
corner – early apoptotic cells, the top right corner – late apoptotic/necrotic cells, and the 
top left corner – necrotic cells.  
 
 
4.3.6.2 Apoptosis and necrosis in J774A.1 cells supplemented with selenium 
and treated with HOSCN and HOCl 
 
The level of apoptosis (early apoptotic cell population, Figure 4.6 bottom right corners) 
and necrosis (late apoptotic/necrotic and necrotic cell populations, Figure 4.6 top right 
and left corners, respectively) in cells exposed to 100 – 200 µM HOSCN was not 
significantly different from untreated (0 µM oxidant) control cells (Figure 4.7 A and C). 
Selenium supplementation made a minimal difference to these levels, with the exception 
of a small increase in necrosis in seleno-L-methionine supplemented cells treated with 
200 µM HOSCN (Figure 4.7 C, grey bars). However, this increase was not significantly 
different from sodium selenite-treated or non-supplemented cells. This finding suggests 
that changes in mitochondrial function, measurable by MTT assay (Figure 4.5 A), 
precede changes associated with apoptosis. 
 
A) B)
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HOCl (200 µM) treatment resulted in lower levels of apoptosis in J774A.1 cells 
compared to untreated control cells, 100 µM HOCl-treated cells, and cells exposed to   
200 µM HOSCN (Figure 4.7 B vs. A). This decrease in the levels of apoptosis 
corresponded with a significant increase in the levels of necrosis (Figure 4.7 D). This 
suggests that cells could be progressing thought the apoptotic stage (100 µM HOCl 
treatment, no significant increase in necrosis) to the necrotic stage (200 µM HOCl 
exposure; significant drop in apoptosis and increase in necrosis) rather than dying by 
necrosis alone. Time-dependent, rather than concentration-dependent, experiments might 
help to elucidate the exact mechanism. 
 
Similarly to HOSCN treatment, the effects of HOCl on mitochondrial function assessed 
by MTT assay were apparent at lower concentrations of the oxidant (Figure 4.5 B). 
However, flow cytometric analysis provided some insights on the nature of changes, 
associated with cell death.   
 
Neither MTT, nor flow cytometry showed any benefit of selenium supplementation on 
J774A.1 mitochondrial function or cell viability following HOCl treatment. 
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Figure 4.7 J774A.1 viability following selenium supplementation and oxidant 
treatment (Flow cytometric analysis) 
J774A.1 cells were not supplemented (white bars) or supplemented with either sodium 
selenite (500 nM, black bars) or seleno-L-methionine (5 μM, grey bars) and treated with 
oxidants as per Figure 4.1 caption and Section 2.3.10.1. The levels of apoptosis and 
necrosis were determined by flow cytometry, using an Annexin V-FITC/PI Apoptosis 
Detection kit. Cells negative for both PI and Annexin V were identified as viable, cells 
positive for Annexin V only were designated as early apoptotic, cells positive for both 
Annexin V and PI were identified as late apoptotic/necrotic. **/*** represents statistically 
significant differences (P < 0.01/0.001, respectively) compared to the respective         
PBS-treated controls (2-way ANOVA with Bonferroni‘s post-hoc tests). There were no 
significant differences between the non-supplemented cells and cells supplemented with 
either seleno compounds. Values are means ± SEM. (n = 3) 
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4.4 Discussion 
The studies presented in this Chapter examined the effects of MPO-derived oxidants, 
HOSCN and HOCl, on the activity of two intracellular seleno enzymes, GPx and TrxR, in 
murine macrophage-like J774A.1 cells. The activities of these enzymes were up-regulated 
by supplementing the cells with two forms of selenium. Subsequent experiments assessed 
whether the up-regulation of TrxR and GPx activity protected cells from hypohalous 
acid-induced cell death. These showed that whilst selenium supplementation provided 
protection for GPx from inhibition by HOCl, no significant effects on cell survival were 
observed. The studies also examined the redox state of GSH following oxidant treatment 
and showed that HOSCN caused a dose-dependent loss in GSH levels that was not 
modulated by selenium supplementation, and a respective increase in GSSG formation 
which was significantly elevated by seleno-L-methionine supplementation. 
 
With regard to the inhibition of TrxR and GPx, previous studies have revealed that TrxR 
and GPx have differential susceptibilities to HOSCN and HOCl. It has been shown that 
HOSCN rapidly inactivates isolated mammalian TxrR and GPx in a concentration-
dependent manner (262). The present study showed that 200 µM HOSCN significantly 
inhibited the activity of TxrR in J774A.1 macrophage cells, whereas the enzyme 
inhibition induced by HOCl was less pronounced. To the best of our knowledge, the 
results presented here are the first studies that have provided evidence for HOSCN-
induced inhibition of TrxR in murine macrophage-like cells. There was no corresponding 
decrease in TrxR protein levels (determined by Western blotting, Figure 4.3 A), 
suggesting that the reduction in enzyme activity may be due to a modification of the 
active site residues (Cys-Sec) inflicted by the oxidant. The higher loss of TrxR activity, 
observed upon treatment with HOSCN, is consistent with the greater selectivity of 
HOSCN towards the highly nucleophilic low pKa Sec residue, present at the active site of 
TrxR in the selenol (Se-H) form, compared to the less discriminate oxidant HOCl (262). 
One of the previously proposed mechanisms of TrxR inhibition was via the formation of 
advanced oxidation products, such as seleninic (SeO2) and selenonic (SeO3) acids, 
following the HOSCN-induced formation of Se-SCN species at the active site (262). The 
results presented here are consistent with this theory. 
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Although the findings presented in this Chapter are in agreement with some previous 
work, they are in contrast to a recent study by Chandler et al., where it has been shown 
that HOSCN is metabolised by mammalian TrxR and does not cause any measurable 
inhibition of the enzyme activity in both cell-free systems and in human bronchial 
epithelial cell lysates (16HBE) (301). Such a discrepancy might be due to the significant 
differences in the experimental conditions and cell type used, as it is known that certain 
cell types, including airway epithelial cells, whilst producing large quantities of HOSCN 
to kill pathogens, are resistant to its damaging effects (reviewed in (37, 302)) and 
therefore cannot be directly compared to macrophage cells.  
 
The observation that the activity of GPx, another seleno enzyme, was significantly 
reduced by HOCl is in accordance with previously published studies (249). In contrast, 
GPx activity was unaltered by HOSCN. As GPx uses GSH as a co-factor, it was of 
interest to investigate whether there was also any depletion of GSH caused by HOCl. 
HPLC analysis of GSH/GSSG levels in these cells revealed a lack of GSH oxidation by 
HOCl, suggesting a direct effect of this oxidant on GPx, which is in line with previous 
studies (262). 
 
The absence of any significant effect of HOSCN treatment on GPx activity was 
unexpected, given the relatively high rate constant for reaction of HOSCN with purified 
mammalian GPx1, and evidence of GPx inhibition by HOSCN in vitro (262). This might 
be due to an adequate supply of reductants in J774A.1 cells, or an abundance of other, 
preferred targets of HOSCN, including TrxR, GSH and protein thiols (reviewed in (37)). 
 
The expression and activity of TrxR and GPx depends on the supply of selenium, as these 
enzymes contain Sec residues at their active sites. The level of selenium and its 
availability in cells can be modulated by selenium supplementation or limitation. A 
number of studies have reported an increase in TrxR and GPx activity upon 
supplementation with inorganic (sodium selenite) or organic (seleno-L-methionine) forms 
of selenium (141, 148, 254, 298, 303). In the present study these two seleno compounds 
were compared for their ability to enhance the activity of TrxR and GPx. The increase in 
GPx activity was significantly greater with sodium selenite than with seleno-L-
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methionine supplementation (3.7 vs. 1.7-fold change, respectively), compared to the 
control, non-supplemented cells. Conversely, TrxR activity was only 1.5-fold and 1.2-
fold higher in J774A.1 cells cultured with sodium selenite and seleno-L-methionine, 
respectively, than in non-supplemented cells. Such moderate increases might explain the 
apparent lack of difference in the HOSCN-induced loss of TrxR activity in non-
supplemented and supplemented cells. In contrast, both sodium selenite and seleno-L-
methionine supplementation provided a significant degree of protection from HOCl-
dependent inhibition of GPx activity. The greater increase in the activity of both enzymes 
with sodium selenite than with seleno-L-methionine supplementation is in agreement with 
previous studies (reviewed in (150)). 
 
It has been shown previously that in erythrocytes GSH is rapidly oxidised by HOCl, with 
only 11% of the oxidised GSH being present as GSSG (242). In J774A.1 cells, however, 
the GSH levels are not significantly reduced by HOCl treatment and no GSSG was 
detected, regardless of selenium supplementation. These data are consistent with previous 
reports (101, 304) that suggest that HOCl targets primarily cell membrane components in 
some cell types. Another possibility is that HOCl reacts with other molecular targets 
present at similar level as GSH, or with higher sensitivity to HOCl (e.g. Cys and Met 
residues on proteins, reviewed in (37)). 
 
In contrast, HOSCN treatment resulted in a concentration-dependent decrease in GSH 
with a corresponding increase in GSSG formation, which is in agreement with previously 
reported results (101). Seleno-L-methionine supplementation significantly increased the 
formation of GSSG following 200 µM HOSCN treatment. This might be due to the GSH-
dependent reduction of seleno-L-methionine selenoxide, a product of seleno-L-methionine 
oxidation (305). 
 
Despite a significant decrease in TrxR activity and GSH levels, HOSCN treatment was 
associated with only a relatively small drop in cell viability (~20%, following exposure to 
200 µM HOSCN). This suggests that TrxR, together with GSH, by reacting specifically 
with HOSCN, might divert the damage from other thiol or seleno-containing targets, 
thereby maintaining metabolic activity and viability. In contrast, HOCl treatment did not 
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markedly deplete GSH, and only caused minor inhibition of TrxR, but led to significant 
cell death. Interestingly, HOCl-induced cell death was associated with a significant 
decrease in GPx activity, whereas GPx activity was unperturbed by HOSCN treatment. 
Perhaps the preservation of GPx catalytic activity is of a greater importance during 
oxidative insult owing to the ability of this enzyme to remove H2O2, lipid hydroperoxides 
and protein hydroperoxides. In this case, and as implicated in Chapter 3, elevated levels 
of SCN
-
 might increase cell resistance against oxidative stress by diminishing the toxic 
effects of HOCl on GPx through the increased formation of HOSCN.  
4.5 Conclusions 
Overall, the studies presented in this Chapter indicate that although selenium 
supplementation of J77A.1 cells significantly increased the activities of the seleno 
enzymes TrxR and GPx, it did not contribute to a significant increase in cell survival 
following treatment with MPO-derived oxidants. TrxR, GPx and GSH appeared to have 
differential sensitivities to HOSCN and HOCl. TrxR, being inhibited by HOSCN but not 
by HOCl, might be a specific target of HOSCN, which can facilitate the removal of this 
oxidant. The consequences of TrxR inhibition are addressed in more detail in the next 
Chapter by examining the redox state of Prxs. The Prxs are responsible for the removal of 
H2O2 and other peroxides, with their activity tightly dependent on TrxR activity. Prxs 
contain low pKa thiols at the active site and therefore might be also directly targeted by 
HOSCN, providing another line of defence against this oxidant. 
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CHAPTER 5. Effects of myeloperoxidase-derived oxidants and 
selenium supplementation on the redox state of peroxiredoxins      
and total protein S-glutathionylation in J774A.1 murine 
macrophage-like cells  
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5.1 Introduction 
It has been shown previously that the redox state of the Prxs depends on the activity of 
the TrxR/Trx system, the efficiency of which varies not only between cell types, but also 
between cell compartments (306). The studies presented in Chapter 4 showed that the 
TrxR activity of J774A.1 murine macrophage-like cells can be modulated by selenium 
supplementation. In the present Chapter, the selenium supplementation method was once 
again exploited in order to elucidate the potential benefits of an increased activity of TrxR 
for Prx redox cycling under oxidative stress conditions induced by hypohalous acids. 
 
Prxs are a family of non-heme, non-seleno peroxidases that consists of six isoforms   
(Prx1 - 6) in mammals, including humans (293, 307, 308). Various studies have 
implicated the involvement of Prxs in a number of human pathologies, including type I 
diabetes (309), stroke (310), various cancers (169, 311, 312), neurodegenerative diseases 
((313, 314), reviewed in (315)) and male infertility (316). 
 
Prxs, along with SOD, catalase and GPx, are known to directly detoxify ROS and RNS, 
including H2O2, ONOO
-
 and organic peroxides (306, 317-320). Whilst H2O2 is 
undoubtedly detrimental to cells and tissues at high concentrations, low levels can act as a 
second messenger intracellularly, transmitting signals, coming from various surface 
receptors (308, 321). Extracellularly formed H2O2 is quickly eliminated after completing 
its function; consequently, Prx can regulate cell signal transduction through the control of 
H2O2 levels (322). Indeed, it has been shown that transfection of HeLa cells with a Prx2-
expressing vector (which causes the overexpression of Prx2), resulted in a decrease in 
intracellular H2O2, generated in response to epidermal growth factor, and also inhibited 
H2O2- and TNFα-dependent activation of the major transcription factor NF-κB (323). 
 
As thiol-dependent enzymes, the high reactivity of Prxs with H2O2 is unusual. As such, 
they are more similar to selenium-containing enzymes that are known to have much 
higher reaction rates with H2O2 than thiol enzymes (246). Although the reactivity of Prxs 
with H2O2, ONOO
-
 and hydroperoxides is well documented (318) (324-327), their role in 
the defence against MPO-derived oxidants has not been studied as extensively. However, 
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a number of studies have investigated Prx involvement in the detoxification of HOCl and 
chloramines in various cell types, including RBC (242) and HUVEC (245). To this end, 
purified human Prx2 has been shown to react rapidly with HOCl, however the oxidation 
of Prx2 Cys residues was not selective to the active site Cys (246). Despite the fact that 
HOSCN reacts preferentially with low pKa thiols (98), which are present at the active site 
of all 2-Cys Prxs (reviewed in (164)), no studies to date have examined the effects of 
HOSCN on the redox state of Prxs.  
5.2 Aims 
In the light of the above data, indicating the importance of Prxs as antioxidant enzymes, 
and their dependence of their activity on TrxR/Trx system, the aims of this Chapter were: 
a) to investigate the effects of HOSCN and HOCl on typical 2-Cys Prx (Prx1 - 3) redox 
state in J774A.1 cells with modulated levels of TrxR achieved by supplementation with 
sodium selenite or seleno-L-methionine; b) to examine the nature of the oxidant-induced 
Prx redox changes (oxidation vs. hyperoxidation); and c) to determine whether these 
changes were associated with S-glutathionylation, a posttranslational protein 
modification, believed to be an oxidative damage biomarker as well as a modulator of 
protein function (reviewed in (220)). Protein S-glutathionylation can occur via the 
reaction of GSH with ―activated‖ (i.e. partially oxidised) low pKa Cys residues or protein 
sulfenic acid derivatives. The results described in Chapter 4, indicate that HOSCN causes 
a concentration-dependent loss in GSH which could not be completely accounted for by 
an increase in GSSG formation. In addition, previous studies have reported evidence for 
the formation of protein sulfenic acid intermediates by HOSCN (103). Taken together, 
this information provides a rationale for investigating the formation of mixed protein 
disulfides (S-glutathionylated proteins) upon HOSCN (vs. HOCl) exposure. 
5.3 Results 
5.3.1 Redox state of J774A.1 peroxiredoxins 
The effects of HOSCN and HOCl on three isoforms of J774A.1 typical 2-Cys Prxs (Prx1, 
Prx2 and Prx3) were investigated by supplementing the cells with selenium (500 nM 
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sodium selenite or 5 µM seleno-L-methionine) as described previously (Section 4.3.1). 
These isoforms of Prx were chosen for investigation due to their high level of expression 
in many cells (including macrophages) and also because of the identical mechanism of 
catalysis employed by all three of them (163), which would allow the direct comparison 
of the effects HOSCN and HOCl on these class of enzymes. Prx4 (ER protein, with some 
appearing extracellularly), Prx5 (atypical 2-Cys Prx) and Prx6 (1-Cys Prx) were not 
examined in this study. 
 
Following supplementation, cells were treated with 0, 100 or 200 μM HOSCN or HOCl 
for 1 hr. Cells were then washed and lysed in the presence of 100 mM NEM in order to 
preserve reduced Prx Cys residues present at the time of lysis and protect them from 
further oxidation (Scheme 5.1, oxidised disulfide-linked Prxs migrate as dimers, whereas 
reduced Prxs migrate as monomers). Cellular proteins were electrophoretically separated 
on non-reducing 15% polyacrylamide gels. Following transfer to nitrocellulose 
membranes, separated proteins were immunoblotted with anti-Prx1 (Figure 5.1), anti-
Prx2 (Figure 5.2) or anti-Prx3 (Figure 5.3) rabbit polyclonal antibodies. 
 
Reaction of Prxs with H2O2 results in Prx oxidation to its dimeric form. Under 
physiological conditions Prxs are predominantly in the reduced form, as are the Cys 
residues on the majority of intracellular proteins (328). The presence of Prx dimers       
(10 - 40%) in untreated cells (Figure 5.1, Figure 5.2 and Figure 5.3, white bars, 0 µM 
oxidant) suggests that despite the alkylation with NEM, a proportion of J774A.1 Prxs 
were present or converted to their oxidised forms even in the absence of oxidant 
treatment. This might be due to the presence of trace amounts of H2O2 in the buffers 
which reacted with Prx before they had a chance to react with NEM. This is in accord 
with previous studies which have reported similar levels of Prx oxidation in various cell 
types, and difficulties in preserving reduced Prx (180, 329). Any further increase in Prx 
dimer formation was assumed to be the result of oxidant treatment. 
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Scheme 5.1 Preservation of Prx redox state with NEM 
 
5.3.1.1 Effects of HOSCN and HOCl on oxidative state of J774A.1 Prx1 
Densitometric analysis of Western blots showed that cytosolic Prx1 appeared to be more 
sensitive to HOSCN (Figure 5.1 A and C) than to HOCl treatment (Figure 5.1 B and D). 
The increase in Prx1 dimer formation was statistically significant upon treatment with 
100 µM HOSCN, with this resulting in ~98% prevalence of the oxidised Prx1 dimer over 
the reduced monomer (Figure 5.1 A). A further increase in HOSCN concentration to    
200 µM resulted in the complete oxidation of Prx1 (Figure 5.1 A and C). Conversely, 
HOCl treatment over the concentration range examined did not cause any significant 
dimerisation of Prx1 (Figure 5.1 B and D). Selenium supplementation did not have any 
significant effect on Prx1 redox state irrespective of oxidant treatment (Figure 5.1 A and 
B, black and grey bars vs. white bars). 
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Figure 5.1 Redox state of J774A.1 Prx1 following oxidant treatment 
J774A.1 cells (5 x 10
5
 cells/mL) were either not supplemented (white bars) or 
supplemented with seleno-compounds (500 nM sodium selenite (black bars) or 5 µM 
seleno-L-methionine (grey bars)) for 17 hr, followed by treatment with 0, 100 or 200 μM 
(A) HOSCN or (B) HOCl for 1 hr. Cells were collected in extraction buffer containing 
100 mM NEM and proteins separated by non-reducing SDS-PAGE. Following 
electrophoresis, proteins were transferred to a nitrocellulose membrane by Western 
blotting and probed with an anti-Prx1 antibody. Representative blots of (C) HOSCN- and 
(D) HOCl-treated non-supplemented cells. Prx1 D denotes Prx1 dimer; Prx1 M denotes 
Prx1 monomer. The percentage of oxidised Prx1 was quantified using densitometry 
(ImageJ). *** represents a significant difference (P < 0.001) in Prx1 oxidation compared 
with control cells. Statistical analysis was by 2-way ANOVA with Bonferroni‘s post-hoc 
tests. Values are means ± SEM obtained from 3 independent experiments. 
5.3.1.2 Effects of HOSCN and HOCl on the oxidative state of J774A.1 Prx2 
HOSCN- and HOCl-mediated oxidation of Prx2, another cytosolic Prx, was also 
examined. Although Prx1 and Prx2 are >90% identical in the amino acid sequence, their 
functional roles are believed to be different according to several studies with Prx1- or 
Prx2-KO mice (171, 330). Prx1-KO mice tended to develop numerous tumours in various 
tissues (fibrosarcoma, osteosarcoma, hepatocellular carcinoma, B- and T-lymphomas) 
(171), whereas Prx2-KO mice suffered from hemolytic disorders and splenomegaly, but 
no tumour formation was observed (330). Therefore, it was of interest to elucidate 
whether Prx2 had a similar reactivity with MPO-derived oxidants as Prx1. 
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Irrespective of selenium supplementation, 100 µM HOSCN treatment did not produce 
any significant increase in Prx2 dimer formation compared to control cells, whereas      
200 µM HOSCN completely oxidised Prx2 to its dimer (Figure 5.2 A and C). This is in 
contrast to the pattern of Prx1 oxidation by HOSCN (Figure 5.1 A and C). This suggests 
that there are differential sensitivities of Prx1 and Prx2 to oxidation by HOSCN, with the 
tendency for Prx1 to be more easily oxidised. On the contrary, the level of Prx2 oxidation 
by HOCl was similar to Prx1, with no statistically significant difference between control 
(0 μM HOCl) and treatment (100 and 200 μM HOCl) (Figure 5.2 B and D). 
 
 
                 
Figure 5.2 Redox state of J774A.1 Prx2 following oxidant treatment 
J774A.1 cells were prepared as per Figure 5.1 and Sections 2.3.8 and 2.3.10.1. White bars 
represent non-supplemented cells, black bars – sodium selenite supplemented and grey 
bars – seleno-L-methionine supplemented cells. Nitrocellulose membranes were probed 
with an anti-Prx2 antibody. (A) HOSCN treatment, (B) HOCl treatment. Representative 
blots of (C) HOSCN- and (D) HOCl-treated non-supplemented cells. Prx2 D denotes 
Prx2 dimer, Prx2 M denotes Prx2 monomer, ns – non-specific protein binding. The 
percentage of oxidised Prx2 was quantified using densitometry (ImageJ). *** represents a 
significant difference (P < 0.001) in Prx2 oxidation compared with control cells. 
Statistical analysis was by 2-way ANOVA with Bonferroni‘s post-hoc tests. Values are 
means ± SEM obtained from 3 independent experiments. 
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5.3.1.3 Effects of HOSCN and HOCl on the oxidative state of J774A.1 
mitochondrial Prx3 
Mitochondrial Prx3 has been previously reported to play a major role in removing H2O2 
generated by the mitochondrial respiratory chain (331). In addition, the oxidation of Prx3 
in Jurkat cells treated with TNFα has been shown to be an early predictor of apoptosis 
and subsequent cell death (329). Therefore, it was of interest to examine whether HOSCN 
and HOCl have more pronounced effects on mitochondrial Prx3 than on the cytosolic 
isoforms Prx1 and Prx2. The data obtained show that, in contrast to cytosolic Prx1 and 
Prx2, mitochondrial Prx3 was significantly oxidised by HOCl in a dose-dependent 
manner, with nearly complete oxidation with 200 µM HOCl treatment (Figure 5.3 B and 
D). Conversely, HOSCN caused less Prx3 dimer formation (~60% oxidised Prx3 
following exposure to 200 µM HOSCN, Figure 5.3 A and C) compared to HOCl.  
5.3.2 Hyperoxidation of J774A.1 Prxs 
Previous studies have reported the formation of hyperoxidised Prx species (sulfinic and 
sulfonic acid derivatives) upon treatment with H2O2, leading to inactivation of the 
peroxidase activity of Prxs (306, 322, 332). Sulfinic acid intermediates of Prxs can be 
slowly recycled back to the reduced, active state by sulfiredoxin (Srx), whereas the 
formation of sulfonic acid derivatives is irreversible, rendering Prxs permanently 
inactivated. Both temporary and permanent inactivation of Prx reductase activity may be 
detrimental to cells especially under oxidative stress conditions, though it has also been 
suggested that reversible oxidation to the sulfinic acid may be a deliberate protective 
mechanism against irreversible damage ((333), reviewed in (334)). To explore whether 
MPO-derived oxidants cause hyperoxidation of J774A.1 Prxs, and whether selenium 
supplementation affects the extent of hyperoxidation, cells were treated as previously 
described (Section 5.3.1) and immunoblotted with an antibody specific to the 
hyperoxidised forms (sulfinic/sulfonic derivatives, PrxSO2/3). Due to the lack of 
specificity of the anti-PrxSO2/3 antibody to any particular Prx, the following results 
describe the changes to all J774A.1 2-Cys Prxs.  
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Figure 5.3 Redox state of J774A.1 Prx3 following oxidant treatment 
J774A.1 cells were prepared as per Figure 5.1 and Sections 2.3.8 and 2.3.10.1. White bars 
represent non-supplemented cells, black bars – sodium selenite supplemented and grey 
bars – seleno-L-methionine supplemented cells. Nitrocellulose membranes were probed 
with an anti-Prx3 antibody. (A) HOSCN treatment, (B) HOCl treatment. Representative 
blots of (C) HOSCN- and (D) HOCl- treated non-supplemented cells. Prx3 D denotes 
Prx3 dimer, Prx3 M denotes Prx3 monomer, ns – non-specific protein binding. The 
percentage of oxidised Prx3 was quantified using densitometry (ImageJ). */**/*** 
represent a significant difference (P < 0.05/0.01/0.001 respectively) in Prx3 oxidation 
compared with control cells as assessed by 2-way ANOVA with Bonferroni‘s post-hoc 
tests. Values are means ± SEM obtained from 3 independent experiments. 
 
 
A concentration-dependent increase in hyperoxidised Prx monomer formation was 
detected following HOSCN treatment (Figure 5.4 A and C). This increase was most 
pronounced in non-supplemented cells treated with 200 µM HOSCN (Figure 5.4 A, white 
vs. grey bars; C, blot (a) vs. blot (c)). J774A.1 cells supplemented with sodium selenite 
also showed evidence of hyperoxidised Prx monomer formation in response to 200 µM 
HOSCN treatment (Figure 5.4 A, black bars; C, blot (b)), whilst seleno-L-methionine 
supplemented cells had the lowest (and not statistically-significant) level of 
hyperoxidised Prx monomer compared to the untreated (0 µM oxidant) cells (Figure 5.4 
A, grey bars and C, blot (c)). There was a trend towards an increase in hyperoxidised 
dimer formation in non-supplemented and sodium selenite supplemented cells, but 
variability in the Western blots precluded statistical significance being reached (Figure 
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5.4 B and C). In contrast, HOCl treatment did not produce any measurable increase in 
either hyperoxidised Prx monomer or dimer formation (Figure 5.4 D). This result is in 
accordance with previously reported studies on erythrocytes and HUVEC (242, 245) 
which demonstrated reversible Prx dimer formation without hyperoxidation upon 
treatment with HOCl.  
 
Figure 5.4 Hyperoxidation of J774A.1 Prxs following HOSCN treatment 
J774A.1 cells were prepared as per Figure 5.1 caption and Sections 2.3.8 and 2.3.10.1. 
White bars represent non-supplemented cells, black bars – sodium selenite supplemented 
and grey bars – seleno-L-methionine supplemented cells. Nitrocellulose membranes were 
probed with an anti-PrxSO2/3 antibody. Relative density of hyperoxidised Prx (A) 
monomer and (B) dimer following HOSCN treatment. Representative blots of (C) 
HOSCN- and (D) HOCl-treated non-supplemented cells, (a) non-supplemented, (b) 
sodium selenite supplemented and (c) seleno-L-methionine supplemented cells. PrxSO2/3 
D denotes hyperoxidised Prx dimer, PrxSO2/3 M denotes hyperoxidised Prx monomer, ns 
– non-specific. Relative density of hyperoxidised Prx monomer (A) and dimer (B) was 
determined using densitometry (ImageJ). */*** represent a significant difference (P < 
0.05/0.001 respectively) in Prx hyperoxidation compared with control cells. ^^ denotes a 
significant difference (P < 0.01) between non-supplemented and seleno-L-methionine 
supplemented cells. Statistical analysis was by 2-way ANOVA with Bonferroni‘s post-
hoc tests. Values are means ± SEM obtained from 3 independent experiments. 
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5.3.3 The effects of selenium supplementation and oxidant treatment on 
J774A.1 total cellular protein S-glutathionylation 
Recent studies have reported evidence for the formation of Cys-sulfenic acid (Cys-OH) 
derivatives on intracellular proteins upon treatment with HOSCN (103). Cys-OH 
intermediates are reactive with other protein thiols and GSH (335). Upon reaction with 
GSH, mixed protein-GSH disulfides are formed via S-glutathionylation (336). This 
process can be reversed in the reaction catalysed by Grx (de-glutathionylation). Protein   
S-glutathionylation plays various important roles in cells, one of which is the protection 
of reactive protein Cys residues from hyperoxidation (reviewed in (220)). Having 
established that HOSCN-mediated Prx hyperoxidation was significantly decreased with 
seleno-L-methionine supplementation compared to non-supplemented J774A.1 cells 
(Figure 5.4 A), it was of interest to examine whether this protection involved                  
S-glutathionylation. In order to examine this hypothesis, the level of J774A.1 protein      
S-glutathionylation was determined by Western blotting. 
 
J774A.1 cells were supplemented with selenium and treated with HOSCN or HOCl in the 
same manner as previously (detailed in Section 5.3.1). Following Western transfer, 
membranes were probed with antibodies specific to S-glutathionylated proteins         
(anti-GSH). Total protein S-glutathionylation was quantified using densitometric analysis 
and was adjusted to the protein load, determined by Coomassie staining of the 
membranes (Section 2.3.13). 
 
Exposure of J774A.1 cells to HOSCN caused a concentration-dependent increase in total 
protein S-glutathionylation (Figure 5.5 A) which was statistically significant at              
100 μM and 200 μM HOSCN treatment for non-supplemented (white bars), sodium 
selenite supplemented (black bars) and seleno-L-methionine supplemented cells (grey 
bars). The greatest increase in S-glutathionylation was observed in seleno-L-methionine 
supplemented cells (Figure 5.5 A, grey bars) and this increase was significantly greater 
than in non-supplemented cells at both oxidant concentrations (Figure 5.5 A). This 
elevation in protein S-glutathionylation corresponds to the previously observed decrease 
in the hyperoxidised Prx monomer formation (Figure 5.4 A). However, the current 
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method does not allow for the identification of individual S-glutathionylated proteins, 
therefore it is not possible at this stage to confirm that Prxs are S-glutathionylated. 
 
HOCl treatment also increased total protein S-glutathionylation (Figure 5.5 B), albeit to a 
lesser extent than HOSCN, and this was only statistically significant in seleno-L-
methionine supplemented cells exposed to 200 µM oxidant (Figure 5.5 B, grey bars).  
 
 
Figure 5.5 Total S-glutathionylation of J774A.1 proteins following HOSCN and 
HOCl treatment 
J774A.1 cells were prepared as per Figure 5.1 caption and Sections 2.3.8 and 2.3.10.1. 
White bars represent non-supplemented cells, black bars – sodium selenite supplemented 
and grey bars – seleno-L-methionine supplemented cells. Nitrocellulose membranes were 
probed with an anti-GSH antibody. (A) HOSCN treatment, (B) HOCl treatment. Relative 
density of each lane was determined using densitometry (ImageJ). Representative 
Western blots of (C) HOSCN- and (D) HOCl-treated cells (a) not supplemented or 
supplemented with (b) sodium selenite or (c) seleno-L-methionine. **/*** represent a 
significant difference (P < 0.01/0.001 respectively) in S-glutathionylation compared with 
the control cells. ^^^ denotes a significant difference (P < 0.001) between non-
supplemented and seleno-L-methionine supplemented cells. Statistical analysis was by 2-
way ANOVA with Bonferroni‘s post-hoc tests. Values are means ± SEM obtained from 3 
independent experiments. 
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5.4 Discussion 
The studies reported in this Chapter have investigated the effects of HOSCN and HOCl 
on a class of thiol-dependent antioxidant enzymes; the Prxs. The presence of low pKa 
Cys residues in the catalytic sites of Prxs make them potential targets for the thiol-
specific oxidant HOSCN. The data are consistent with differential sensitivity of the Prxs 
which is both oxidant- and isoform-specific. In addition, protein S-glutathionylation was 
also examined; these studies showed that J774A.1 cell proteins were more susceptible to 
HOSCN-derived S-glutathionylation than HOCl. 
 
The results reported in Chapter 4 showed that selenium supplementation significantly 
increased the activity of TrxR. This enzyme is critical for the Prx peroxidase cycle and 
therefore the changes in Prx redox state upon hypohalous acid treatment were monitored 
for both selenium-supplemented and non-supplemented J774A.1 cells. Exposure of cells 
to HOSCN revealed differential sensitivities of the three Prx isoforms to this oxidant. 
Specifically, cytosolic Prx1 was found to be the most sensitive to oxidation by HOSCN; 
100 µM HOSCN was sufficient to completely oxidise Prx1 (Figure 5.1 A and C) whilst 
200 µM oxidant was required to induce a comparable extent of oxidation of Prx2 (Figure 
5.2 A and C). Although there are no published studies that have examined and compared 
the reactivity of Prx1 and Prx2 with HOSCN, differential reactivity of Prx1 and Prx2 with 
H2O2 has been reported (337). This previous study examined isolated Prxs and their 
peroxidase activity with various concentrations of H2O2. Greater loss of Prx1 peroxidase 
activity was reported relative to Prx2, with this ascribed to the formation of inactive, 
hyperoxidised derivatives, facilitated by the additional, unique for Prx1, Cys residue at 
the position 83. It is however, unlikely that Prx1 in the current study was hyperoxidised 
with 100 µM HOSCN, as no significant formation of hyperoxidised monomer or dimer 
was detected at this oxidant concentration with an antibody specific to Prx SO2/3 species 
(Figure 5.4 C). HOSCN-induced formation of oxidised Prx dimers may be reversed by 
the NADPH/TrxR/Trx system and accordingly cytosolic Prxs might be involved in 
HOSCN removal. Some evidence for the direct effects of HOSCN on J774A.1 Prxs 
(sulfenic acid formation) has been previously reported by Barrett et al (338). Also, 
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preliminary experiments conducted with purified Prx1 suggest that HOSCN causes 
dimerisation of the pure Prx1 (Talib et al, unpublished data). 
 
HOCl treatment of J774A.1 cells did not cause any statistically significant changes in the 
oxidative state of either cytosolic Prxs (Figure 5.1 B, Figure 5.2 B). This is in contrast 
with previous studies (242, 245) where exposure of RBC or HUVEC to 0 – 100 µM 
HOCl resulted in the formation of reversibly oxidised Prx1, Prx2 or Prx3 dimers. The 
intrinsic differences between the cell types used in the previous studies (RBC and 
HUVEC) and the current study (murine macrophages) might explain this discrepancy. 
However, Stacey et al. reported a lack of the formation of hyperoxidised Prx species upon 
treatment with HOCl (242, 245); this is in agreement with the results obtained in the 
current study, where no measurable HOCl-mediated hyperoxidation of Prxs was detected 
(Figure 5.4 C). 
 
Interestingly, significant hyperoxidation of Prx was apparent in J774A.1 cells following 
exposure to 200 µM HOSCN (Figure 5.4 A). This may suggest a fast initial reaction 
between an oxidised Prx-SOH intermediate and a second molecule of HOSCN to produce 
Prx-SO2H, prior to the disulfide bond formation with the resolving Cys on the adjacent 
Prx subunit. This effect has not been described previously. Thus far, only H2O2, ONOO
-
 
and various organic hydroperoxides have been reported to be able to induce Prx 
hyperoxidation. Hyperoxidation of certain Prxs has been shown to be associated with a 
decrease in peroxidase activity and a concurrent increase in molecular chaperone activity 
(339), as well as the induction of H2O2-mediated cell signalling due to a temporary 
increase in H2O2 levels. The ability of HOSCN to hyperoxidise (inactivate) Prx might 
also play a role in the regulation of various signalling pathways in a similar way to    
H2O2-mediated signalling (162).  
 
Alternatively, Prx hyperoxidation might be a mechanism by which availability of Trx is 
modulated. Apart from being the specific and only known reductant for oxidised Prxs, 
Trx regulates cellular protein thiol/disulfide homeostasis by reducing a wide range of 
intracellular proteins, including ribonucleotide reductase and Msr, thereby participating in 
the repair of oxidative damage (340). It has been shown recently that hyperoxidation of 
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the 2-Cys Prx of Schizosaccharomyces pombe, Tpx1, by high doses of H2O2 (up to           
6 mM) was associated with increased cell viability (341). The authors suggested that 
hyperoxidation of Prx increased the availability of reduced Trx for the repair of other 
proteins that were oxidised by the high levels of H2O2. A similar shift in cellular 
protective mechanisms might also be occurring in the presence of elevated levels of 
HOSCN (200 µM), which specifically targets Cys and Sec residues on many crucial 
antioxidant enzymes. The results presented in Chapter 4 indicate that TrxR is susceptible 
to HOSCN damage. This may contribute to a decreased efficiency of the 
NADPH/TrxR/Trx/Prx system and oxidised/hyperoxidised Prx dimer accumulation. This 
change does not, however, appear to lead to a decrease in cellular viability (Figure 4.5 A). 
HOCl, on the other hand, is a more indiscriminate oxidant, targeting various amino acids 
on a wide range of proteins, resulting in extensive damage (237, 342-344). The fact that 
HOCl did not induce an inhibition of TrxR activity (Chapter 4, Figure 4.2 B) and 
cytosolic Prx dimer accumulation or hyperoxidation (Figure 5.1 B, Figure 5.2 B,     
Figure 5.4 C) suggests a preservation of the efficiency of the cytosolic NADPH/TrxR/Trx 
system in J774A.1 cells. Such efficiency, however, might have the downside of 
decreasing the availability of Trx for the reduction of other proteins and enzymes 
potentially damaged by HOCl, with a consequential decrease in cellular viability (Figure 
4.5 B).  
 
Surprisingly, the effects of HOSCN and HOCl on mitochondrial Prx3 were markedly 
different. Specifically, HOSCN caused only a slight increase in Prx3 dimer formation 
with 200 µM treatment (Figure 5.3 A), whereas 200 µM HOCl treatment resulted in 
marked accumulation of Prx3 dimer (Figure 5.3 B). This might be explained by a less 
efficient TrxR/Trx system in mitochondria (345) and hence a slower recycling of Prx3 
dimers following exposure to HOCl. In addition, the pool of mitochondrial NADPH, 
necessary for the TrxR/Trx/Prx redox cycle, might be diminished by a decreased level or 
activity of glucose-dependent sources of mitochondrial NADPH, such as the enzyme 
glucose-6-phosphate dehydrogenase (346). Indeed, in the current study J774A.1 cells 
were treated with oxidants in the absence of exogenous glucose (in PBS). The diminished 
effect of HOSCN on the mitochondrial isoforms of Prx could be due to the abundance of 
the exposed low pKa protein thiols in the mitochondrial matrix (20 – 25-fold greater 
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concentration than GSH, (284)) which might be expected to readily react, and deactivate, 
HOSCN prior to possible reaction with Prx3.  
   
The elevation in TrxR activity following selenium supplementation, reported in Chapter 
4, does not appear to be associated with any TrxR/Trx-dependent increase in the 
efficiency of Prx redox cycling (Figure 5.1, Figure 5.2, Figure 5.3 black and grey bars). 
The only significant effect of selenium supplementation was related to a decreased 
formation of hyperoxidised Prx species observed with HOSCN treatment. However, 
decreased hyperoxidation may be detrimental if the availability of reduced Trx is 
important for the repair of oxidative damage. The absence of any overall advantage of 
selenium supplementation to J774A.1 cell survival following HOSCN treatment (Figure 
4.5 A) suggests that the benefits and disadvantages of selenium supplementation might 
negate each other giving a net zero effect. Perhaps when the level of HOSCN is 
sufficiently increased, or the exposure is long enough as to inflict a substantial damage to 
thiol- and seleno-dependent enzymes and proteins, then the difference in TrxR activity 
and Txr/Prx availability might play a deciding role in cell survival. This possibility is 
worth further investigation. To this end, preliminary experiments, described in Chapter 4, 
provided evidence of a significant decrease in J774A.1 function after the exposure to 400 
µM HOSCN (Figure 4.5 A). 
 
Additionally, a potential antioxidant role of seleno-L-methionine itself cannot be 
dismissed. It has been previously reported that seleno-L-methionine, similarly to 
methionine, can be readily oxidised to seleno-L-methionine selenoxide by various 
oxidants, including HOCl and HOSCN, which then can be reduced back to seleno-L-
methionine by GSH and protein bound thiols ((347), Carroll et al., unpublished data). 
Accordingly, seleno-L-methionine might be protecting cells from MPO-derived oxidants 
directly, in addition to an indirect effect through an elevation of the activities of seleno 
enzymes. 
 
Protein S-glutathionylation has often been regarded as a reversible protein modification 
that protects highly reactive Cys residues from hyperoxidation (220, 336, 348). As the 
data presented in this Chapter demonstrate a decrease in Prx hyperoxidation is associated 
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with selenium supplementation, a possible correlation with protein S-glutathionylation 
was investigated. The increase in total protein S-glutathionylation in seleno-L-methionine 
supplemented cells treated with HOSCN appeared to mirror the decrease in Prx 
hyperoxidation, thus it is tempting to conclude that Prx S-glutathionylation is the reason 
for this decrease. However, HOSCN has been reported to react rapidly with Sec residues 
resulting in the formation of Sec-OH (262) intermediates which can potentially become 
glutathionylated in a manner analogous to Cys-OH. Selenium supplementation might also 
have increased the amount of Sec incorporated into proteins and consequentially 
increased the number of sites for HOSCN-mediated modification and glutathionylation.  
5.5 Conclusions 
The data reported in this Chapter show that Prxs are oxidised by both HOSCN and HOCl, 
however different Prx isoforms demonstrate differential sensitivities to both oxidants. It 
has been shown for the first time that exposure of J774A.1 cells to HOSCN results in the 
formation of hyperoxidised Prx species. Furthermore, the degree of hyperoxidation was 
alleviated by seleno-L-methionine supplementation, with a corresponding increase in total 
protein S-glutathionylation. The role of S-glutathionylation as well as individual Prx 
isoforms as a defence against hypohalous acids is investigated further in Chapter 6. 
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CHAPTER 6. The effects of myeloperoxidase-derived oxidants on 
J774A.1 cells with reduced levels of peroxiredoxins. 
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6.1 Introduction 
A number of recent studies, aimed at the elucidation of the role of mammalian Prxs in 
disease, have provided evidence for multiple cellular functions, including peroxidase 
activity, molecular chaperone function and signal transduction (314, 349-351). The 
majority of these studies have examined the reactions of various Prxs with H2O2 and 
ONOO
-
; limited information is available about Prx reactivity with other oxidants.  
 
It has been shown in Chapter 5 that murine macrophage Prxs form reversibly oxidised 
dimers upon treatment with HOCl, and hyperoxidised dimers and monomers upon 
exposure to HOSCN. Selenium supplementation of the cells, which indirectly affects the 
reductive capacity of Prxs through an increase in seleno-dependent TrxR activity 
(Chapter 4), did not affect Prx reversible dimerisation, but decreased the extent of 
hyperoxidation induced by HOSCN, and increased the level of total protein                     
S-glutathionylation. Other strategies that might help to further elucidate the role of each 
Prx in the defence against MPO-derived oxidants include selective inhibition of Prx 
protein by a pharmacological agent, or knock-down of Prx gene expression. The latter 
approach was chosen due to a lack of specific Prx inhibitors.  
 
One way of achieving a knock-down of a certain gene is by using a short interfering RNA 
(siRNA) technique. A double-stranded siRNA molecule, typically 20 - 22 base pairs long, 
which is specific to the gene of interest, is introduced into cells where it is recognised by 
a ribonuclease enzyme - Dicer. Dicer separates the siRNA into two single strands, one of 
which is degraded whilst the other binds to the messenger RNA (mRNA) of the target 
gene (352). Subsequently, the mRNA molecule is cleaved by an RNA-induced silencing 
complex (RISC) and protein translation is prevented (353). Specific inhibition of target 
gene expression can help elucidate the role of this gene and its protein product in various 
cellular processes. The results of siRNA-mediated silencing of Prx1, Prx2 and Prx3 are 
described in this Chapter. 
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6.2 Aims 
The aims of the studies reported in this Chapter were: a) to investigate whether Prx 
silencing affects metabolic activity on exposure to HOSCN and HOCl; b) to examine 
whether Prx silencing has any effect on protein S-glutathionylation; and c) to determine 
whether Prx silencing combined with any changes in S-glutathionylation, affects cellular 
GSH/GSSG levels. 
6.3 Results 
6.3.1 Prx silencing optimisation 
6.3.1.1 Initial experiments 
Initial Prx silencing experiments were performed according to an established protocol for 
human umbilical vein smooth muscle cells (HUVSMC), kindly provided by Dr. Christina 
Bursill of the Heart Research Institute. To this end, ~30% confluent J774A.1 cells were 
transfected with 50 or 100 nM siRNA prepared in Lipofectamine® 2000 transfection 
reagent, followed by further incubation in normal cell media for 24 – 72 hr. Subsequently 
the levels of Prx proteins were examined relative to control (scrambled siRNA0 cells by 
Western blotting. These pilot experiments showed that both siRNA concentrations 
inhibited protein expression of all three Prxs studied (Prx1, Prx2 and Prx3) by 65 - 70% 
at 48 hr post transfection (24 hr and 72 hr incubations resulted in <50% silencing, data 
not shown). Figure 6.1 shows representative Western blots for 50 nM siRNA transfection. 
However, cellular mitochondrial function, as assessed using the MTT assay (Section 
2.3.17), was decreased to a significantly greater extent with 100 nM siPrx compared to 50 
nM siPrx (Figure 6.2, B vs. A, ~25% vs. 70% functional cells, respectively). The shorter 
(24 hr) incubation time post-transfection proved to be insufficient for the effective 
silencing of any of the Prx isoforms, whereas the longer 72 hr incubation period did not 
further increase silencing efficiency for siPrx1 or siPrx3 and decreased it for siPrx2. 
Therefore, these incubation times and 100 nM siRNA concentrations were not considered 
in further experiments. 
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Figure 6.1 Confirmation of Prx silencing efficiency with 50 nM siRNA 
Prxs silencing efficiency was confirmed by Western blotting (detailed procedure 
described in Section 2.3.12) with (A) anti-Prx1, (B) anti-Prx2 or (C) anti-Prx3 antibodies 
following 48 hr of transfection with siPrx or scrambled (SCR) siRNA (50 nM), as 
described in Section 6.3.1.1.  
6.3.1.2 Transfection reagent modulation to improve metabolic activity 
The success of siRNA transfection strongly depends on a transfection reagent, typically a 
cationic lipid-based material (liposome) which binds to siRNA molecules. The resulting 
transfection complex can easily attach to negatively-charged cell membranes and enter 
cells through endocytosis. The siRNA can then undergo diffusion through the cytoplasm 
to the nucleus where the siRNA can interfere with gene expression. The concentration 
and type of transfection reagent have been shown to be critical for cell function following 
transfection (354). Therefore, in attempt to improve cell survival, these two parameters 
were considered.  
 
Firstly, the amount of Lipofectamine® 2000, a widely used transfection reagent for both 
DNA and RNA delivery, was reduced from 1.5 µL/well to 1 µL/well. This did not result 
in any significant increase in metabolic activity (data not shown). Secondly, an alternative 
reagent, Lipofectamine® RNAiMAX, was chosen for the transfection experiments. The 
reason for the selection of Lipofectamine® RNAiMAX is its specificity for siRNA 
delivery, low cytotoxicity and its superior efficiency of transfection compared to 
Lipofectamine® 2000 (355). Lipofectamine® RNAiMAX was used at 1.5 µL/well,      
and resulted in an ~10 - 15% increase in metabolic activity compared to 1.5 µL/well 
Lipofectamine® 2000 (Figure 6.3 vs. Figure 6.2 A). Taken together, Lipofectamine® 
RNAiMAX (1.5 µL/well)-facilitated transfection of 50 nM siRNA resulted in ~70% 
silencing efficiency for all Prxs, and ~80 - 85% cell survival. 
 
A)
siPrx1 siPrx2 siPrx3
SCR
siRNA
SCR
siRNA
SCR
siRNA
B) C)
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Figure 6.2 Metabolic activity (% cell function) following 50 and 100 nM siRNA 
transfection 
J774A.1 cells were transfected with (A) 50 nM or (B) 100 nM siRNA targeting Prx1 (red 
bars), Prx2 (blue bars), Prx3 (purple bars) or with non-specific, scrambled (SCR) control 
siRNA (white bars) as described in Section 6.3.1. Transfection was facilitated by 1.5 
µL/well Lipofectamine® 2000. Data are mean ± SEM of 2 independent experiments, 
expressed as a percentage of non-transfected control cells (black bars). 
                           
Figure 6.3 Metabolic activity (% cell function) following transfection using 50 nM 
siRNA and 1.5 µL/well RNAiMAX 
J774A.1 cells were transfected with 50 nM siRNA targeting Prx1 (red bars), Prx2 (blue 
bars), Prx3 (purple bars) or non-specific, scrambled (SCR) control siRNA (white bars), as 
described in Section 6.3.1. Transfection was facilitated by 1.5 µL/well Lipofectamine® 
RNAiMAX. Data are mean ± SEM of 2 independent experiments, expressed as a 
percentage of non-transfected control cells (black bars). 
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6.3.1.3 Effects of silencing on protein S-glutathionylation 
In order to check that the above conditions were optimal, Western blotting experiments 
were performed to estimate the extent of total protein S-glutathionylation following 
HOSCN or HOCl treatment. Unfortunately, these experiments revealed that J774A.1 
proteins were significantly S-glutathionylated in siRNA transfected cells even without 
oxidant treatment. The extent of S-glutathionylation was greater in cells transfected with 
siPrx, control SCR siRNA, and cells treated with Lipofectamine® RNAiMAX alone, 
compared to non-transfected cells (Figure 6.4 A). A possible cause of this undesirable 
effect was a higher than optimal concentration of siRNA (50 nM) and/or transfection 
reagent. Thus, further method optimisation was deemed necessary.  
6.3.1.4 Effect of decreased siRNA concentration 
A range of siRNA (10 - 40 nM) and Lipofectamine® RNAiMAX (1 - 1.5 µL/well) 
concentrations were tested in order to achieve the best balance between metabolic 
activity, transfection efficiency and low off-target effects (i.e. S-glutathionylation). All of 
the tested siRNA concentrations up to 35 nM (10, 20 and 35 nM), in combination with          
1 µL/well Lipofectamine® RNAiMAX, reduced the level of S-glutathionylation 
compared to non-transfected cells (representative Western blot of 35 nM siRNA 
transfection in 1 µL/well Lipofectamine® RNAiMAX shown in Figure 6.4 B). However, 
the corresponding silencing efficiency also dropped, becoming unacceptably low below 
35 nM siRNA, as evidenced by the representative Western blots of Prx silenced with      
20 nM siRNA shown in Figure 6.5.  
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Figure 6.4 Total S-glutathionylation in J77A.1 cells following siRNA transfection 
J774A.1 cells, transfected with either (A) 50 nM or (B) 35 nM siRNA specific for Prx1, 
Prx2, Prx3 or scrambled siRNA (SCR) control, were incubated with HBSS for 1 hr at 22 
ºC. Cells were then lysed and proteins separated by non-reducing SDS-PAGE, followed 
by Western transfer and immunoblotting with an anti-GSH antibody, in order to 
determine the levels of total protein S-glutathionylation (as described in Section 6.3.3). 
Lanes labelled as ―Non-transfected‖ represent a protein sample from J774A.1 cells which 
did not contain any siRNA or transfection reagent in the media, whereas ―RNAiMAX‖ 
labelled lanes denote cells incubated with the transfection reagent only (1 µL/well). 
 
 
 
 
 
Figure 6.5 Prx silencing efficiency with 20 nM siRNA transfection 
Prxs silencing efficiency was confirmed by Western blotting with (A) anti-Prx1, (B) anti-
Prx2 or (C) anti-Prx3 antibodies following the transfection with 20 nM siRNA specific to 
each of the three Prxs, and SCR control siRNA.  
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6.3.1.5 Optimal silencing conditions 
The efficiency of Prx silencing in J774A.1 cells, transfected with 35 nM siRNA, was 
confirmed by Western blotting. This concentration was chosen because it was the highest 
concentration of siRNA which did not cause extensive S-glutathionylation, and it was 
hoped that this level would produce marked silencing of all Prxs. Prx1 and Prx3 silencing 
was approximately 99% and 51% respectively 72 hr post transfection (Figure 6.6 A and 
C), whereas Prx2 was 50% silenced after 48 hr (Figure 6.6 B) with a diminishing 
silencing efficiency at longer incubation times (72 hr, not shown). In the case of Prx3 
silencing, an attempt to increase silencing efficiency further by prolonging post-
transfection incubation to > 72 hr resulted in extensive cell death (the majority of cells 
lifted off the plate by the time of harvesting and therefore were considered dead). 
Metabolic activity was ~10% higher in Prx2 silenced and the respective SCR control cells       
(~83% functional cells compared to non-transfected cells, Figure 6.7 A) compared to 
Prx1 and Prx3 silenced cells and their respective SCR control cells (~73 - 75% functional 
cells relative to non-transfected cells, Figure 6.7 B) due to the shorter post transfection 
incubation time. These parameters were deemed to be the best combination to ensure 
significant Prx silencing with low cytotoxicity and minimal protein S-glutathionylation. 
Therefore all experiments that followed were conducted with these conditions which gave 
near complete silencing of Prx1 (~99% silenced) and partially silenced Prx2 and Prx3 
(~52% silenced).  
 
Figure 6.6 Prx silencing efficiency. 
Prxs silencing efficiency was confirmed by Western blotting with (A) anti-Prx1, (B) anti-
Prx2 or (C) anti-Prx3 antibodies 48 hr (B) or 72 hr (A and C) after transfection with siPrx 
or SCR siRNA (35 nM). Band densities were quantified by ImageJ software and the 
silencing efficiency was expressed as a percentage of SCR control. The percentage 
silencing data are the mean ± SD from 3 independent experiments. 
siPrx1
SCR
siRNA siPrx2
SCR
siRNA siPrx3
SCR
siRNA
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Having established the baseline parameters for J774A.1 cells transfected with Prx-
specific or SCR siRNA, including metabolic activity and S-glutathionylation, any 
changes/effects observed in further experiments were attributed to oxidant treatment. 
 
 
Figure 6.7 Metabolic activity (measured by MTT) following 35 nM siRNA 
transfection 
J774A.1 cells were transfected with 35 nM siPrx2 (blue bar), siPrx1 (red bar), siPrx3 
(purple bar) or SCR siRNA (white bars) and incubated in normal media for (A) 48 hr or 
(B) 72 hr post transfection. Transfection was mediated by 1 µL/well Lipofectamine® 
RNAiMAX. Data are mean ± SEM of 2 independent experiments, expressed as a 
percentage of non-transfected control cells (black bars). 
 
6.3.2 Cellular metabolic activity following siRNA transfection and oxidant 
treatment 
J774A.1 metabolic activity with silenced Prx1 has been previously measured after 
treatment with t-Bu-OOH and oxLDL (294). However, the effects of MPO-derived 
oxidants on J774A.1 cell survival with knocked-down Prx1, Prx2 or Prx3 have not been 
assessed. Therefore, J774A.1 cells were transfected with siPrx1, siPrx2, siPrx3 or SCR 
control siRNA and then treated with oxidants as described previously (Section 2.3.19). 
Following oxidant removal, cells were washed twice with HBSS and 425 µL of media 
was returned to each well. Metabolic activity was subsequently evaluated in comparison 
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to control untreated cells (HBSS in the place of oxidant) using the MTT assay (Section 
2.3.17). 
 
Exposure of J774A.1 cells to HOCl (Figure 6.8 B, D, F) caused a concentration-
dependent decrease in cellular mitochondrial function; this decrease was significantly 
higher than for HOSCN-treated cells (Figure 6.8 A, C, E). Surprisingly, there was no 
significant difference in metabolic activity between Prx silenced (black bars) and SCR 
siRNA control cell (white bars) under any treatment conditions. Prx2 silencing appeared 
to be the least detrimental to cells, as no change in metabolic activity was detected with 
HOSCN treatment (Figure 6.8 C); the effect of HOCl was also less pronounced (Figure 
6.8 D). This could be due to Prx2 being less critical to metabolic activity. Alternatively 
the method used may be an issue, with a shorter transfection time (48 hr) utilised for Prx2 
silencing compared to Prx1 (Figure 6.8 A, B) and Prx3 (Figure 6.8 E, F) silencing (72 hr). 
6.3.3 S-glutathionylation of J774A.1 proteins following Prx silencing and 
oxidant treatment 
In order to further examine the differences in metabolic activity observed with Prx 
silenced cells treated with HOSCN vs. HOCl, the extent of S-glutathionylation of 
J774A.1 total cell proteins was examined. Western blotting was utilised to examine this, 
following Prx1, Prx2 or Prx3 silencing and subsequent oxidant treatment (as detailed in 
Sections 2.3.19, 2.3.12 and 2.3.10.1). J774A.1 proteins were separated by non-reducing          
SDS-PAGE (4 - 15%), transferred onto nitrocellulose membranes by Western blotting 
and then probed with a mouse monoclonal anti-GSH antibody overnight at 4 °C in 
blocking buffer (5% non-fat milk, TBS and 0.01% Tween 20). After probing with a 
secondary goat anti-mouse HRP-conjugated IgG, S-glutathionylated proteins were 
visualised by enhanced chemiluminescence using a LAS4000 imager. Total protein S-
glutathionylation was quantified using densitometric analysis and expressed as fold 
change in density compared to control (0 μM oxidant) conditions. 
 
Overall, the results showed that J774A.1 proteins were differentially S-glutathionylated 
by HOSCN and HOCl. Representative Western blots of Prx1, Prx2 and Prx3 silenced and 
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control cells treated with HOSCN or HOCl are shown in Figure 6.9; the following 
sections detail the results for each silenced Prx.  
 
Figure 6.8 Metabolic activity (% cell function) following Prx silencing and oxidant 
treatment 
J774A.1 cells were transfected with either siPrx1 for 72 hr (A and B, black bars), siPrx2 
for 48 hr (C and D, black bars), siPrx3 for 72 hr (E and F, black bars) or SCR control 
siRNA for the same duration as respective Prx siRNAs (A-F, white bars). Cells were 
treated with 100 – 200 µM HOSCN (A, C and E) or HOCl (B, D and F) for 1 hr (22 ºC). 
Metabolic activity was determined by MTT assay as described in Section 2.3.17. Results 
are expressed as the percentage of MTT reduction to formazan compared to cells treated 
with 0 µM oxidant (denoted as 100% cell function). */**/*** represent a statistically 
significant difference (P < 0.05/0.01/0.001, respectively) compared to untreated controls, 
as assessed by 2-way ANOVA with Bonferroni‘s post-hoc tests. Values are means ± 
SEM (n = 4). 
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Figure 6.9 Total protein S-glutathionylation in Prx1, Prx2 and Prx3 silenced and 
control J774A.1 cells following treatment with HOSCN or HOCl. 
J774A.1 cells, transfected with either siRNA specific for (A and B) Prx1, (C and D) Prx2, 
(E and F) Prx3 or respective scrambled siRNA (SCR) control were treated with                
0 – 200 μM (A, C and E) HOSCN or (B, D and F) HOCl for 1 hr at 22 ºC. Cells were 
then lysed and proteins separated by non-reducing SDS-PAGE followed by western 
transfer and immunoblotting with an anti-GSH antibody as described in Section 6.3.3.  
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6.3.3.1 Effects of HOSCN and HOCl on siPrx1 J774A.1 cells 
J774A.1 cells with silenced Prx1 treated with HOSCN showed a statistically       
significant concentration-dependent increase (1.5 – 2.5-fold change) in total protein S-
glutathionylation compared to non-HOSCN treated Prx1 silenced cells. However there 
was no significant difference in S-glutathionylation between Prx1 silenced cells and SCR 
control cells at either HOSCN concentration (Figure 6.10 A). Similarly, HOCl treatment 
caused a dose-dependent increase in S-glutathionylation; however the increase in protein 
S-glutathionylation was only significant in the SCR control cells at 200 µM HOCl 
treatment (Figure 6.10 B). There was a trend towards decreased S-glutathionylation in 
Prx1-silenced cells in comparison to SCR control cells at both 100 µM and 200 µM 
HOCl treatment concentrations (Figure 6.10 B), however this did not reach statistical 
significance. Overall, HOCl treatment caused a higher level of S-glutathionylation           
(2 – 3-fold change) at a lower concentration of the oxidant (100 μM) in both control and 
silenced cells compared to HOSCN treatment, but variability in the Western blots 
precluded statistical significance being reached. 
 
Figure 6.10 Effects of HOSCN and HOCl treatment on total protein  
S-glutathionylation of J774A.1 cells transfected with Prx1 or SCR siRNAs. 
J774A.1 cells were transfected with either siPrx1 (black bars) or SCR siRNA (white bars) 
for 72 hr and treated with 100 – 200 µM (A) HOSCN or (B) HOCl for 1 hr (22 ºC). This 
was followed by immunoblotting with an anti-GSH antibody as outlined in Section 
2.3.12. The image intensity of each lane was quantified by ImageJ and expressed as a fold 
change compared to the 0 µM oxidant samples. */** represent significant changes (P < 
0.05/P < 0.01) in band density determined by 2-way ANOVA with Bonferroni‘s post-hoc 
tests. There was no significant difference between Prx silenced cells and SCR control 
cells at each oxidant concentration. 
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6.3.3.2 Effects of HOSCN and HOCl on siPrx2 J774A.1 
Unlike siPrx1, Prx2 silencing was most efficient 48 hr after transfection; therefore all 
Prx2 silencing was performed for 48 hr. The total level of S-glutathionylation was higher 
compared to siPrx1-transfected cells (2 – 8-fold increase (Figure 6.11) vs. 1.5 – 3.5-fold 
increase (Figure 6.10), respectively). HOSCN caused a concentration-dependent trend 
towards an increase in S-glutathionylation, but this did not reach significance           
(Figure 6.11 A). In J774A.1 cells treated with HOCl, S-glutathionylation was 
significantly elevated in both Prx2 silenced and control cells at 200 µM HOCl (Figure 
6.11 B). In contrast, the difference in S-glutathionylation between control and silenced 
cells, treated with either HOSCN or HOCl, was not significant, though the extent of S-
glutathionylation tended to be lower in Prx2 silenced cells than in SCR siRNA control 
cells. 
 
 
Figure 6.11 Effects of HOSCN and HOCl treatment on total protein  
S-glutathionylation of J774A.1 cells transfected with Prx2 or SCR siRNAs. 
J774A.1 cells were transfected with either siPrx2 (black bars) or SCR siRNA (white bars) 
for 48 hr and treated with 100 – 200 µM (A) HOSCN or (B) HOCl for 1 hr (22 ºC) 
followed by immunoblotting with an anti-GSH antibody as described in Section 2.3.12. 
The density of each lane was quantified by ImageJ and expressed as a fold change 
compared to the 0 µM oxidant condition. */** represent significant change (P < 0.05/P < 
0.01) in band density determined by 2-way ANOVA with Bonferroni‘s post-hoc tests. 
There was no significant difference between Prx silenced cells and SCR control cells at 
either oxidant concentration. 
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6.3.3.3 Effects of HOSCN and HOCl on siPrx3 J774A.1 
There was no significant change in S-glutathionylation in siPrx3 cells upon treatment 
with HOSCN (Figure 6.12 A, black bars). Conversely, in control cells treated with 
HOSCN there was a significant, dose-dependent increase in S-glutathionylation              
(2 – 3-fold change) (Figure 6.12 A, white bars). There was no significant difference in    
S-glutathionylation between control and siPrx3-transfected cells at any HOSCN 
concentration. HOCl treatment caused a significant increase in S-glutathionylation in both 
SCR siRNA control and Prx3-silenced cells (Figure 6.12 B). In contrast to Prx1 and Prx2 
silencing, J77A.1 cells with silenced Prx3 showed a significantly lower level of              
S-glutathionylation compared to control cells (Figure 6.12 B). 
 
 
 
Figure 6.12 Effects of HOSCN and HOCl treatment on total protein                          
S-glutathionylation of J774A.1 cells transfected with Prx3 or SCR siRNAs. 
J774A.1 cells (4.5 x 10
5
) were transfected with either siPrx3 (black bars) or SCR siRNA 
(white bars) for 48 hr and treated with 100 – 200 µM (A) HOSCN or (B) HOCl for 1 hr 
(22 ºC) followed by immunoblotting with an anti-GSH antibody as detailed in Section 
2.3.12. The density of each lane was quantified by ImageJ and expressed as fold change 
compared to the 0 µM oxidant treatment. **/*** represent significant change                   
(P < 0.01/0.001, respectively) in band density compared to 0 µM controls; ##/### 
designate significant difference (P < 0.01/0.001, respectively) between siPrx3 and SCR 
siRNA treated cells at a given oxidant concentration, as determined by 2-way ANOVA 
with Bonferroni‘s post-hoc tests. 
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6.3.4 Identification of the S-glutathionylated 37 kDa band 
One particular protein band at ~37 kDa showed significantly more S-glutathionylation 
with HOCl treatment than with HOSCN (Figure 6.9). It has been shown previously that 
GAPDH, a glycolytic enzyme with molecular weight of 37 kDa, is prone to                     
S-glutathionylation by various oxidants, including chloramines (248). As Prx dimers have 
a molecular mass of ~40 - 42 kDa it was of interest to elucidate the identity of the band in 
the ~37 kDa region. The identity of this band was examined by cutting the membrane 
with transferred J774A.1 proteins into 3 parts prior to immunoblotting. Prior to cutting 
the membrane, it was stained with the temporary protein dye Ponceau S in order to 
visualise individual lanes. The membrane contained 2 identical lanes (200 μM oxidant 
treatments); each lane was cut vertically in half to obtain 3 pieces. One piece was probed 
with the relevant anti-Prx antibody, the second piece with anti-GSH antibody and the last 
piece with anti-GAPDH antibody. Prior to visualisation using chemiluminescence, the 
membrane pieces were carefully realigned. The combined image showed that the 37 kDa 
band, observed with anti-GSH, co-localised with the GAPDH band, whereas the Prx band 
was positioned slightly above it. Figure 6.13 shows an example of a membrane probed 
with these 3 different antibodies, as described above; in this case the anti-Prx3 antibody 
was used. Antibodies against Prx1 and Prx2 (data not shown) detected a Prx dimer of the 
same molecular mass (~40 - 42 kDa) as the anti-Prx3 antibody, consistent with the 
molecular masses of these proteins. Thus, it was concluded that the ~37 kDa band 
corresponded to GAPDH. 
 
Densitometric analysis of the GAPDH band, confirmed that exposure of J774A.1cells to 
both concentrations of HOCl (100 µM and 200 µM) resulted in significant increases in 
band intensity when the membranes were immunoblotted to examine S-glutathionylation 
(Figure 6.14 B, D and F). The greatest difference in band density was observed between 
HOCl-treated Prx1 silenced cells and SCR siRNA controls (Figure 6.14 B, black vs. 
white bars). Silencing of Prx2 (Figure 6.14 D) or Prx3 (Figure 6.14 F) did not appear to 
affect GAPDH S-glutathionylation following HOCl treatment. 
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In contrast, HOSCN treatment resulted in only a modest increase in the GAPDH band 
intensity upon treatment with 200 µM HOSCN, whilst no change was observed with 100 
µM treatment (Figure 6.14 A, C and E). This increase was not significant in Prx1 silenced 
cells and their respective SCR siRNA controls (Figure 6.14 A). The increase in                
S-glutathionylation of the GAPDH band in SCR siRNA control cells was significantly 
higher than in Prx2-silenced cells treated with 200 µM HOSCN (Figure 6.14 C white vs. 
black bars); though this increase was still significantly lower than with HOCl treatment 
(Figure 6.14 D). HOSCN caused a small, but statistically significant, increase in             
S-glutathionylation in Prx3 silenced and SCR control cells (Figure 6.14 E). 
              
Figure 6.13 Identification of the 37 kDa protein band by immunoblotting. 
J774A.1 cells were treated as previously described (Section 6.3.3); four samples (2 x 200 
µM HOSCN-treated cells and 2 x 200 µM HOCl-treated cells) were subjected to 
electrophoresis (SDS-PAGE, 4 - 15% non-reducing gels) prior to Western transfer onto a 
nitrocellulose membrane, followed by staining the membrane with Ponceau S in order to 
visualise individual lanes. Lanes 1 and 2, containing samples treated with (A) 200 µM 
HOSCN or (B) 200 µM HOCl were cut vertically in half and then each piece of the 
membrane was probed with a) antiPrx3 antibody, b) anti-GSH antibody or c) anti-
GAPDH antibody. Prior to immunodetection, membrane pieces were realigned and the 
combined image was taken using enhanced chemiluminescence. Prx3  – band detected 
with antiPrx3 antibody;  GAPDH – band, detected with anti-GAPDH antibody. 
GAPDH
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Figure 6.14 Oxidant-induced S-glutathionylation of the GAPDH protein band in Prx 
silenced and control J774A.1 cells. 
J774A.1 cells were transfected with either siPrx1 for 72 hr (A and B, black bars), siPrx2 
for 48 hr (C and D, black bars), siPrx3 for 72 hr (E and F, black bars) or SCR control 
siRNA for the same duration as respective Prx siRNAs (A-F, white bars) and treated with 
100 – 200 µM HOSCN (A, C and E) or HOCl (B, D and F) for 1 hr (22 ºC) followed by 
cell lysis, SDS-PAGE, and immunoblotting with an anti-GSH antibody as previously 
described (Section 2.3.12). The density of 37 kDa band was quantified by ImageJ and 
expressed as the fold change compared to the 0 µM oxidant condition. Values are mean 
(n = 3) ± SEM */**/*** represent significant changes (P < 0.05/0.01/0.001, respectively) 
in band density compared to 0 µM control; ##/### designate significant differences (P < 
0.01/0.001, respectively) between siPrx and SCR, as determined by 2-way ANOVA with 
Bonferroni‘s post-hoc tests. 
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6.3.5 GSH levels in siPrx J774A.1 cells following oxidant treatment. 
Multiple mechanisms have been proposed by which S-glutathionylated proteins might 
form (356), with all of these being tightly dependent on intracellular GSH/GSSG levels. 
Therefore, levels of GSH and GSSG were measured by HPLC (described in Section 
2.3.11), in order to establish the extent of GSH oxidation following oxidant treatment in 
Prx silenced and control cells. 
6.3.5.1 GSH levels in siPrx1 J774A.1 cells. 
HOSCN treatment over the concentration range examined did not cause any significant 
depletion of intracellular GSH irrespective of siRNA treatment (Figure 6.15 A). In 
contrast, HOCl caused a dose-dependent loss of GSH in both Prx1-silenced (black bars) 
and SCR control (white bars) cells; however there was no significant difference in the 
extent of GSH loss between siPrx1 and SCR control cells (Figure 6.15 B).  
 
 
Figure 6.15 GSH levels in Prx1 silenced and control J77A.1 cells 
GSH levels in J774A.1 cells were quantified by HPLC with fluorescence detection after 
derivatisation with dansyl chloride, as described in Section 2.3.11. Results are expressed 
as a percentage of the GSH concentration in the 0 µM oxidant treatment. The 
concentration of GSH measured in the 0 µM control samples was 64 ± 7 µM. Values are 
mean (n = 3) ± SEM, */** indicate significant differences (P < 0.05/0.01, respectively) 
compared to the 0 µM controls as assessed by 2-way ANOVA with Bonferroni‘s post-hoc 
tests. 
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6.3.5.2 GSH level in siPrx2 J774A.1 cells 
Exposure of J774A.1 cells (either siPrx2 or SCR siRNA) to HOSCN did not cause any 
measurable change in GSH levels (Figure 6.16 A). Similarly, HOCl did not cause 
significant oxidation of GSH (Figure 6.16 B). Thus, Prx2 silencing does not appear to 
have any significant effect on intracellular GSH levels. 
 
 
Figure 6.16 GSH levels in Prx2 silenced and control J77A.1 cells 
GSH levels in J774A.1 cells were quantified by HPLC with fluorescence detection after 
derivatisation with dansyl chloride as described in Section 2.3.11. Results are expressed 
as a percentage of the GSH concentration present in the 0 µM oxidant treatment. The 
concentration of GSH measured in the 0 µM control samples was 63 ± 5 µM. Values are 
mean (n = 3) ± SEM. 
 
6.3.5.3 GSH level in siPrx3 J774A.1 cells 
As with Prx1- and Prx2-silenced cells, treatment of Prx3 silenced J774A.1 cells with 100 
or 200 μM HOSCN for 1 hr (22 °C) did not produce any significant changes in GSH 
levels compared to both 0 μM HOSCN treatment and non-silenced control cells      
(Figure 6.17 A). In contrast, HOCl treatment (100 or 200 μM) caused a significant 
decrease in GSH levels in control cells (30 to 50%) (Figure 6.17 B). Prx3 silenced cells 
also showed a trend towards decreased GSH levels, with this reaching significance only 
at 200 μM HOCl (30% decrease).  
 
 
0 1 0 0 2 0 0
0
5 0
1 0 0
1 5 0
H O S C N  (  M )
G
S
H
 (
%
 o
f
 c
o
n
t
r
o
l)
0 1 0 0 2 0 0
0
5 0
1 0 0
1 5 0
H O C l  (  M )
A ) B )
136 
 
 
Figure 6.17 GSH levels in Prx3 silenced and control J77A.1 cells 
GSH levels in J774A.1 cells were quantified by HPLC with fluorescence detection after 
derivatisation with dansyl chloride as described in Section 2.3.11. Results are expressed 
as a percentage of the GSH concentration present in the 0 µM oxidant treatment. The 
concentration of GSH measured in the 0 µM control samples was 58 ± 3 µM. Values are 
mean (n = 3) ± SEM, */** indicate significant difference (P < 0.05/0.01, respectively) 
compared to 0 µM controls according to 2-way ANOVA with Bonferroni‘s post-hoc 
tests. 
 
6.3.5.4 GSSG levels in J774A.1 cells silenced with siPrx1, siPrx2 or siPrx3 
There were no detectable changes in GSSG levels in J774A.1 cells under any oxidant 
treatment conditions with silenced Prx1, Prx2, Prx3 or respective SCR siRNA control 
cells. 
 
6.3.5.5 GSH/GSSG measurements in the absence of glucose 
The absence of any GSH loss, particularly in the HOSCN-treated cells, was somewhat 
surprising, given the observed significant increase in protein S-glutathionylation (Figure 
6.10 and Figure 6.12). However, it has been shown previously that the presence of 
glucose aids the recycling of GSH in cells (126). In the absence of glucose the loss of 
GSH has been reported to be greater, and accompanied by an increase in GSSG levels. To 
examine this as a possible cause of the lack of significant GSH loss, J774A.1 cells 
transfected with siPrx2 or SCR siRNA were incubated with HOSCN or HOCl prepared in 
PBS (as opposed to HBSS containing glucose) in order to compare the extent of GSH 
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oxidation in the presence and absence of glucose. Following oxidant treatment, samples 
were prepared for HPLC analysis as described previously (Section 2.3.11).  
 
In contrast to the data obtained in the presence of glucose, there was a concentration-
dependent decrease in GSH in both Prx2 silenced and SCR siRNA control cells treated 
with HOSCN (Figure 6.18 A) or HOCl (Figure 6.18 C). However, the corresponding 
increase in GSSG levels was significantly higher in the SCR siRNA control cells 
compared to the Prx2 silenced cells treated with HOSCN (Figure 6.18 B, white vs. black 
bars). HOCl treatment resulted in a significant increase in GSSG formation in both 
silenced and control cells with 200 µM oxidant (Figure 6.18 D); however, this increase 
was significantly lower than the HOSCN-induced elevation in GSSG levels (Figure 6.18 
B). This suggests that the higher proportion of GSH lost in the absence of glucose was 
due to some other mechanism, potentially including S-glutathionylation or extracellular 
transport of GSSG. 
 
It is worth noting that the initial GSH levels in the absence of glucose were significantly 
lower than in its presence (~10 µM vs. ~60 µM, respectively), suggesting an impaired 
regeneration of GSH possibly due to the lack of NADPH, the generation of which 
depends on glucose availability.  
  
Unfortunately, quantification of GSH levels in the Prx1 and Prx3-silenced cells proved to 
be impossible, due to the extensive cell death that occurred during 1 hr exposure to the 
oxidants in PBS. 
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Figure 6.18 GSH/GSSG levels in Prx2 knocked-down cells following HOSCN or 
HOCl treatment. 
J774A.1 cells were transfected with siPrx2 (black bars) or SCR control siRNA (white 
bars), and then treated with 0 – 200 µM HOSCN (A and B) or HOCl (C and D), in PBS 
for 1 hr (22 ºC). GSH and GSSG were quantified by HPLC with fluorescence detection 
after derivatisation with dansyl chloride as described in Section 2.3.11. Results are 
expressed as a percentage of the GSH/GSSG levels for the 0 µM oxidant treatment. 
Values are mean (n = 3) ± SEM, */** indicate significant difference (P < 0.05/0.01, 
respectively) compared to 0 µM controls; ##/### denote significant difference                
(P < 0.01/0.001, respectively) between siPrx2 and SCR siRNA treated cells as assessed 
by 2-way ANOVA with Bonferroni‘s post-hoc tests. 
 
 
6.4 Discussion 
The experiments reported in this Chapter were aimed at investigating the effects of 
HOSCN and HOCl on metabolic activity, GSH/GSSG levels and S-glutathionylation of 
proteins in J77A.1 cells with knocked-down expression of Prx1, Prx2 or Prx3. These 
experiments were performed to determine whether these three Prxs play an important role 
in protecting cells from HOSCN- or HOCl-derived damage. Initial experiments focused 
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on optimisation of the Prx siRNA transfection conditions, as the success of the following 
experiments was dependent on the combination of efficient transfection, high metabolic 
activity and minimal off-target effects such as S-glutathionylation. Treatment with         
35 nM siPrx1 resulted in effective reduction of Prx1 protein expression (~99% reduction 
after 72 hr) without significant reduction in Prx2 or Prx3 protein levels. Conversely, Prx2 
and Prx3 protein expression was reduced by ~50% following treatment with the 
respective siRNAs at 35 nM siPrx (48 – 72 hr). The transfection process itself did not 
cause any significant change in Prx expression, metabolic activity or S-glutathionylation 
compared to non-transfected cells; this was confirmed by running control experiments 
with scrambled siRNA (SCR), or transfection reagent only. In contrast, cell treatment 
with higher concentrations of siRNA (40 and 50 nM) and/or exposure to a longer 
incubation time (> 72 hr) resulted in significant cell death and undesirable off-target 
effects (increased S-glutathionylation in SCR siRNA control cells compared to non-
transfected cells).  
 
The absence of significant differences in metabolic activity on oxidant treatment of Prx 
silenced cells and SCR siRNA control cells suggests that the absence/decrease of only 
one of these Prxs might be compensated for by the activity of the other Prxs. The effects 
of silencing of each Prx individually are also difficult to compare, owing to the variable 
degree of Prx silencing. It is worth noting, however, that there was a (non-significant) 
trend toward decreased metabolic activity in Prx1 silenced cells treated with HOCl 
compared to SCR control. This might be associated with the high efficiency of Prx1 
knock-down (~99% silenced). 
 
It has been shown in Chapter 5 that different isoforms of Prxs have different sensitivities 
to MPO-derived oxidants. HOSCN, similarly to H2O2 (357-359), but unlike HOCl 
(Chapter 5, (242)) was shown to cause Prx hyperoxidation (Prx-SO2H, sulfinic and     
Prx-SO3H, sulfonic acid species formation) at the levels of HOSCN that might be found 
in smokers (i.e. ≤ 200 μM). Hyperoxidation of Prxs can be slowly reversed by Srx if the 
active site Cys is overoxidised to a sulfinic form; however, hyperoxidation to a sulfonic 
acid is believed to be irreversible (360). In both cases, Prxs become temporarily (or 
permanently) inactivated and lose their peroxidase activity. It has been argued that a 
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temporary (reversible) loss of function may facilitate H2O2-mediated cell signalling 
through a local increase in H2O2 levels (the ―floodgate‖ hypothesis) (163). Another 
possibility is the formation of higher molecular mass Prx complexes (decamers) upon 
hyperoxidation, which are known to have molecular chaperone activity and are associated 
with improved cell survival under oxidative stress conditions (339).   
 
HOSCN has been shown to generate sulfenic acids from protein Cys (103); this protein 
modification is unstable and short-lived but can be highly reactive towards another Cys or 
GSH to form disulfides or S-glutathionylated species respectively. S-glutathionylation has 
been regarded as not only a cellular protective mechanism against irreversible Cys 
oxidation, but also as a modulator of the activity of certain enzymes ((356, 361, 362), 
reviewed in (348)). Oxidative stress conditions have been reported to differentially affect 
the degree of S-glutathionylation of various proteins (363). In light of these data it was of 
interest to examine the effect of the knock-down of the important antioxidant enzymes 
Prxs on the extent of cellular protein S-glutathionylation under the conditions of        
MPO-derived oxidative stress. 
 
Initial experiments were aimed at measuring metabolic activity in Prx silenced cells 
following oxidant treatment. The extent of S-glutathionylation was also assessed 
following oxidant treatment by immunoblotting with an anti-GSH primary monoclonal 
antibody, and the association between S-glutathionylation and GSH levels was 
investigated. Although HOSCN or HOCl treatment increased protein S-glutathionylation, 
in both siPrx and SCR siRNA control cells, the knock-down of J774A.1 Prxs resulted in a 
lesser extent in protein S-glutathionylation after oxidant treatment compared to SCR 
siRNA control cells at each oxidant concentration examined. This trend reached statistical 
significance only in siPrx3 cells treated with 100 – 200 μM HOCl (Figure 6.12). Prx3 is 
one of the major mitochondrial enzymes that remove H2O2 (331). Knock-down of Prx3 
has been shown to result in a reduced cellular ability to withstand oxidative stress induced 
by TNFα or staurosporin (364), as well as inhibition of cell proliferation and cell cycle 
disruption (365). The decreased levels of protein S-glutathionylation observed in the 
present study might be an indication of a greater oxidative burden inflicted by HOCl on 
Prx3 knocked-down cells, with this associated with irreversible thiol modifications 
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(hyperoxidation) and/or GSH depletion. The difference between GSH levels in siPrx3 and 
SCR control cells treated with HOCl was not however statistically significant (Figure 
6.17). Despite this, there was a significant dose-dependent decrease in cellular GSH 
concentration with HOCl treatment in both Prx3 knocked-down and control cells, though 
this was not associated with any increase in GSSG formation. The absence of GSH loss 
upon HOCl treatment of J774A.1 cells, reported in Chapter 4, might be associated with a 
greater number of available functional targets for HOCl, such as protein thiols and Met 
residues. It is possible that these residues might be affected/diminished by the 
transfection procedure, described in this Chapter, making GSH the next line of defence 
against HOCl. 
 
Whereas some GSH loss might be accounted for by the formation of S-glutathionylated 
proteins, most GSH was lost without a corresponding intracellular accumulation of 
GSSG. Prx3 silencing was associated with lower levels of S-glutathionylated proteins, 
suggesting that in these cells GSH loss was not due to mixed disulfide formation or its 
oxidation to GSSG, but possibly due to the formation of other products (e.g. glutathione 
sulphonamide; as seen with other oxidants (366)) or GSSG export from cells. These 
findings are consistent with previous studies with activated neutrophils (124), RBC (126, 
242) and HUVEC (245), where GSH levels were measured in the presence of glucose, 
which allows for NADPH-dependent recycling of GSSG. In the present study, glucose 
was one of the components of the HBSS buffer in which oxidants were prepared (the 
final concentration of glucose was 4.5 mM). Comparative studies in the absence of 
glucose were complicated by poor cell survival in the glucose-free PBS. The only 
conditions that allowed measurements of GSH without exogenous glucose were when 
J774A.1 cells were transfected with siPrx2 (and their respective SCR control siRNA) for 
48 hr. Longer transfection times, as used with siPrx1 and siPrx3 (72 hr), significantly 
reduced the ability of these cells to counteract the effects of MPO-derived oxidants. 
  
Nevertheless, the results obtained with Prx2 knocked-down cells demonstrate that 
without added glucose, GSH was rapidly lost on treatment with either oxidant; HOSCN 
(100 – 200 µM) caused 70% – 85% GSH loss (Figure 6.18 A), whereas 100 – 200 µM 
HOCl treatment resulted in 50% – 92% decreases in GSH levels (Figure 6.18 C). The 
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corresponding GSSG increase was significantly higher for HOSCN (Figure 6.18 B) than 
HOCl (Figure 6.18 D), however the level of GSSG detected still did not account for all of 
the lost GSH. One possible explanation is that accumulation of GSSG might be attributed 
to the impairment of its recycling by GR or a depletion of NADPH required by GR (230). 
In the presence of glucose, GSH levels did not change significantly after oxidant 
exposure and no GSSG was detected (Figure 6.16).  
 
The higher degree of total protein glutathionylation observed in SCR siRNA cells might 
also be associated with the impairment of de-glutathionylation reactions catalysed by 
Grxs (160). This reaction is also dependent on GSH and NADPH availability. 
Additionally, it has been previously reported that TrxR can directly reduce the oxidised 
form of Grx2 and thereby increase its availability for de-glutathionylation reactions (285). 
TrxR is also involved in the regulation of Prx redox cycling by supplying reducing 
equivalents in the form of Trx. It would be logical to suppose that with a decreased level 
of Prx due to siRNA knock-down, more reducing equivalents (such as reduced Trx) from 
TrxR would be available to react with other substrates, such as Grx, and that this might 
therefore decrease the level of S-glutathionylation in the Prx silenced cells. However, this 
conclusion is only speculative, as the measurement of Grx levels and activity was beyond 
the scope of this study.  
 
Both HOSCN and HOCl increased protein S-glutathionylation in J774A.1 cells, however 
to different degrees. HOSCN treatment caused less S-glutathionylation in cells 
transfected with siPrx1, siPrx3 and their SCR siRNA controls, compared to HOCl at the 
same concentrations (Figure 6.10 and Figure 6.12). Both HOSCN-induced oxidation (98, 
263) and S-glutathionylation (reviewed in (356)) occur most rapidly with low pKa thiols, 
and it is possible that HOSCN competes with GSH for further reactions with Cys-S-SCN 
or Cys-S-OH, the HOSCN-derived intermediates. In such a case, HOSCN might cause 
hyperoxidation of Cys residues before GSH has a chance to react and prevent further 
oxidation (Scheme 6.1). 
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Scheme 6.1 Proposed mechanism of competition between GSH and HOSCN for 
reaction with protein sulfenic acids. 
R-Cys-S-H – any protein with low pKa Cys; R-Cys-S-SCN – sulfenyl thiocyanate; R-
Cys-S-OH – protein sulfenic acid; R-Cys-S-SG – S-glutathionylated protein; R-Cys-S-
O2H – hyperoxidised protein. 
 
 
In contrast, total protein S-glutathionylation in the cells transfected with siPrx2 was 
higher with HOSCN than HOCl treatment at 200 μM (Figure 6.11; 6.5 – 9 vs. 5 – 6-fold 
increase respectively). This difference might be explained by the fact that the transfection 
conditions were maintained for 48 hr in order to knock down Prx2 and for 72 hr in the 
case of Prx1 and Prx3 silencing. Longer incubation times with siRNA and transfection 
reagent could be detrimental to cells and affect their ability to cope with oxidative stress 
induced by MPO-derived oxidants. The higher S-glutathionylation levels detected at 48 hr 
could be an indication of adequate levels of GSH present in cells, which allows reaction 
with protein Cys residues to form mixed disulfides, and thereby protects them from 
further oxidation. Indeed, the measurement of intracellular GSH showed no significant 
decrease in GSH levels (Figure 6.16), and no elevation of GSSG. Decreased levels of 
GSH, GSSG accumulation, and increased hyperoxidation to give sulfinic and sulfonic 
acids, may therefore all contribute to the decrease in protein S-glutathionylation observed 
after 72 hr post-transfection compared to 48 hr. 
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The pattern of S-glutathionylation differed between HOSCN and HOCl (see Figure 6.9). 
Barrett et al. previously reported the formation of sulfenic intermediates on GAPDH, 
mediated by HOSCN (103). Sulfenic acid derivatives on protein Cys residues are known 
to be reactive with GSH, which leads to the formation of S-glutathionylated proteins. This 
scenario is likely in the case of GAPDH glutathionylation following HOSCN treatment. 
HOCl has been previously shown to inactivate GAPDH in HUVEC and cause GSH loss 
(125). Although GAPDH activity was not investigated in the present study, it is possible 
that HOCl-induced GAPDH S-glutathionylation (Figure 6.9, 37 kDa protein band) might 
be associated with a loss of enzymatic activity.  
6.5 Conclusions 
Altogether, the results obtained from the experiments reported in this Chapter suggest 
that the effects produced by MPO-derived oxidants on J774A.1 cells are diverse and 
complex. The degree of total protein S-glutathionylation appears to be more dependent on 
the nature of the oxidant (HOSCN vs. HOCl) than on the Prx isoforms that had been 
silenced. However, S-glutathionylation of some individual protein bands was also 
affected by the silencing of certain Prx, and possibly the extent of such silencing, as 
evidenced by the increase in S-glutathionylation of a band corresponding to GAPDH in 
J774A.1 cells with knocked-down Prx1. Unfortunately, the significance of each Prx 
isoform in the defence against MPO-derived oxidants has been hard to establish due to 
the different (and in some cases incomplete) silencing efficiency of the different 
isoforms. Overall, however, silencing of 2-Cys Prx1 - 3 did not seem to affect metabolic 
activity following the treatment with hypohalous acids. These data suggest that cells have 
multiple and redundant defences against these oxidants and that cells can, at least 
partially, cope with a decreased or complete loss of activity of individual Prx isoforms as 
long as adequate supplies of reducing equivalents can be generated/regenerated. 
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CHAPTER 7. General discussion 
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7.1 Overview 
Myeloperoxidase, a heme enzyme secreted by activated phagocytes at sites of 
inflammation, catalyses the oxidation of Cl
-
, Br
-
 and SCN
-
 to the powerful oxidants 
HOCl, HOBr and HOSCN acids (reviewed in (1)). MPO-derived oxidants are powerful 
bactericidal and bacteriostatic agents, playing an essential role in innate immunity. 
However, the misregulated production of these oxidants can be detrimental to the host. 
To this end, MPO and MPO-derived oxidants have been implicated in a number of 
inflammatory diseases such as cystic fibrosis, neurodegenerative disorders, some cancers 
and atherosclerosis (1). Elevated MPO levels, found in human atherosclerotic lesions, are 
diagnostic of CVD, and prognostic of long-term post-myocardial infarction mortality (47, 
56, 367).  
 
Thiocyanate is a preferred substrate of MPO (84), and higher SCN
-
 levels are present in 
the plasma of smokers (292, 368), suggesting that HOSCN formation may contribute to 
the enhanced risk of atherosclerosis (and other diseases) in smokers. In order to better 
understand the role of this oxidant in both extra- and intracellular settings, the studies 
described in this thesis used both plasma samples, and the murine macrophage-like 
J774A.1 cell model. Elevated levels of plasma SCN
-
 positively correlated with thiol 
oxidation under conditions mimicking an inflammatory episode. In addition, higher levels 
of plasma SCN
-
, in combination with low levels of MPO, correlated with lower rates of 
12-year all-cause mortality, thus suggesting a protective role of SCN
-
 (possibly via 
HOSCN formation) under certain conditions. Cell-based experiments examined             
the effects of HOSCN on NADPH-dependent antioxidant enzymes and                    
GSH/S-glutathionylation, and compared them to the more extensively studied HOCl. 
These studies demonstrated the inhibition of TrxR activity, oxidation and hyperoxidation 
of Prxs, and GSH loss following HOSCN treatment, whilst HOCl caused a significant 
decrease in GPx activity. Differential susceptibility of various antioxidant enzymes and 
thiols suggests the presence of intracellular defence mechanisms for different            
MPO-derived oxidants. 
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7.2 Discussion and future directions 
7.2.1 SCN-, MPO and disease 
Initial studies were aimed at elucidating the effects of MPO and SCN
-
 on plasma thiol 
levels under oxidative stress conditions in patients who survived a first myocardial 
infarction. In accord with previous studies on healthy volunteers (90), elevated levels of 
SCN
-
 were strongly correlated with increased plasma thiol oxidation (under conditions 
mimicking an inflammatory episode), particularly in smokers. In contrast, the 
concentrations of other MPO plasma substrates, including Br
-
 and NO2
-
, did not correlate 
with plasma thiol oxidation levels.  
 
It has previously been proposed that elevated thiol oxidation might be due to an increased 
formation of HOSCN by the MPO/H2O2 system in the presence of high levels of SCN
-
, 
which is a preferred substrate not only for MPO, but also for LPO  and EPO ((81), 
reviewed in (302)). In some cases, production of HOSCN can be beneficial due to the 
bacteriostatic properties of this oxidant, for example when HOSCN is produced by lung 
epithelial cells to neutralise harmful bacteria present in airways (97), or in saliva to 
protect tissues of the oral cavity from a plethora of pathogens (369). Despite the 
production of large quantities of HOSCN, host cells are left unharmed and only the 
invading pathogens are inactivated, suggesting that some cell types possess an 
evolutionary predisposition to withstand the effects of HOSCN. However, in other cases, 
excessive production of HOSCN has been implicated in host tissue damage (101, 108, 
370). One of the mechanisms by which HOSCN is proposed to be damaging is via 
selective oxidation of protein thiols, especially low pKa thiols located at active sites of 
critical antioxidant enzymes (37, 98, 101, 103, 371).  
 
Surprisingly, increased SCN
-
 was also associated with lower levels of 12-year all-cause 
mortality following myocardial infarction, especially in patients with below-median 
levels of plasma MPO. Although these findings were unexpected they, to some degree, 
are supported by previous reports concerning the ―smoker‘s paradox‖ (275, 372). The 
smoker‘s paradox is characterised by increased survival following a myocardial infarction 
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by smokers; this is mainly, but not exclusively, attributed to the younger age of smokers. 
As the majority of people with high plasma SCN
-
 consuming a western diet represent 
smokers, the elevated levels of this anion may be one of the contributors to the etiology 
of the smoker‘s paradox. Indeed, the associated increased production of HOSCN by the 
MPO/H2O2 system, together with non-enzymatic production of HOSCN upon reaction of 
HOCl or HOBr with SCN
-
, could significantly change the balance of oxidants formed. 
The nature of the oxidants formed may be important due to the different types of damage 
that can be inflicted by them. As HOCl and HOBr are highly damaging non-specific 
oxidants, the decreased production of these oxidants in favour of thiol-specific HOSCN 
(98) might be beneficial under certain conditions, for example in plasma, where the 
amount of antioxidants is relatively low compared to the intracellular environment (61, 
373). HOSCN-induced damage is highly specific to low pKa thiols and selenols, and is 
mostly reversible (103), whereas HOCl and HOBr have been shown to cause irreversible 
modification of various protein residues (Cys, Met, Tyr etc.) (reviewed in (37)). A lower 
level of irreversible damage may be a tipping point when it comes to survival and 
subsequent recovery from a major cardiac event such as myocardial infarction. Although 
this hypothesis needs further investigation, the measurements of plasma SCN
-
 in 
myocardial infarction patients, in addition to measurements of MPO levels, may be of 
potential importance in clinical outcomes. 
 
The studies presented in Chapter 3 might be extended to a larger cohort of myocardial 
infarction patients to confirm that these trends are reproducible; furthermore, comparison 
to a control group of healthy volunteers would add the strength to the study. Especially 
useful would be multi-logistic regression analyses adjusting for potential confounders, 
including age, gender, LDL and HDL cholesterol, triglycerides, renal function, 
hypertension and CRP. Also, information on the antioxidant status in subjects of each 
group (non-smokers, smokers and past-smokers) might help to explain the observed 
differences. Additionally, knowledge about specific mortality from cardiovascular events, 
rather than all-cause mortality, would add strength to the correlation observed. 
 
The protective effects of HOSCN could also be studied in greater detail using a mouse 
model of atherosclerosis. SCN
-
 levels can be easily elevated by inclusion of this anion in 
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drinking water, or by supplementation with SCN
-
 rich foods, such as broccoli and other 
cruciferous vegetables. The extent of atherosclerosis (e.g. lesion area and phenotype), 
systemic inflammation (e.g. measurement of serum amyloid A, the murine equivalent of 
CRP) and lipid levels (e.g. triglycerides, LDL and HDL) in mice could be assessed in 
order to confirm (or otherwise) the protective effects of SCN
-
. 
 
Alternatively, the effects of SCN
-
 on the degree of MPO-derived damage could be 
investigated by using cells that are physiologically relevant to atherosclerosis, including 
human coronary artery endothelial and SMC, or isolated tissue sections such as aortic 
rings.  
7.2.2 Cellular defence mechanisms against MPO-derived oxidants 
Exposure to high levels of HOSCN (100 – 200 µM) for a prolonged period of time (up to 
4 hr) have been shown to induce significant damage to cell types that are relevant to 
atherosclerosis, including murine macrophage-like J774A.1 cells, and HCAEC (101). 
With regard to the mechanisms of the observed damage, recent work by Barrett and 
colleagues has provided evidence for the formation of sulfenyl thiocyanate and protein 
sulfenic acid intermediates on a number of intracellular proteins with low pKa active site 
Cys residues, exposed to HOSCN. These protein modifications can alter the catalytic 
properties of the affected enzymes and potentially lead to the perturbation of intracellular 
metabolism and possibly redox signalling. Although a number of enzymes have been 
previously reported to be modified by HOSCN, including CK, GAPDH and PTPs (103, 
104), information about other potential targets and the existence of specific intracellular 
defence mechanisms against this oxidant is currently lacking. In this thesis, J774A.1 
murine macrophage-like cells were used in order to examine the reactivity of HOSCN 
with the seleno enzymes TrxR and GPx, GSH (Chapter 4), as well as the family of low 
pKa thiol protective enzymes, the Prxs (Chapters 5 and 6). The effects of HOSCN were 
compared with those of HOCl as this oxidant has been relatively well studied. The 
following sections discuss the findings from the cellular experiments in this thesis, and 
their relevance to human disease. 
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7.2.2.1 TrxR and GPx and selenium supplementation 
Marked differences were observed between the effects of HOSCN and HOCl on TrxR 
and GPx activities. Surprisingly, whilst HOCl markedly diminished GPx activity, 
HOSCN had no effect on GPx activity, but significantly decreased TrxR activity. The 
catalytic activity of both enzymes depends on active site Sec residues, which would be 
expected to be specifically targeted by HOSCN on the basis of previous data (262). 
However, in addition to the C-terminal Gly-Cys-Sec-Gly active site, TrxR also contains a 
catalytically active -Cys-Val-Asn-Val-Gly-Cys- site located in the vicinity of the flavin 
ring of FAD. The presence of this additional potential HOSCN target in TrxR may 
potentially contribute to its overall greater loss of activity than in GPx. These findings are 
of possible importance as TrxR regulates a wide range of redox-sensitive proteins and 
transcription factors through the reduction of oxidised Trx (194). The levels of plasma 
TrxR have been used as a measure of oxidative stress, and the importance of this enzyme 
has been demonstrated by the lethal phenotype of TrxR-KO mice (374). Furthermore, the 
expression of TrxR has been shown to be upregulated in atherosclerotic plaques upon 
exposure to oxLDL (375). An elevated level of TrxR may be especially important in 
smokers, as smoking is a major risk factor for atherosclerosis, and is associated with 
increased levels of the HOSCN precursor, SCN
-
, in plasma. Impairment of TrxR activity 
could occur in smokers due to elevated levels of HOSCN, with this leading to an 
exacerbation of atherosclerosis.  
 
Previous studies have provided evidence for the caspase-independent induction of 
apoptosis by HOSCN in J774A.1 and HUVEC under certain conditions (101). Alternative 
apoptosis inducing pathways might explain the involvement of HOSCN in this process; 
these include activation of the apoptosis signalling kinase 1 (ASK1) pathway, which is 
negatively regulated by Trx (376). Reduced Trx binds ASK1, rendering it inactive (377). 
When Trx becomes oxidised, it dissociates from ASK1 which in a free form (i.e. released 
from Trx) can induce an apoptosis signalling cascade. Thus, inactivation of TrxR by 
HOSCN, which would be unable to reduce oxidised Trx, may promote apoptosis 
signalling through an ASK1/Trx mechanism. In the current study, despite a significant 
loss in TrxR activity, metabolic activity and viability were not decreased by HOSCN 
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treatment, suggesting that TrxR successfully removes HOSCN, with possible transitory 
loss of activity, although the recovery of the enzymatic activity was not further 
investigated. Together with GSH, which was also depleted with HOSCN but not HOCl 
treatment, TrxR appears to represent a defence mechanism against HOSCN-derived 
damage. 
 
In contrast, decreased GPx activity has been associated with an increased cardiovascular 
risk and greater extent of atherosclerosis (378). Furthermore, the activity of this enzyme 
has been found to be diminished in human atherosclerotic plaques (379). Assuming the 
studies in murine macrophages presented in this thesis reflect the inflammatory 
conditions associated with atherosclerotic plaques, HOCl may potentially be one of the 
contributors to such decreased GPx activity. To this end, selenium supplementation, 
which demonstrated a marked degree of protection from HOCl-mediated inhibition of 
GPx activity, might be of some benefit under inflammatory conditions, although the 
benefits of selenium supplementation for the primary prevention of CVD remains to be 
confirmed (380). 
 
The involvement of the seleno-dependent enzymes TrxR and GPx in the intracellular 
defence against MPO-derived oxidants was investigated in the current study by 
supplementing J77A.1 cells with seleno compounds. The role of these enzymes could be 
further elucidated by growing cells in selenium-deficient medium or inhibiting their 
expression by siRNA-mediated silencing. Pharmacological inhibition of TrxR and GPx 
by use of gold complexes (such as auranofin (247, 291)) or other species could provide 
some information about the global effects of these oxidants. Additionally, the 
reversibility of the observed inhibition of TrxR and GPx activity could be assessed by 
removing the oxidants after treatment, and monitoring the regeneration of activity (or 
lack thereof) over time. 
 
The exact sites of modification on TrxR, GPx and Prxs caused by MPO-derived oxidants 
as well as extent of damage to particular Cys and Sec residues, could be examined by 
mass spectrometry with peptide mass mapping. 
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7.2.2.2 Prxs and GSH 
TrxR reduces oxidised Trx, which in turn is essential to keep Prxs in their reduced active 
state. The results described in Chapter 4 suggested the possibility that MPO-derived 
oxidants exert their effects on Prx through a diminished activity of TrxR. Immunoblotting 
with antibodies against 3 mammalian Prx isoforms (Prx1, Prx2 and Prx3), as well as 
antibodies specific to a hyperoxidised form of typical 2-Cys Prxs, enabled the 
characterisation of their redox state following HOSCN and HOCl treatment. Prxs form 
dimers upon oxidation by oxidants such as H2O2, organic peroxides, and ONOO
-
, and can 
undergo hyperoxidation when treated with an excess of oxidant (162, 174, 381). In 
addition to peroxides, Prxs have been recently shown to react with various chloramines 
and HOCl, with the formation of dimeric and oligomeric but not hyperoxidised forms 
(242, 245). Given the rapid oxidation of Cys residues by both HOSCN and HOCl, one 
might expect a similar pattern of Prx oxidation by these two oxidants, with perhaps a 
greater effect of HOSCN due to its specificity for low pKa Cys, such as those present at 
the active sites of Prxs. However, the data presented in Chapter 5 revealed differential 
(oxidant-specific and Prx isoform-specific) sensitivities of macrophage Prxs towards 
HOSCN and HOCl. 
 
The cytosolic isoforms (Prx1 and Prx2) appeared to be readily oxidised by HOSCN, with 
the formation of dimers, whereas HOCl caused more pronounced dimerisation of the 
mitochondrial isoform (Prx3). Moreover, it has been shown for the first time that 
HOSCN, but not HOCl, induces the formation of the hyperoxidised Prx monomers and 
dimers. Based on reports that HOSCN can form sulfenyl thiocyanate and sulfenic acid 
intermediates with reactive protein thiols (103), the Prx active site Cys may also be 
similarly modified by HOSCN. This would be worthy of further study. The formation of 
an unstable sulfenic acid intermediate, may potentially favour further reactions of Prx-
SOH with excess HOSCN, leading to the formation of hyperoxidised species (sulfinic 
and sulfonic acids). Prx hyperoxidation by H2O2 is believed to occur via fast reaction of 
H2O2 with the Prx active site thiolate as well as with the sulfenic acid intermediate. H2O2-
induced Prx hyperoxidation has been linked to the regulation of cell signalling by H2O2, 
where this oxidant acts as a second messenger (175). The observed similarities in the 
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action of both H2O2 and HOSCN suggest the possibility of the participation of HOSCN in 
the regulation of cell signalling in a manner analogous to H2O2. In support of this 
hypothesis, previous studies have provided evidence for HOSCN-mediated modulation of 
cell signalling through the inhibition of PTPs and subsequent alteration of MAPK 
signalling (104).  
 
The data presented in Chapter 5, indicate that selenium supplementation caused a 
concentration-dependent increase in total protein S-glutathionylation in J774A.1 cells 
upon HOSCN treatment. At the same time, the extent of formation of hyperoxidised Prx 
species, induced by HOSCN, was lower in the selenium-supplemented cells compared to 
non-supplemented controls. S-glutathionylation has been reported to be a mechanism by 
which protein Cys residues are protected from hyperoxidation, and also an indicator of 
oxidative stress (356). It has been previously reported that S-glutathionylation regulates 
the activity and oligomerisation of 2-Cys Prxs (382). Although the identification of Prx 
protein S-glutathionylation was not pursued in this study due to technical difficulties 
associated with this method (previously unsuccessfully attempted by Tessa Barrett and 
described in her PhD thesis (338)), the ability of macrophage cells to cope with HOSCN 
or HOCl-induced oxidative stress in the absence of one of the major Prxs was 
investigated by measuring the degree of total protein S-glutathionylation. 
 
Prxs, despite being relatively recently discovered (383), have attracted significant 
attention as they have been implicated in a number of human pathologies, including 
cancer (169, 365, 384) and neurodegenerative diseases (385, 386) (discussed in Chapter 
1). CVD has recently emerged as one of the pathologies associated with modulated 
expression and activity of certain Prxs (387, 388). Thus, Prx2 deficiency has been shown 
to aggravate atherosclerosis in ApoE
-/-
 mice (389), and decreased expression of Prx1 has 
been linked to the elevated expression and release of P-selectin by endothelial cells from 
storage granules (Weibel-Palade bodies) and consequential activation of endothelium, 
and atherosclerotic lesion formation (390). Furthermore, excessive production of H2O2, 
associated with activation of a number of cell surface receptors, has been shown to be 
quenched by Prx2 (391). The results reported in this thesis extend the roles of Prxs to 
HOSCN-detoxification agents, which may be particularly important for smokers.  
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Assessment of the relative importance of each of the Prx isoforms in possible defences 
against MPO-derived oxidants was attempted by siRNA-mediated silencing; the results of 
these studies are described in Chapter 6. Pharmacological inhibitors of Prxs have been 
used in cancer research, however the lack of isoform specificity significantly diminishes 
the value of this approach (392). Prx1 silencing in J774A.1 cells has been utilised in 
previous studies investigating the role of Prxs in macrophage foam cells (294). In the 
study reported here, Prx1 was nearly completely (99%) silenced in J774A.1 cells, 
whereas Prx2 and Prx3 silencing was more modest (~50%). The inability of siRNA to 
induce complete silencing of Prx2 and Prx3 without significant cell toxicity is a major 
limitation of this study, as it was difficult to directly compare the consequences of the 
deficiency of each Prx isoform. It is worth noting that failure to achieve 100% silencing 
without toxicity may also indicate the importance of these species in cell metabolism. 
Nevertheless, some interesting patterns have emerged.  
 
Both HOSCN and HOCl treatments increased the total protein S-glutathionylation in Prx-
silenced and SCR siRNA control cells. This increase was only moderately, and not 
statistically-significantly, higher in the SCR siRNA control cells, treated with HOSCN, 
when compared to Prxs silenced cells irrespective of the isoforms being silenced. This 
pattern was similar for HOCl treatment, with the exception of Prx3 silenced cells, for 
which a dose-dependent increase in total protein S-glutathionylation was significantly 
lower when compared to SCR siRNA control cells. The pattern of protein                       
S-glutathionylation was clearly different for HOSCN and HOCl, suggesting a variation in 
the targets oxidised by these species. For instance, HOCl caused significant                             
S-glutathionylation of GAPDH protein which was most pronounced in Prx1 silenced 
cells, possibly due to the highest silencing efficiency of this Prx isoforms, but this 
enzyme did not appear to be significantly S-glutathionylated in HOSCN-treated cells. 
GAPDH S-glutathionylation has been linked to an inhibition of its enzymatic activity 
(393); the decrease in Prx1 activity is likely to increase the burden of HOCl-induced 
damage on other intracellular targets in J774A.1 cells, including GAPDH. 
 
Levels of GSH were also measured in Prx silenced cells following oxidant treatment, and 
compared to non-silenced controls. When glucose was present in the buffers, there was 
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no significant change in GSH levels under any of the treatment conditions investigated. 
HOCl caused a small, dose-dependent decrease in intracellular GSH without any increase 
in GSSG formation in both control and Prx-silenced cells, whereas HOSCN did not cause 
any detectable changes in GSH levels. This suggests that adequate amounts of reducing 
equivalents can be produced/regenerated in J774A.1 cells in the presence of glucose to 
provide protection against MPO-derived oxidant damage, even under conditions of major 
antioxidant enzyme deficiency. In contrast, in the absence of glucose (in PBS), there was 
a marked loss in GSH levels and corresponding accumulation of GSSG in cells treated 
with HOSCN. The increase in GSSG formation was significantly higher in the control 
cells than in Prx2 silenced cells. This might be due to the formation of mixed disulfides 
(protein-S-SG), GS-SCN species (via a direct reaction of GSH with HOSCN (394)), 
GSSG extracellular export, or GSSG sequestration in the cells, although this phenomenon 
has been only observed in yeast so far (395). HOCl treatment also caused significant 
decreases in GSH levels in the control and Prx2 silenced cells, with only small increases 
in GSSG formation. This decrease in HOCl-induced GSH levels was observed in J774A.1 
siRNA-transfected (SCR or siPrx) cells (Chapter 6) but not in the cells incubated in 
normal media without any siRNA of transfection reagent (Chapter 4). The transfection 
procedure caused a significant decrease in the initial GSH levels in the untreated cells 
compared to non-transfected conditions (~10 µM vs. ~40 µM, respectively), which might 
explain the difference in GSH antioxidant efficiency against HOCl. This is in accord with 
previous studies which showed that decreased levels of GSH increase cellular 
susceptibility to oxidative stress and subsequent damage to intracellular targets (243, 
244). 
 
Although there was an increase in GSSG levels in the absence of glucose, it was rather 
low relative to GSH loss in J774A.1 cells, which might be due to the formation of 
glutathione sulfonamide and/or glutathionylated proteins. Previous studies with RBC 
treated with HOCl or various chloramines demonstrated a similar loss of GSH without a 
corresponding increase in GSSG levels and limited formation of glutathione sulfonamide 
or mixed disulfides (242). It would be of interest to investigate the GSH oxidation 
products formed upon treatment of J774A.1 cells with MPO-derived oxidants and 
compare it to other cells types such as RBC, HCAEC and human monocyte-derived 
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macophages (HMDM). This could be achieved using a previously described LC-MS/MS 
method (366).  
 
These data indicate that there is a complex interplay between multiple intracellular 
defence mechanisms against HOSCN- and HOCl-induced damage, represented by low-
molecular mass antioxidants, protein thiols and intracellular enzyme systems. The 
TrxR/Trx/Prx system, together with GSH and protein thiols, appear to be involved in 
HOSCN detoxification, whereas GPx seems to be more effective against HOCl. The 
accumulation of GSSG following HOSCN treatment also suggests a possible impairment 
in GR activity, which would be worth investigating further. Under circumstances where 
an additional cellular stress was imposed, such as siRNA transfection, GSH was also 
oxidised by HOCl, without any corresponding increase in GSSG formation, suggesting 
the formation of alternative oxidation products. 
 
The studies described in Chapter 5 led to the identification of a differential susceptibility 
of mammalian Prx1, Prx2 and Prx3 to HOSCN and HOCl damage. The role of Prxs in the 
antioxidant defence under inflammatory conditions induced by MPO-derived oxidants 
may be further examined by the determination of the redox state of other Prxs isoforms, 
including mitochondrial Prx5 (182, 313) and the secreted Prx4 isoform (350, 387). The 
rate of recovery of Prx redox state following oxidant treatment can differ between the 
isoforms (396), therefore it would be of interest to establish how rapidly Prxs1 - 3 recover 
after exposure to HOSCN or HOCl, and whether hyperoxidised forms of Prxs are also 
reduced to the active form. Sulfinic acid intermediates of Prx can be slowly reduced back 
by the unique eukaryotic enzyme Srx. Srx itself might be a target for HOSCN oxidation 
due to the presence of a relatively low pKa Cys residue at its active site (~7.3), although 
previous studies have shown that this residue is insensitive to oxidation by high 
concentrations of H2O2 (397).  
 
Finally, the biological significance of various Prxs in protecting against MPO-derived 
oxidants could be assessed in in vivo animal models, such as Prx-KO mice. Prx1-KO and 
Prx2-KO mice models have been used previously to study the role of Prx1 and Prx2 in 
the protection of the RBC against oxidative stress and the suppression of tumour 
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development in ageing mice (171, 330). Dietary supplementation of Prx-KO mice with 
SCN
-
 may help to study the effects of HOSCN-induced oxidative stress and how well this 
stress is tolerated by animals lacking one of the major antioxidant enzymes. 
7.3 Concluding remarks 
The data presented in this thesis provide novel insights into the role of HOSCN in 
disease, its intracellular targets, and defence mechanisms against both HOSCN and HOCl 
which have not been characterised before. It has been shown that elevated levels of 
plasma SCN
-
 may be beneficial under some circumstances through a presumed increased 
formation of HOSCN at the expense of HOCl, and a consequent switch in the pattern of 
damage from irreversible/irreparable to mostly reversible. This change in the nature of 
MPO-produced oxidants, among other factors, may have played a role in the better long-
term survival of people with elevated plasma levels of SCN
-
, who have suffered a 
myocardial infarction.  
 
Furthermore, the effects of HOSCN and HOCl have been investigated at the cellular 
level. The results presented in this thesis have not only shown that HOSCN and HOCl 
target the components of both GSH/GPx/Grx and TrxR/Trx/Prx intracellular enzyme 
systems, but have also provided evidence for differential susceptibilities of these 
antioxidants to HOSCN or HOCl-induced damage. This is important for smokers in 
particular, as they may have elevated levels of SCN
-
 and, consequently, may be exposed 
to potentially higher levels of HOSCN.  
 
These findings significantly contribute to the current knowledge of targets of MPO-
derived oxidants, biological consequences of damage to these targets, and may help to 
explain some of the mechanisms involved in the development and progression of diseases 
associated with smoking, including atherosclerosis. Further understanding of the relative 
importance of different MPO-derived oxidants in various biological settings 
(extra/intracellular localisation, physiological/pathological conditions), may potentially 
lead to the development of new therapeutic options, directed at the prevention and/or 
modulation of the effects produced by these oxidants.  
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